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Normal hematopoiesis
Hematopoiesis is the formation and development of blood cells. Adult blood cell formation 
occurs mainly in the bone marrow where 500 billion blood cells are produced daily.1 All types 
of blood cells are derived from a small population of hematopoietic stem cells (HSCs). HSCs 
are capable of self-renewal to retain a small amount of HSCs during our life-span. In addition, 
they are able to differentiate into all types of mature blood cells (Figure 1).2 These mature 
blood cells have their own unique functions: red blood cells (erythrocytes) are important for 
oxygen transport, platelets (thrombocytes) for coagulation and white blood cells (leukocytes) 
are part of the immune system that protects us against pathogens. Several models for 
hematopoiesis have been described. The classical model suggests that multipotent HSCs 
differentiate into several types of more committed progenitor cells that become progressively 
more restricted and finally give rise to terminally differentiated blood cells. This model is 
based on a strict developmental hierarchy with an early segregation of the myeloid and 
lymphoid lineages.3 Interestingly, more recent studies suggest that progenitor cells are more 
versatile than expected and that multiple routes of differentiation can lead to the same type 
of mature blood cells (Figure 1).4,5 Hematopoiesis is tightly regulated by transcription factors 
and cytokines to ensure the presence of enough functional mature blood cells of each cell 
type.6,7
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Figure 1. Hematopoiesis. All mature cells in the peripheral blood are derived from hematopoietic stem cells (HSCs) 
which reside in the bone marrow. HSCs are able to self-renew and to differentiate into all types of mature blood cells 
via several intermediate steps. Dashed lines indicate recently discovered alternative routes of differentiation towards 
mature blood cells; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte-
erythrocyte progenitor; GMP, granulocyte-macrophage progenitor.
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Malignant hematopoiesis
Genetic alterations in early hematopoietic stem or progenitor cells can cause abnormal 
proliferation and differentiation of blood cells, which is a hallmark of hematological 
malignancies. Hematological malignancies are a heterogeneous group of diseases that can 
be stratified according to the affected cell lineage and the degree of maturation of the cells 
using the world health organization (WHO) classification system. This thesis focuses on 
malignancies affecting the myeloid lineage.
Different entities of myeloid malignancies
Myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) are a group of diseases characterized by an 
overproduction of one or more mature blood cell type(s). MPN has an incidence rate of 2.8 
per 100,000 individuals per year (2013) in the Netherlands.8 The median age at diagnosis is 
60 years.9 The 4 major MPN subtypes are chronic myelogenous leukemia (CML), essential 
thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). CML is 
characterized by an overproduction of white blood cells, ET by an overproduction of platelets 
and PV by an overproduction of red blood cells. PMF is a condition in which bone marrow 
tissue is gradually replaced by fibrous scar-like tissue, thereby disrupting normal blood 
cell production. Some less frequently occurring disease subtypes also belong to the MPN 
category, see Table 1.10 If controlled well, MPN patients can live without many symptoms. 
Complications that can arise in MPN patients are heart attacks and strokes (caused by platelet 
aggregation) and an enlarged spleen (because the spleen needs to clear a greater number 
of blood cells). Transformation to acute myeloid leukemia is seen in 5-10% of MPN patients 
(particularly PMF patients).
Myelodysplastic syndromes
Myelodysplastic syndromes (MDSs) are a heterogeneous group of hematopoietic disorders 
characterized by bone marrow dysplasia and one or more peripheral blood cytopenias.11 Due 
to an increased proliferation and ineffective differentiation and maturation, MDS patients 
may have up to 20% blasts in their bone marrow and a shortage of mature blood cells in the 
peripheral blood. As a consequence of their cytopenias, patients with MDS may experience 
infections, fatigue and bleedings. MDS has an incidence rate of 2.6 per 100,000 individuals 
per year (2013) in the Netherlands and a 5-year overall survival rate of 47%.8 It is a disease of 
elderly people with a median age at diagnosis of 65-70 years.12 MDS patients can be classified 
in different WHO subtypes depending on the morphology of the cells, the cell lineages that 
are affected and specific chromosomal aberrations (Table 1).10 The prognosis depends on 
cytogenetics, bone marrow blast percentage, hemoglobin level, platelet count and absolute 
neutrophil count, which are all combined in a revised international prognostic scoring system 
(IPSS-R).12 Approximately 30% of MDS patients ultimately develop acute myeloid leukemia.
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Table 1. 2008 WHO classification of myeloid malignancies
Acute myeloid leukemia and related neoplasms Myeloproliferative neoplasms
Acute myeloid leukemia with recurrent genetic abnormalities Chronic myelogenous leukemia, BCR-ABL1 positive
        AML with t(8;21)(q22;q22) Chronic neutrophilic leukemia
        AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22) Polycythemia vera
        APL with t(15;17)(q22;q12) Primary myelofibrosis
        AML with t(9;11)(p22;q23) Essential thrombocythemia
        AML with t(6;9)(p23;q34) Chronic eosinophilic leukemia, NOS
        AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2) Mastocytosis
        AML (megakaryoblastic) with t(1;22)(p13;q13) Myeloproliferative neoplasm, unclassifiable
        Provisional entity: AML with mutated NPM1 Myelodysplastic/myeloproliferative neoplasms
        Provisional entity: AML with mutated CEBPA Chronic myelomonocytic leukemia
Acute myeloid leukemia with myelodysplasia-related changes Atypical chronic myeloid leukemia, BCR-ABL1 negative
Therapy-related myeloid neoplasms Juvenile myelomonocytic leukemia
Acute myeloid leukemia, not otherwise specified (NOS) Myelodysplastic/myeloproliferative neoplasms, unclassifiable
        AML with minimal differentiation Provisional entity: refractory anemia with ring sideroblasts 
        AML without maturation                                  and thrombocytosis
        AML with maturation Myelodysplastic syndromes
        Acute myelomonocytic leukemia Refractory anemia with unilineage dysplasia
        Acute monoblastic/monocytic leukemia         Refractory anemia
        Acute erythroid leukemia         Refractory neutropenia
        Acute megakaryoblastic leukemia         Refractory thrombocytopenia
        Acute basophilic leukemia Refractory anemia with ring sideroblasts
        Acute panmyelosis with myelofibrosis Refractory cytopenia with multilineage dysplasia
Myeloid sarcoma Refractory anemia with excess blasts
Myeloid proliferations related to Down syndrome Myelodysplastic syndrome associated with isolated del (5q)
        Transient abnormal myelopoiesis Myelodysplastic syndrome, unclassifiable
        Myeloid leukemia associated with Down syndrome Childhood myelodysplastic syndrome
Blastic plasmacytoid dendritic cell neoplasm Provisional entity: refractory cytopenia of childhood
Acute leukemias of ambiguous lineage
Acute undifferentiated leukemia
Mixed phenotype acute leukemia with t(9;22)(q34;q11.2)
Mixed phenotype acute leukemia with t(v;11q23)
Mixed phenotype acute leukemia with B/myeloid, NOS
Mixed phenotype acute leukemia with T/myeloid, NOS
Provisional entity: NK cell lymphoblastic leukemia/
lymphoma
Myelodysplastic/myeloproliferative neoplasms
Some patients display features of myelodysplastic syndromes (dysplastic features) as well as 
myeloproliferative neoplasms (increased number of circulating cells in one or more lineages). 
These patients are classified as having a myelodysplastic/myeloproliferative neoplasm (MDS/
MPN). MDS/MPN has an incidence rate of 0.6 per 100,000 individuals per year (2013) in the 
Netherlands and a 5-year overall survival rate of 28%.8 The 3 major subtypes in this category 
are atypical chronic myeloid leukemia (aCML), chronic myelomonocytic leukemia (CMML) and 
juvenile myelomonocytic leukemia (JMML), see Table 1.10 aCML is characterized by myeloid 
dysplasia and an increased number of leukocytes, which lack the BCR-ABL translocation that 
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is present in classical CML.13 CMML and JMML are characterized by an increased number 
of monocytes and dysplasia in one or more lineages (dysplasia is less prominent in JMML). 
In addition, there is a category of MDS/MPN-unclassifiable, which consists of patients with 
dysplastic and proliferative features that do not fulfill the criteria for one of the other MDS/
MPN subtypes.14
Acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous group of clonal malignancies characterized 
by an uncontrolled proliferation of immature cells of the myeloid lineage together with a 
block in cellular differentiation. This results in an excess of blasts in the bone marrow and 
peripheral blood, often accompanied by a lack of functional mature cells in the peripheral 
blood.15 To be classified as leukemia the percentage of bone marrow blasts should be equal to 
or exceed 20%. In addition, all patients with a RUNX1-RUNX1T1, CBFB-MYH11 or PML-RARA 
translocation are classified as AML regardless of the blast count.10 AML has an incidence rate 
of 3.3 per 100,000 individuals per year (2013) in the Netherlands.8 The incidence of AML 
increases with age, with a median age at diagnosis of 67 years.16 The 5-year overall survival 
rate for all age categories is 20%, but younger patients do better than older patients with 
a 5-year overall survival of 65% for patients <15 years, 40% for patients aged between 25 
and 65 years, and 5% for patients >65 years.8,17-20 The survival rate also strongly depends on 
the molecular aberrations that are present in the patients. Depending on the cell type that 
is affected, the maturation status of the cells and the genetic abnormalities, AML can be 
divided into several subcategories (Table 1).10
Diagnosis of myeloid malignancies
To diagnose patients with hematological malignancies, several techniques are currently 
combined. A correct diagnosis is important for prognostication and for the prediction of 
response to specific forms of therapy. The diagnostic tests that are used differ per suspected 
disease entity. The most commonly used techniques are described below.
Morphology
Bone marrow morphology remains a very important diagnostic tool for myeloid malignancies.21 
Besides bone marrow, the morphology of peripheral blood cells is often examined. The cells 
from a bone marrow aspirate or peripheral blood sample are stained with May-Grünwald-
Giemsa or Wright-Giemsa to properly visualize the structure of the cells. It is recommended 
that at least 200 leukocytes on blood smears and 500 nucleated cells on marrow smears are 
counted to ensure correct classification.22 In addition, a bone marrow biopsy is often taken. 
This small piece of bone tissue together with the enclosed marrow is fixed, sectioned and 
stained with hematoxylin and eosin to examine bone marrow fibrosis and cell morphology.23 
Based on the number, morphology and size of the different blood cells in the aspirate and 
biopsy, experts are able to discriminate between different disease (sub)types.
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Immunophenotyping
A second important tool for the diagnosis of myeloid malignancies is immunophenotyping. 
Cells express a variety of cell surface markers. The combination of markers is dependent 
on the cell type and degree of maturation. Abnormal growth and maturation of blood cells 
may interfere with the natural expression of cell surface markers resulting in overexpression 
or under-representation of markers. Flow cytometry can be used to distinguish between 
healthy and abnormal cells.22 Cells can be visualized on a flow cytometer by staining their cell 
surface markers with antibodies. An excess of a certain cell type or an unusual combination 
of markers can be detected using this technique, and used for diagnosis, classification and 
follow-up of myeloid malignancies.23
Karyotype analysis/FISH
A third tool used for diagnosis and prognostication is conventional karyotype analysis. A 
karyotype is a visual representation of the chromosomes within a single cell, where the 
number of chromosomes, the size and their arrangement can be analyzed. To visualize the 
chromosomes, cells are arrested in the metaphase of the cell cycle and stained with Giemsa. 
With this technique large chromosomal aberrations (translocations, inversions, losses and 
gains) can be detected. It is recommended to analyze at least 20 metaphases.22 In addition 
to conventional karyotyping, fluorescence in situ hybridization (FISH) can be performed. 
FISH uses a sequence-specific fluorescent probe that binds to the sequence of interest. 
Based on the number and location of fluorescent spots in a cell, deletions, duplications and 
translocations can be visualized. The fluorescent probe can bind to condensed chromosomes 
as well as to DNA during interphase and can therefore be used for samples where metaphase 
analysis failed. Furthermore, FISH allows the detection of small or cryptic abnormalities that 
may be missed using karyotype analysis.12,24
Molecular genetic analysis
Large genetic defects can be detected by karyotype analysis or FISH. In addition, more novel 
techniques like single nucleotide polymorphism (SNP) array analysis and sequencing are 
also able to detect various types of genetic defects. SNP array analysis uses a large set of 
polymorphisms to determine regions with deletions, duplications or copy neutral loss of 
heterozygosity (uniparental disomy).25 Sequencing techniques are used to screen for small 
genetic defects (often point mutations). The last decade, many recurrently mutated genes 
have been characterized. Mutations in some of these genes have been associated with an 
impact on survival or with a better response to (a particular) therapy, which makes screening 
for these mutations important. Sanger sequencing is used in most laboratories to screen for 
mutations. However, next generation sequencing techniques are currently being implemented 
in routine diagnostics in many laboratories. Next generation sequencing is more sensitive 
than Sanger sequencing because many DNA strands are sequenced individually, which makes 
it possible to detect mutations in a low number of cells.26 In addition, multiple different 
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targets can be sequenced simultaneously.
Genetic abnormalities
Types of genetic abnormalities in hematological malignancies
The genetic defects that accumulate in the genome during cancer development can be placed 
in several groups of aberrations. First of all, there are different types of large chromosomal 
alterations: deletions, duplications, inversions, insertions, translocations and uniparental 
disomy (UPD) (Figure 2). Deletions and insertions/duplications lead to a loss and gain of 
genetic material, respectively. Translocations and inversions can result in the formation of 
fusion proteins if the breakpoints are located inside genes, or a promoter or enhancer can be 
repositioned in the vicinity of a gene and cause ectopic expression.27,28 Uniparental disomy
 
Segments from different chromo-
somes have been exchanged
Part of a chromo-
some is reversed 
Part of a chromo-
some is duplicated
Part of a chromo-
some is missing
Deleon Duplicaon Inversion
Translocaon
Inseron
Part of a chromosome is inserted
in a random place in the genome
Both homologs of a chromosome 
(region) come from the same parent
Uniparental disomy
* * *
Figure 2. Chromosomal aberrations. Types of large chromosomal aberrations seen in patients with myeloid 
malignancies. * indicates mutation.
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is a situation in which both homologs of a chromosome (region) are derived from the same 
parent. This often occurs in regions that contain a mutation, resulting in a homozygous 
mutation (Figure 2). The most frequently occurring large chromosomal abnormalities in 
myeloid malignancies are listed in Table 2.29 Besides affecting a large part of a chromosome, 
deletions, insertions and duplications can also affect a few or a single nucleotide(s). The 
insertion or deletion of a (few) nucleotide(s) may lead to a shift in the reading frame of a 
gene, called a frameshift mutation, which in most cases leads to a premature stopcodon 
and the formation of a truncated protein. Finally, a single nucleotide can also be replaced by 
another nucleotide, which is called a point mutation. When the changed base does not lead 
to the coding for a different amino acid, this is called a silent mutation.27,30 Silent mutations 
may be implicated in pathogenesis by altering motifs that regulate splicing or by affecting 
RNA stability.31 A changed base can also result in a codon that codes for a different amino acid 
or a stop codon, which are called missense and nonsense mutations, respectively.27,30
Table 2. Frequently occurring cytogenetic abnormalities in myeloid malignancies32-34
Cytogenetic abnormality Type of abnormality Fusion product Myeloid malignancy
t(8;21) Translocation RUNX1-RUNX1T1 AML
t(15;17) Translocation PML-RARA AML
11q23 rearrangement Translocation MLL-x AML
t(9;21) Translocation BCR-ABL CML/AML
t(6;9) Translocation DEK-NUP214 AML
t(16;16) or inv(16) Translocation/Inversion CBFB-MYH11 AML
t(3;3) or inv(3) Translocation/Inversion GATA2 enhancer-EVI1 AML/MDS
-5/del(5q) Deletion - AML/MDS
-7/del(7q) Deletion - AML/MDS
del(20q) Deletion - MDS
+8 Duplication - AML/MDS
Classes of genes affected by genetic abnormalities
The number of identified genes affected by genetic aberrations in hematological malignancies 
has considerably increased the last decades. Some genes are mutated in several types of 
hematological malignancies, while others are more confined to one specific type of disease. 
In BCR-ABL-negative MPN, the most frequently mutated genes are JAK2 (>95% of patients 
with PV and 60-65% of patients with ET or PMF), followed by CALR (20-25% of patients with 
ET or PMF) and MPL (5% of patients with ET or PMF).35,36 The mutational spectra of MDS 
and AML show quite some overlap, however some genes are more frequently mutated in 
MDS than in AML and vice versa.37 The 10 most frequently mutated genes in MDS are TET2, 
SF3B1, SRSF2, ASXL1, DNMT3A, RUNX1, U2AF1, TP53, EZH2, STAG2.32,37-39 In AML, the 10 
most frequently mutated genes are FLT3, NPM1, DNMT3A, CEBPA, IDH1, IDH2, TET2, NRAS, 
PML-RARA and AML1-ETO.40-43 The genes mutated in myeloid malignancies can be subdivided 
into several functional classes: DNA methylation, chromatin modifiers, cohesin complex, 
splicing machinery, JAK-STAT pathway, RAS pathway and transcription. The most frequently 
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mutated genes are listed in Figure 3. Mutations within a functional group (especially within 
JAK-STAT pathway, RAS pathway, cohesin complex or splicing machinery) are largely mutually 
exclusive.37 Many patients have mutations in several genes belonging to different functional 
gene classes. For example FLT3 mutations frequently co-occur with mutations in NPM1 and/
or DNMT3A, and TET2 mutations frequently co-occur with mutations in ZRSR2, SRSF2 or 
CEBPA.32,39,43 However, there are also some exceptions, for example DNMT3A mutations co-
occur with IDH mutations, while both play a role in DNA methylation.41,42 For many mutated 
genes, the exact involvement in the pathogenesis and the cooperation with other genes is 
not completely known yet and requires further investigation.
Myeloid
malignancies
DNA methylaon
Chroman modifiers
Cohesin complex
Splicing machinery
JAK-STAT pathway
RAS pathway
Transcripon
Other
DNMT3A
IDH1
IDH2
TET2
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ATRX
EZH2
KDM6A
MLL-PTD or fusions
RAD21
SMC1A
SMC3
STAG1
STAG2
PRPF40B
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SF3A1
SF3B1
SRSF2
U2AF1
U2AF2
ZRSR2CALR
JAK2
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BRAF
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TP53
BCR-ABL
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CEBPA
CUX1
ETV6
GATA2
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Figure 3. Gene classes mutated in myeloid malignancies.32,37,39,40,44 Recurrently mutated genes in myeloid 
malignancies can be grouped into several functional classes. Most genes are mutated in several types of myeloid 
malignancies, however, the frequencies can differ considerably between disease subtypes.
Clonal evolution
Cancer arises through an evolutionary process in which cells accumulate genetic aberrations 
over time. Mutations may be gathered during aging because mistakes during DNA replication 
sometimes slip through the DNA repair machinery.45 In addition, exposure to external 
mutagens may induce mutations. The transformation from a healthy cell to a cancer cell 
requires acquisition of multiple mutations that collectively lead to a survival or proliferation 
advantage, which may result in a malignant phenotype.44
Interestingly, recent studies reported clonal hematopoiesis with somatic mutations 
in more than 10% of persons older than 65 years of age without signs of hematological 
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malignancies.46,47 The incidence of clonal hematopoiesis clearly increased with age, which 
is in line with the accumulation of mutations during aging. The majority of the detected 
mutations occurred in three genes that have been implicated in hematological malignancies: 
DNMT3A, TET2 and ASXL1.46-49 The presence of clonal hematopoiesis with somatically 
acquired mutations was associated with an increased risk of hematological cancers and 
an increased mortality.46,47 Although there is an increased risk to develop hematological 
malignancies, this risk is still small since the percentage of persons above 65 years of age with 
clonal hematopoiesis (~10%) greatly exceeds the age-specific incidence of hematological 
malignancies (<0.1%).48 More than 90% of the individuals with clonal hematopoiesis had only 
one hematological-cancer-associated gene mutation, which suggests that this might be an 
initiating event, and that additional mutations are required to develop a malignancy.47
On average each AML patient harbors 10-13 mutations (excluding synonymous 
mutations) in the exonic regions, which is less than in many other adult cancers.40,45,50 Around 
3 to 5 of these mutations affect recurrently mutated genes.40 Hematological malignancies are 
not (always) stable; more mutations may accumulate during disease progression or at relapse, 
leading to tumor heterogeneity.51-53 All cells in a tumor contain shared somatic mutations that 
reflect their clonal origin (the founding clone), but additional mutations may be present in 
subpopulations of cells (subclones).54 The clonal evolution in a tumor may follow a linear or 
branching pathway. During linear evolution the stepwise accumulation of mutations results 
in a final clone which carries all the mutations that arose during the evolutionary history and 
outcompetes earlier clones carrying only some of the mutations (Figure 4A). In a branching 
evolution pattern, different clones arise through divergent mutational pathways (Figure 4B). 
Both evolutionary models have been observed in AML patients.44
In the majority of AML patients the clonal composition in the bone marrow and 
peripheral blood is similar; all variants detected in the bone marrow are also detected in the 
peripheral blood, but the percentage of affected cells may differ.54 In most cases, mutations 
are not detected in lymphocytes, indicating that lymphocytes are not part of the malignant 
clone.54 Some studies reported the presence of recurrent AML-associated mutations (mainly 
DNMT3A) in around 10% of the lymphocytes, which suggests that these are initiating 
mutations present in a multipotent hematopoietic stem cell.55
The heterogeneity and clonal architecture of hematological malignancies makes 
treatment challenging. Sometimes it is possible to eradicate the founding clone, but 
additional mutations (e.g. a TP53 mutation) present in a subclone may cause resistance to 
therapy, leading to the outgrowth of this subclone. In relapsed AML patients, two major 
evolutionary patterns have been observed. In some patients, the dominant clone in the 
primary tumor gained mutations and evolved into a relapse clone, suggesting that the first 
treatment did not eradicate all tumor cells. In other patients, a small subclone survived 
therapy and expanded at relapse.51 Therefore, combined therapies efficiently targeting the 
founding clone and all subclones may be necessary to cure patients.44 Monitoring the clonal 
composition and outgrowth of the tumor cells during treatment may facilitate the early 
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identification of resistant clones, which makes it possible to adapt the treatment regimen. At 
the moment there are many targeted therapies in phase I or II clinical trials, like IDH mutant 
inhibitors56,57 and FLT3 inhibitors.58,59 Hopefully in the future these agents could be used when 
such mutations are detected.
Linear evoluon
Normal hematopoiesis MDS/Leukemia
A
B Branching evoluon
Figure 4. Clonal evolution. During aging each cell accumulates mutations. When one of the mutations leads to 
a survival advantage and/or increased proliferation, this may result in clonal hematopoiesis. Extra mutations in 
these cells could eventually lead to cancer. Clonal evolution can follow two pathways. (A) Linear evolution: linear 
architecture with stepwise accumulation of mutations. (B) Branching evolution: different clones arise through 
divergent mutational pathways. The symbols each indicate a specific (set of) mutation(s). Cells carrying an identical 
set of mutations are visualized in the same color (a clone).
Epigenetics
The term epigenetics literally means ‘on top of genetics’. It refers to external modifications 
that influence gene expression without changing the DNA code. Epigenetic modifications are 
often heritable as they are copied to the daughter cells during cell division.60 The two most 
well-known epigenetic modifications are histone modifications and DNA methylation. Several 
genes involved in epigenetic regulation are mutated in myeloid malignancies, see Figure 3.61
Histone modifications
The nucleus of a human cell contains approximately 1.8 meters of DNA. This DNA is wrapped 
around histone proteins, tightly folded and divided into 46 chromosomes. The histone-
DNA complexes are called nucleosomes. Each nucleosome contains a histone octamer 
composed of two copies of the histones H2A, H2B, H3 and H4, and 147 base pairs of DNA. 
The N- an C-terminal tails of the histone proteins protrude from the nucleosome and may 
contain a wide range of modifications, including methylation, acetylation, phosphorylation 
and ubiquitination.62,63 The type of modification and the position on the histone protein 
determines whether the modification leads to a more open or a more condensed chromatin 
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structure, which is associated with transcriptional activation or repression, respectively 
(Figure 5).64 The effect on transcription is also dependent on the cross-talk between different 
histone modifications and between histone modifications and DNA methylation.62 For each 
modification there are proteins responsible for the formation of the modification, called 
‘writers’ and for the removal of the modification, called ‘erasers’.65  In addition, some proteins 
specifically bind to these modifications, called ‘readers’.
PRC2 complex
Composition and function of the PRC2 complex
The polycomb repressive complex 2 (PRC2) catalyzes the transfer of a methyl group from the 
universal methyl donor, S-adenosyl-L-methionine (SAM), to the lysine side chain of lysine 27 
on histone 3 (H3K27). PRC2 mediates the mono-, di- and trimethylation of H3K27, the latter 
being associated with transcriptional repression. The PRC2 complex consists of three core 
subunits: EZH2, SUZ12 and EED. EZH2 is the catalytically active component of the complex, 
while EED and SUZ12 are required for stability and full activity of the complex. Besides these 
three proteins several other proteins can also be part of the complex, including RbAP46/48, 
AEBP2, PCL and JARID2, see Figure 5.66 These proteins play a role in recruiting the complex to 
the genome and are able to modulate the activity of the complex.67 Interestingly, EZH2 has a 
family member, EZH1, which can substitute EZH2 in the complex. Both proteins contain a SET 
domain, which possesses catalytic activity. However, PRC2 complexes containing EZH2 have 
higher methyltransferase activity than PRC2 complexes with EZH1.68 EZH2 is more abundant 
during embryogenesis, while EZH1 predominates in non-dividing cells and adult tissues. 
EZH1- and EZH2-containing PRC2 complexes have shared targets, but also individual targets. 
Therefore, in most tissues EZH1 and EZH2 are not able to fully compensate for each other’s 
loss.67 In mammals, recent studies suggest that several long non-coding RNAs, including XIST, 
HOTAIR and MEG3, play an important role in recruiting PRC2 to the genome.69,70 PRC2 is 
believed to function predominantly as a transcriptional repressor. First of all, H3K27me3 itself 
is associated with epigenetic silencing. In addition, the PRC2 complex cooperates with other 
epigenetic silencing mechanisms. H3K27me3 is recognized and bound by the PRC1 complex, 
which strengthens the silencing by ubiquitinating lysine 119 of histone H2A (H2AK119ub). 
Furthermore, EZH2 is able to transiently interact with DNA methyltransferase (DNMT) and 
histone deacetylase (HDAC) proteins.66 DNMTs can be recruited to PRC2 target genes and 
enhance gene silencing by methylating CpGs. HDAC proteins can help modify the local histone 
code by deacetylating H3K27, and thereby making this residue available for methylation by 
PRC2.71 PRC2 plays an important role in many biological processes including X-chromosome 
inactivation, imprinting and early embryonic development. In embryonic stem cells (ESCs), 
some chromatin regions are marked with both H3K27 trimethylation (repressive mark) and 
H3K4 trimethylation (active mark). These regions, known as bivalent domains, repress key 
developmental genes in ESCs, but keeps them poised for later activation in response to 
differentiation stimuli.
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Figure 5. PRC2 complex. The PRC2 complex mediated trimethylation of H3K27. This histone modification leads to a 
condensed chromatin structure, which is associated with transcriptional repression.
EZH2 defects in cancer
EZH2 overexpression has been described in several solid cancers, including lymphoma, 
prostate, breast, bladder, gastric, lung and hepatocellular cancer, and is frequently associated 
with a poor clinical outcome.72-76 Besides elevated expression,77 acquired mutations in 
EZH2 have also been described in lymphoma. 7% of patients with follicular lymphomas 
and 22% of patients with germinal center B-cell lymphomas harbor heterozygous EZH2 
missense mutations.78 These mutations target tyrosine 641 (Y641) in the SET domain of the 
protein. In contrast to the wild-type protein, which displays greatest catalytic activity for 
monomethylation, Y641 mutants have enhanced catalytic activity for mono- to di-, and di- to 
trimethylation of H3K27. In conjunction with wild-type EZH2, heterozygous Y641 mutant EZH2, 
induces increased H3K27me3 levels and therefore represents a gain-of-function mutation.79 
Interestingly, loss-of-function EZH2 mutations, leading to decreased H3K27me3 levels, have 
been described in various myeloid malignancies. EZH2 mutations are found in 6% of MDS 
patients, 12% of MDS/MPN patients and 6% of MPN patients.38,39,80,81 In contrast to the single 
residue mutations in lymphoma, mutations in myeloid malignancies are spread throughout 
the gene and comprise missense, nonsense, splice site and frame shift mutations. Some of 
the EZH2-mutated patients showed uniparental disomy or a deletion on chromosome 7 (del 
7, del(7q) or a microdeletion), leading to homo- or hemizygous EZH2 mutations, respectively. 
EZH2 mutations confer a poor prognosis in myeloid malignancies.38,81,82
A recent study indicated that patients with myeloid malignancies that harbor a deletion 
on chromosome 7 involving the EZH2 locus, showed decreased EZH2 expression. In addition, 
EZH2 expression was decreased in patients harboring mutations in the splicing factors U2AF1 
and SRSF2. These mutated splicing factors were shown to cause dysfunctional processing 
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of the EZH2 pre-mRNA, leading to reduced EZH2 expression and H3K27me3 levels.83 The 
effect of SRSF2 mutations on EZH2 splicing has recently been studied more extensively.84 The 
commonly occurring SRSF2 P95H mutation resulted in altered sequence specific RNA binding 
of the SRSF2 protein, leading to the inclusion of an additional EZH2 exon. This resulted in 
a premature stopcodon and breakdown of EZH2 mRNA via nonsense-mediated decay. All 
together, this suggests that EZH2 may have a dual role as an oncogene and tumor suppressor 
gene depending on the cellular context. Therefore, caution is warranted when investigating 
drugs targeting EZH2 methyltransferase activity.
DNA methylation
DNA methylation refers to the covalent addition of a methyl group (CH
3
) to the fifth carbon of 
a cytosine ring in the DNA, resulting in 5-methylcytosine.85 DNA methylation predominantly 
occurs on cytosine residues present in a CpG context. Methylation on promoter regions is 
associated with transcriptional repression, whereas actively transcribed genes may contain 
high levels of gene body methylation.86 Tight regulation of DNA methylation is important for 
many biological processes including X-chromosome inactivation, imprinting and transcriptional 
regulation.87 DNA methylation is mediated by DNA methyltransferases; DNMT3A and DNMT3B 
are responsible for de novo methylation, while DNMT1 is mainly implicated in maintaining 
methylcytosine marks during DNA replication.88 DNA demethylation may take place as a 
passive or active process. Passive demethylation occurs when DNA methylation is not copied 
to the newly synthesized DNA strand during DNA replication, leading to a gradual loss of 5mC 
during successive cell divisions. Active DNA demethylation is initiated by TET proteins, which 
mediate the conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC).89,90 
5hmC can be further oxidized by TET proteins to 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC), which both can be recognized and excised by thymine DNA glycosylase (TDG). Finally, 
TDG activates the base excision repair pathway, which replaces the modified cytosine with an 
unmodified cytosine (Figure 6).91,92
Aberrant DNA methylation has been observed in many types of cancer.93,94 In 
hematological malignancies, global hypomethylation and promoter hypermethylation have 
been described.95,96 These alterations in methylation can lead to repression of tumor suppressor 
genes or activation of oncogenes. Recent studies have shown that DNA hydroxymethylation 
levels are also altered in various types of cancer,97-99 including myeloid malignancies (reviewed 
in detail in chapter 5).100,101 Changes in DNA methylation are interesting targets for therapy, 
because epigenetic modifications are reversible. Two hypomethylating agents, azacitidine 
and decitabine, are currently approved by the Food and Drug Administration (FDA) for the 
treatment of MDS patients and AML patients with 20-30% blasts. In addition, decitabine 
has been approved in Europe for treatment of AML patients aged 65 years and older who 
are not eligible for initial standard induction chemotherapy. In general, these agents are 
used to treat patients whose condition does not allow intensive chemotherapy or stem cell 
transplantation.102,103
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Figure 6. DNA methylation and demethylation. DNMT proteins are responsible for the methylation of cytosines in 
the DNA. TET proteins play an important role in active DNA demethylation by converting 5mC into 5hmC, 5fC and 
5caC through three consecutive oxidation reactions. 5fC and 5caC can be recognized by thymine DNA glycosylase 
(TDG) proteins which activate the base excision repair pathway (BER).
TET proteins
Structure
The TET protein family consists of three members: TET1, TET2 and TET3. TET1 was first 
identified as a gene fused to the MLL gene in an AML patient with a ten-eleven translocation, 
hence the gene was called Ten-Eleven-Translocation 1 (TET1).104 All three TET proteins contain 
a C-terminal catalytic domain, which exhibits 2-oxoglutarate (2OG) and iron (Fe2+)-dependent 
dioxygenase activity (Figure 7). This catalytic domain consists of a Cys-rich and double-
stranded β-helix (DSBH) region.89 There is also a spacer region present in the catalytic domain, 
which is a low complexity region that varies in length between the different TET proteins and 
is not very conserved between species. The exact function of this region is not yet known, but 
it might be important for protein-protein interaction.105 In addition, a recent 
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Figure 7. Structure of TET proteins. TET proteins contain a C-terminal catalytic domain, which consists of a Cys-rich 
region, a double-stranded β-helix (DSBH) and an low complexity spacer region. In addition, TET1 and TET3 proteins 
contain a CXXC domain in the N-terminus. During evolution a chromosomal inversion event separated the CXXC 
domain of TET2 from the rest of the protein. This CXXC domain is now located upstream of TET2 and transcribed in 
the opposite direction.
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study showed that the low complexity spacer region is subjected to various post-translational 
modifications (phosphorylation, O-GlcNAcylation) that may influence the activity or stability 
of the protein.106 In the N-terminus of TET1 and TET3 proteins a CXXC zinc-finger domain can 
be found. Interestingly, the ancestral CXXC domain of TET2 is located directly upstream of the 
TET2 gene and transcribed in the opposite direction due to a chromosomal inversion event 
during evolution.107 This CXXC domain currently functions as a separate gene, called CXXC4 or 
IDAX, and is able to bind and modulate TET2 activity.108 The CXXC domain plays an important 
role in the binding of TET proteins to DNA.109
Functions
As mentioned above, TET proteins are responsible for the conversion of 5mC into 5hmC, 
5fC and 5caC through three consecutive oxidation reactions, which ultimately leads to 
demethylation of DNA. TET proteins belong to the family of α-ketoglutarate- (αKG) and Fe2+- 
dependent dioxygenases, and require αKG as a co-substrate and Fe2+ and ascorbate as co-
factors to perform the oxidation reactions.89,110 The transcription factor WT1 recruits TET2 
and TET3 proteins to the genome to regulate gene expression of WT1 targets.111,112 There are 
also non-WT1 targets bound by TET proteins, indicating that there are also WT1-independent 
ways to recruit TET proteins to the genome.111
Besides being intermediates in the active demethylation process, several studies suggest 
that 5hmC, 5fC and 5caC modifications may have other functions as well. 5hmC accumulates 
to high levels in neuronal cells and adult liver cells, which might be unexpected if 5hmC would 
only be a transient intermediate.113,114 Furthermore, several proteins have been discovered 
that specifically bind to 5hmC, 5fC and/or 5caC (‘readers’).115 Our knowledge about these 
proteins is still limited, but they may stabilize the modification, stimulate demethylation or 
lead to other unknown downstream effects.
Genome-wide 5hmC studies revealed the genomic distribution of 5hmC. 5hmC is 
preferentially located at genomic regions with moderate CpG density. First of all, 5hmC is 
enriched on promoter regions, just adjacent to the transcription start site. In addition, 5hmC 
is enriched in gene bodies and at enhancer regions (adjacent to transcription factor binding 
sites, but depleted at the precise site of binding).105,116-118 Whether hydroxymethylation 
correlates with gene activation or repression is not completely clear and most likely depends 
on the cell type and the location of the modification.105
All three TET proteins interact with O-linked β-N-acetylglucosamine (O-GlcNAc) 
transferase (OGT), an enzyme that catalyzes the addition of O-GlcNAc onto serine and 
threonine residues of proteins.119-122 TET proteins recruit OGT to the chromatin, where it 
mediates O-GlcNAcylation of histones.120,121 OGT proteins also modify all three TET proteins 
with N-acetylglucosamine.120,123 The exact consequence of O-GlcNAcylation of TET proteins 
is not completely clear yet. Bauer et al. showed that the low complexity region and the 
N-terminus of TET proteins are highly phosphorylated, and that this phosphorylation can be 
suppressed through O-GlcNAcylation of these regions. This suggests that cross-talk between 
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different TET protein modifications could allow rapid adaptation of the activity, stability or 
targeting of TET proteins in response to external stimuli.106
Recent studies showed that TET proteins are also able to convert thymine 
into 5-hydroxymethyluracil (5hmU) in mouse embryonic stem cells,124 and to form 
5-hydroxymethylcytidine (5hmrC) in RNA.125,126 Future studies are required to determine the 
biological relevance of these findings.
TET defects in hematological malignancies
TET1 and TET3 aberrations are rare in hematological malignancies. TET1 has been identified as 
a fusion gene of MLL in a ten-eleven translocation (t(10;11)). This translocation does not occur 
very frequently with less than 20 cases reported in the literature.127 In addition, a few TET1 
aberrations have been discovered using whole exome sequencing.40 The biological impact 
of these TET1 translocations and mutations is still unclear. In contrast, TET2 mutations have 
been described in various hematological malignancies. TET2 mutations in myelodysplastic 
syndromes were discovered in our laboratory.128 The TET2 gene can be affected by deletions 
as well as by splice site, missense, nonsense and frame shift mutations, throughout the TET2 
gene. The majority of the missense mutations are located in the C-terminal catalytic domain 
of the protein. The frequency of TET2 mutations depends on the type of disease, with the 
highest frequencies observed in chronic myelomonocytic leukemia (44-58%)129,130 and angio-
immunoblastic T-cell lymphoma (47-76%).131,132 In addition, TET2 mutations have been 
described in 7-13% of AML,42,133,134 12-15% of MPN135-137 and 21-33% of MDS cases.38,39,128 
In most hematological malignancies, TET2 mutations did not significantly affect prognosis, 
however several studies reported an association with poor prognosis in cytogenetically 
normal AML.41,134 The clinical and biological impact of TET2 mutations in AML is described 
in more detail in chapter 3. In line with an important role for TET2 in hematopoiesis, TET2 
knock-out mice showed an increase in hematopoietic progenitor cells, a bias towards myeloid 
differentiation, and ultimately developed a CMML-like disease.138,139
Besides TET2, three other genes implicated in DNA methylation, namely DNMT3A, IDH1 
and IDH2, are also mutated in myeloid malignancies (Figure 3). The effect of these mutations 
on 5mC and 5hmC levels is investigated in chapter 4. Possible treatment options directed 
against aberrant (hydroxy)methylation levels are described in chapter 5.
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Outline of this thesis
Due to new treatment strategies the outcome of patients with myeloid malignancies has 
improved considerably the last decades, however a substantial amount of patients still die 
from their disease. Deciphering the molecular pathogenesis of the disease may help to 
identify new targets for therapy and improve prognostication. As described in the previous 
paragraphs, many different genetic defects have been discovered in patients with myeloid 
malignancies. One class of genes that is frequently affected represents epigenetic regulators. 
The impact of mutations in epigenetic regulators on survival and treatment response is still 
largely unknown. The aim of the first part of this thesis is to detect mutations in epigenetic 
regulators and determine the consequences of these mutations on overall survival and 
protein function.
Chapter 2 focuses on the PRC2 complex, which is responsible for the formation of 
the repressive H3K27 trimethylation mark. Loss-of-function mutations in EZH2, the main 
component of this complex, have been described in various myeloid malignancies. We 
hypothesized that mutations in other components of this complex, namely EED, SUZ12, EZH1 
and JARID2, might be present in myeloid malignancies as well and lead to a similar phenotype 
as loss-of-function mutations in EZH2. Our sequencing results indicate that genetic defects in 
PRC2 components other than EZH2 are rare in myeloid malignancies, suggesting that EZH2 is 
the most important protein for PRC2 function in myelopoiesis.
In chapter 3 we investigated the clinical and biological impact of TET2 mutations. TET 
proteins play an important role in DNA demethylation by converting 5mC into 5hmC and 2 
other intermediates that can be replaced by an unmodified cytosine. The impact of TET2 
mutations on overall survival and the effect on protein function were still unknown. In our 
study we show that TET2 mutations occur in 7.6% of AML patients and confer a poor prognosis. 
Furthermore, all tested TET2 mutants were unable to form 5hmC in vitro, indicating that TET2 
mutations are loss-of-function mutations.
In chapter 4 we describe an HPLC-MS/MS method to measure 5mC and 5hmC levels 
quantitatively in DNA. We measured 5hmC levels in 206 AML patients and show that low 
5hmC levels in AML correlate with TET2 and IDH1/2 mutations. Interestingly, we also detected 
increased 5hmC levels in some patients. High 5hmC independently correlated with inferior 
overall survival.
Chapter 5 provides a comprehensive review of the literature about aberrant 5hmC levels 
in cancer. The results of our work are combined with the findings in various solid cancers. This 
review shows that mutations in several genes (TET2, IDH1/2, FH, SDH), as well as aberrant 
gene or miRNA expression can underlie aberrant 5hmC levels in cancer. In several types of 
cancer decreased 5hmC levels correlate with an inferior overall survival.
The aim of chapter 6 is to unravel the clonal evolution in MDS patients and correlate the 
evolution patterns with clinical parameters and treatment response. Our study demonstrates 
a great diversity in clonal composition and evolution, which may underlie the clinical 
heterogeneity of MDS. In some patients, clonal composition was very stable over time, 
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whereas in others, a highly dynamic pattern was observed. In several patients, alterations in 
clonal composition correlated with changes in therapy.
Finally, chapter 7 provides a general discussion and future perspectives regarding the 
research described in this thesis.
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Letter to the Editor
Several genetic alterations affecting loci encoding epigenetic regulators have been discovered 
in myeloid malignancies in the last few years. Previously, we and others identified novel 
mutations in the histone methyltransferase gene EZH2.1-3 EZH2 encodes the catalytic subunit 
of the polycomb repressive complex 2 (PRC2), which mediates the methylation of lysine 27 
of histone H3 (H3K27). Trimethylation of H3K27 is an epigenetic modification associated 
with gene silencing. Loss-of-function mutations in EZH2 were found in 6% of patients with 
myelodysplastic syndromes (MDS), 6% of patients with myeloproliferative neoplasms (MPN) 
and 12% of patients belonging to the MDS/MPN intermediate group.1,2
The PRC2 complex consists of three core components, EZH2, SUZ12 and EED, which are 
required for the complex to execute its function (Supplemental Figure 1A). A knock-out of 
any one of these components leads to early embryonic lethality in mice, demonstrating their 
importance during early development.4 Shen et al. showed that EZH1, a homolog of EZH2, 
might substitute for EZH2, because it interacts with the same PRC2 components and likewise 
needs EED and SUZ12 for its histone methyltransferase activity. Moreover, EZH1 and EZH2 bind 
to a largely overlapping set of target genes.5 Considering these data, we hypothesized that 
mutations in EED, SUZ12 and EZH1 might be present in patients with myeloid malignancies, 
leading to a similar phenotype as loss-of-function mutations in EZH2. Furthermore, our 
recent single nucleotide polymorphism (SNP) array analysis of 102 MDS patients identified 
one patient with an acquired 5-Mb deletion at 6p22.3 encompassing 15 genes, including 
JARID2 (Supplemental Figure 1B), as well as one patient who displayed uniparental disomy of 
this region (Supplemental Table 1).6 As JARID2 can interact with the core components of PRC2 
and is involved in the recruitment of PRC2 to specific target genes in embryonic stem cells,7 
mutations in this gene might perturb PRC2 function as well.
To determine whether mutations in PRC2 components other than EZH2 occur in 
patients with various myeloid malignancies, we sequenced the entire coding region and 
splice donor and acceptor sites of SUZ12 (n=256), EED (n=326), EZH1 (n=197) and JARID2 
(n=99) (Supplemental Table 2). We collected bone marrow and blood from patients with 
various myeloid malignancies after obtaining informed consent according to the Declaration 
of Helsinki. This was approved by the medical ethical committee of the Radboud University 
Nijmegen Medical Centre. None of the described genes harbored frameshift or nonsense 
mutations, but we detected 13 novel variants (7 missense, 6 silent) in 19 patients (Table 1). 
Sequencing of available constitutional (T cell) material showed that 4 of these variants (all 
missense) were not somatically acquired. For the remaining 9 variants (3 missense, 6 silent), 
T cells were not available. Among these was a p.E125V variation in EED, which may still be 
interesting because it is located in a WD40 domain involved in binding to EZH2 and thus could 
potentially have consequences for PRC2 function. It therefore remains possible that PRC2 
components other than EZH2 are mutated, albeit at a very low frequency (<1%).
In conclusion, our results indicate that, although the PRC2 complex can be impaired 
in myeloid malignancies because of mutations in EZH2, other important PRC2 proteins are 
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not frequently affected. This suggests that EZH2 is the most vulnerable component of this 
complex, whose proper function is important for normal hematopoiesis.
Table 1. Genetic variations in PRC2 components
UPN Disease DNA variation Protein variation Hetero-/
homozygous
Acquired/
inherited
SUZ12
MDS-3 MDS-RAEBt c.211G>A p.V71M Heterozygous N/A
MDS-14 MDS-RA c.211G>A p.V71M Heterozygous Inherited
MDS-121 MDS-RAEB c.196G>A p.A66T Heterozygous Inherited
PV-20 PV c.211G>A p.V71M Heterozygous Inherited
PV-31 PV c.211G>A p.V71M Heterozygous N/A
PMF-3 PMF c.66A>C p.G22G Heterozygous N/A
CMML-13 CMML-1 c.1220C>T p.T407I Heterozygous N/A
CMML-36 CMML-1 c.211G>A p.V71M Heterozygous N/A
CMML-40 CMML-2 c.1569A>T p.T523T Heterozygous N/A
MDS/MPN-U-19 MDS/MPN-U c.98C>T p.A33V Heterozygous N/A
EED
MDS-41 MDS-RA c.363T>C p.V121V Heterozygous N/A
MDS-45 MDS-RAEB c.1030C>T p.R344C* Heterozygous Inherited
PV-11 PV c.12G>A p.R4R Heterozygous N/A
CMML-60 CMML-2 c.374A>T p.E125V Heterozygous N/A
EZH1
- - - - - -
JARID2
MDS-27 MDS-RARS c.3504C>T p.H1168H Heterozygous N/A
MDS-28 MDS-RAEB c.1474C>T p.R492C Heterozygous N/A
MDS-50 MDS-RA c.1474C>T p.R492C Heterozygous Inherited
MDS-50 MDS-RA c.3504C>T p.H1168H Heterozygous N/A
MDS-55 MDS-RA c.3504C>T p.H1168H Heterozygous N/A
MDS-86 MDS-RA c.1674C>T p.P558P Heterozygous N/A
None of the MDS patients with a genetic variation in SUZ12, EED or JARID2 carried a mutation in EZH2. For the PV, 
PMF, CMML and MDS/MPN-U patients the EZH2 status was not determined. UPN indicates unique patient number; 
RAEBt, refractory anemia with excess blasts in transformation; RA, refractory anemia; RAEB, refractory anemia with 
excess blasts; RARS, refractory anemia with ringed sideroblasts; N/A, not analyzed due to a lack of available T cells 
or because of a silent variation. 
* Variation detected in an exon which is only present in EED isoform ENST00000351625.
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Supplemental data
Study participants
We collected bone marrow and blood from patients with various myeloid malignancies after 
obtaining informed consent; this study abided by the principles laid out in the declaration 
of Helsinki. The myelodysplastic syndrome (MDS) cohort contains samples belonging to all 
different World Health Organization (WHO) and international prognostic scoring system 
(IPSS) categories and the cohort of acute myeloid leukemia (AML) patients contains samples 
of various French-American-British (FAB) classification subtypes.
For genomic sequencing and SNP array analysis of MDS patients (n=99), DNA was 
extracted from FACS-sorted lymphocyte-depleted bone marrow or Ficoll density gradient-
isolated mononuclear cells from bone marrow using Qiagen spin-columns (Qiagen, Venlo, 
The Netherlands). DNA for the other patient cohorts, namely AML (n=46), essential 
thrombocythemia (ET, n=14), polycythemia vera (PV, n=32), chronic myelomonocytic 
leukemia (CMML, n=67), primary myelofibrosis (PMF, n=31) and unclassifiable MDS/MPN 
disease entities (MDS/MPN-U, n=49), was isolated from whole blood or bone marrow using 
salt extraction or from granulocytes using TRIzol reagent (Life Technologies, Carlsbad, CA, 
USA).
SNP array analysis
The SNP array analysis of genomic DNA from 102 MDS patients was performed as described 
previously.6
Sequence analysis 
We performed Sanger-based sequencing on PCR-amplified genomic DNA fragments 
spanning the entire coding region for all known protein-coding splice variants of SUZ12 
(ENST00000322652), EED (ENST00000263360, ENST00000528180, ENST00000327320, 
ENST00000534595, ENST00000534564, ENST00000524673, ENST00000527888, 
ENST00000533228, ENST00000351625), EZH1 (ENST00000264646, ENST00000415827, 
ENST00000428826, ENST00000435174) and JARID2 (ENST00000341776, ENST00000397311). 
All intron-exon boundaries were included to identify possible splice site aberrations 
(Supplemental Table 3-6). Sequence variations were confirmed by independent PCR 
amplification of the original DNA. The variations were compared with SNP databases and EST 
databases to determine whether the variations represented known SNPs. To analyze whether 
the remaining unknown variants were acquired, DNA from T cells was isolated, amplified and 
used for sequencing, whenever available (n=5).
T cell culture
For screening of DNA from non-malignant cells to determine whether variations were 
acquired, polyclonal T cells from frozen mononuclear cells were expanded in vitro. Monocytes 
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were first depleted by adherence to tissue culture flasks. The remaining cells were cultured for 
7-14 days in IMDM medium (Life Technologies) supplemented with 10% human serum (PAA 
Laboratories GmbH, Pasching, Austria), IL-2 (100 IU/ml) and CD3/CD28 coated Dynabeads 
(Life Technologies). After culture, the purity of the T cells was measured by FACS analysis 
using the CD3 surface marker. When the purity of the T cells was >90%, DNA was isolated 
using Qiagen spin-columns and its quality checked by spectrophotometric analysis using a 
NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE, USA).
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Supplemental Table 2. Number of screened patients for each PRC2 gene
SUZ12 EED EZH1 JARID2
MDS 47 88 39 99
   Patients without EZH2 mutation 45 83 31 92
   Patients with EZH2 mutation 2 5 8 7
AML patients without EZH2 mutation 16 46 16 0
PV* 32 32 32 0
ET* 14 14 14 0
PMF* 31 31 31 0
CMML* 67 67 33 0
MDS/MPN-U* 49 48 32 0
Total 256 326 197 99
* EZH2 status not determined
Supplemental Table 3. Primers used for SUZ12 sequencing
Exon PCR primer (5’ to 3’)
Forward/
Reverse
Location Sequence primer (5’ to 3’)
1 GTTGGTATTGCAGGCGCTTG Forward 5’UTR GTTGGTATTGCAGGCGCTTG
CCCTCAAAGCCTCGCACA Reverse Intron 1 CCCTCAAAGCCTCGCACA
2-3 AATACCTTTTGATCTTACTGTGCATACTTT Forward Intron 1 CGTGATTTCCATAGCAGATGATAAGTT
GCCCAGCTAATTTTTGTTTTAGTAGATAC Reverse Intron 3 AAATAAAACTAACATGGTTTGATCAGCTT
4 GCAATTACTGCCCTTCAGGAATA Forward Intron 3 GCAATTACTGCCCTTCAGGAATA
AATGGAAGAAACTGGTAATAAAGATAAACA Reverse Intron 4 AATGGAAGAAACTGGTAATAAAGATAAACA
5 TAGAGTCATGGGCCTGAATAACAG Forward Intron 4 TTTTTTTAGCTTGTCAGCTCATTTG
ACTCCAGCCTTCACTCTGCAC Reverse Intron 5 ACTCCAGCCTTCACTCTGCAC
6 AATGAGTGAACTTTTGAGAAGTCTTACTG Forward Intron 5 AATGAGTGAACTTTTGAGAAGTCTTACTG
TGAATTTATGCCAGATGCTAAAACAT Reverse Intron 6 TGAATTTATGCCAGATGCTAAAACAT
7 AAATGTTTATTTTTGCTTCACAGTTTG Forward Intron 6 AAATGTTTATTTTTGCTTCACAGTTTG
ATGGGCAGGGGGATAAATACA Reverse Intron 7 CAATATTTTCATTGGTTTCTCCATTAAT
8 CATATAGTAAAAATGCAAAATTGGAAACA Forward Intron 7 CATATAGTAAAAATGCAAAATTGGAAACA
GGGATTTTGTTGCCTTCTTAATGTCT Reverse Intron 8 GGGATTTTGTTGCCTTCTTAATGTCT
9 TTAAAATTGCTTTCATCAGGACTGG Forward Intron 8 TTAAAATTGCTTTCATCAGGACTGG
GCAGAATCACAGAATCACAGCTACTT Reverse Intron 9 ATGCTCTGACTAGATCATTTACTTGTGTTT
10 ACAGTGTCTGGTCCATACTTTTACTTTG Forward Intron 9 ACAGTGTCTGGTCCATACTTTTACTTTG
AGGAGAATCATCTGAACCCACAA Reverse Intron 10 GAATCACATAAAGCAAAACACAAATGA
11 TTTCCTGCGATCATCAGTTGAG Forward Intron 10 TTTCCTGCGATCATCAGTTGAG
AGGCGTGAGAATCAGGTTGAA Reverse Intron 11 AGGCGTGAGAATCAGGTTGAA
12 GAATATCTCTAATTTGATTTTCCGCTTAA Forward Intron 11 TTAGTTTCTCTATAACAACAATACAAGGCA
CAATTTTTGAAAGTCATGCTATCTTGTAC Reverse Intron 12 GTGGGTACATAGATGTATATATTTATGGGG
13 AGGTCTTCTGACTGCCTGTTTACC Forward Intron 12 TTTTACATTTTTGTTGCAGTATCATCCA
CAACCCCATAGACACCTAATACTGAA Reverse Intron 13 CAACCCCATAGACACCTAATACTGAA
14 GGGGGTGTGCCTCTAATACTATTG Forward Intron 13 GGGGGTGTGCCTCTAATACTATTG
AAATCCATATTCCCTTTAACTTGGTAACT Reverse Intron 14 TCTAGTTCATAGTAAGCAATTTTCAAAACA
15 TAAGAAATGTTGCCACTTTGCTGTA Forward Intron 14 TAAGAAATGTTGCCACTTTGCTGTA
GGAACGTCTTTGTACCTAAAAAAAACC Reverse Intron 15 GGAACGTCTTTGTACCTAAAAAAAACC
16 GACTGCTTATGTAATTGAAGAACAGAAATT Forward Intron 15 GACTGCTTATGTAATTGAAGAACAGAAATT
CCCTGATACAAATATCCTTGTTGAAAT Reverse 3’UTR CCCTGATACAAATATCCTTGTTGAAAT
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Supplemental Table 4. Primers used for EED sequencing
Exon PCR primer (5’ to 3’)
Forward/
Reverse
Location Sequence primer (5’ to 3’)
1 TTAATCCAACGGACCTTACATCGT Forward 5’UTR CGGCAGCGGCAACTTTG
 CTTTGCCTAGTTCCTGCTTGCT Reverse Intron 1 CTTTGCCTAGTTCCTGCTTGCT
2 tgtaaaacgacggccagtAACCTTCTAACCTGTAGCTGGATTATG Forward Intron 1 CAGTATTGCTGTTTCATGTAATTTTTCCT
 caggaaacagctatgaccTGGACTAAAATAGATACGCAGTCTGAA Reverse Intron 2 GAAATGCGTGCCACAGAGAA
3 tgtaaaacgacggccagtGCGGTTATTACCTAACTTGTGATTTCA Forward Intron 2 tgtaaaacgacggccagt
 caggaaacagctatgaccCGCCAATTCTTTCAACCAAGTATT Reverse Intron 3 caggaaacagctatgacc
4 tgtaaaacgacggccagtCTCACAGGAGGTATTTTAAGGCAGTAGT Forward Intron 3 tgtaaaacgacggccagt
 caggaaacagctatgaccAGGATTCTCTTGGGTGATAGTGAAGA Reverse Intron 4 caggaaacagctatgacc
5 tgtaaaacgacggccagtGTTGTATAAGGAAAATTGAGAACTTTGGT Forward Intron 4 tgtaaaacgacggccagt
 caggaaacagctatgaccGAGCAGTAAGAAAAGTACAAATCAAATGA Reverse Intron 5 caggaaacagctatgacc
6 tgtaaaacgacggccagtCTCAAGTTTGTTGGGTGATTTTAGTATG Forward Intron 5 tgtaaaacgacggccagt
 caggaaacagctatgaccCAGACATACAAGCATGTGGACTCTCT Reverse Intron 6 caggaaacagctatgacc
7 tgtaaaacgacggccagtAGGCTTTACTGTGCATAACTTACATCTAG Forward Intron 6 tgtaaaacgacggccagt
 caggaaacagctatgaccCTTGTTTTATTCCTTCATCTGGAGATT Reverse Intron 7 caggaaacagctatgacc
8 tgtaaaacgacggccagtCATTGTAAATGCTCTTATATTCCGATGT Forward Intron 7 tgtaaaacgacggccagt
 caggaaacagctatgaccTGTGCTACTAAGTTAAGATGACAACACAA Reverse Intron 8 caggaaacagctatgacc
9 tgtaaaacgacggccagtGTGGTTGGTTATGTAGGAACACAGA Forward Intron 8 tgtaaaacgacggccagt
 caggaaacagctatgaccATAAAGTGCTCCCTGCCAAGTT Reverse Intron 9 ACACACGATGGAAGTACAGCTTAACT
10 AGAATGGTACAGTTTGGGACCTTTT Forward Intron 9 AGAATGGTACAGTTTGGGACCTTTT
 GATGAAATGACAAGCTACAGACTGAAA Reverse Intron 10 ATCCAATTAGAAAATGAGCAAAAGATATG
11 tgtaaaacgacggccagtCATCACTGTACTTGATAGATGGATTAACC Forward Intron 10 tgtaaaacgacggccagt
 caggaaacagctatgaccGGGCAAAGTAATCAATACAAAACATC Reverse Intron 11 caggaaacagctatgacc
12 tgtaaaacgacggccagtCAAAGAAATAGCCAAGAGCACAGA Forward Intron 11 tgtaaaacgacggccagt
 caggaaacagctatgaccGTGTCTACCCTAAAACAGCGGATTA Reverse Intron 12 caggaaacagctatgacc
13 tgtaaaacgacggccagtAGTATATTCTGGTTTTAAGTGCTTTTCGT Forward Intron 12 tgtaaaacgacggccagt
 caggaaacagctatgaccCACAATGAAAGTAACTAAACACACAGCTT Reverse 3’UTR caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
PRC2 defects in myeloid malignancies
43
2
Supplemental Table 5. Primers used for EZH1 sequencing
Exon PCR primer (5’ to 3’)
Forward/
Reverse
Location Sequence primer (5’ to 3’)
3 GTTGAACTCACACATTTGGGTTCT Forward Intron 2 ATTTCCAGGCAATAAAATGCTATTTC
TCAAAACAAAAGTTAAAAAGAAATTCCA Reverse Intron 3 CCTTTACACTGGGTCAGTATATTGAAAT
4 tgtaaaacgacggccagtTGGGTGACAACAGAGCAAGACT Forward Intron 3 tgtaaaacgacggccagt
caggaaacagctatgaccTGTGTGAGCCACCATACCTTGT Reverse Intron 4 caggaaacagctatgacc
5 tgtaaaacgacggccagtTCTCCAACTGACTTCAAGTGATCTG Forward Intron 4 tgtaaaacgacggccagt
caggaaacagctatgaccGAGAGCATAAAATCTGACAAGTTAGAACA Reverse Intron 5 caggaaacagctatgacc
6 tgtaaaacgacggccagtTGCAGGAAACTCTGGGACAAA Forward Intron 5 tgtaaaacgacggccagt
caggaaacagctatgaccCAGCCATGTGATGACATTGAAATAT Reverse Intron 6 caggaaacagctatgacc
7 tgtaaaacgacggccagtGCATGTGTAGGAGCCAATCAAAT Forward Intron 6 tgtaaaacgacggccagt
caggaaacagctatgaccCTACTTTCTTCTTCACCCAAGTCACA Reverse Intron 7 caggaaacagctatgacc
8 tgtaaaacgacggccagtGGTAGCATATATCAGATAAGTCCAGATAGC Forward Intron 7 tgtaaaacgacggccagt
caggaaacagctatgaccAGGTAATTGAGTAAGCAAGAAATAATCAAA Reverse Intron 8 caggaaacagctatgacc
9 tgtaaaacgacggccagtTTCTCTTATCAACCAGACCTATAAAAAACA Forward Intron 8 tgtaaaacgacggccagt
caggaaacagctatgaccCACTATAATTGAGCAAGGGAAAATAGAAC Reverse Intron 9 caggaaacagctatgacc
10 tgtaaaacgacggccagtTTGATGTCAGAAATGACTGAATTTTGT Forward Intron 9 tgtaaaacgacggccagt
caggaaacagctatgaccTAAGAGCGGTCCCACAGTAACTG Reverse Intron 10 caggaaacagctatgacc
11 tgtaaaacgacggccagtTTGTTAAGCAGCTCTCATTGTTATATGAT Forward Intron 10 tgtaaaacgacggccagt
caggaaacagctatgaccCCCATCTTTACTGTTTACAAAACTTGTAGA Reverse Intron 11 caggaaacagctatgacc
12 tgtaaaacgacggccagtTTTGTGACAAACTACTGATGACAACTG Forward Intron 11 tgtaaaacgacggccagt
caggaaacagctatgaccCTCACAGAAGCACAGGCTCATC Reverse Intron 12 caggaaacagctatgacc
13 tgtaaaacgacggccagtAATGTTCCAGTGGCACTCTGTCT Forward Intron 12 tgtaaaacgacggccagt
caggaaacagctatgaccGCTGGCTCTCAGTCATGTGATG Reverse Intron 13 caggaaacagctatgacc
14 tgtaaaacgacggccagtGATGGACTCTAGCTTCTGTGTACCAA Forward Intron 13 tgtaaaacgacggccagt
caggaaacagctatgaccCTCCTAAGAGGTCTTCTCAGTTGCA Reverse Intron 14 caggaaacagctatgacc
15 tgtaaaacgacggccagtCTGTCTTCTCACTTCAGGTGCTAAAT Forward Intron 14 tgtaaaacgacggccagt
caggaaacagctatgaccTCCAGAAACGACTCTCCCAGAT Reverse Intron 15 caggaaacagctatgacc
16 tgtaaaacgacggccagtTATTTGATTATTGGGAAGGGAGCTT Forward Intron 15 tgtaaaacgacggccagt
caggaaacagctatgaccCCTACTGGGACTGAAGCCTTTATTAA Reverse Intron 16 caggaaacagctatgacc
17 tgtaaaacgacggccagtAGCAGAAAAGAATGGGTTAGACCTT Forward Intron 16 tgtaaaacgacggccagt
caggaaacagctatgaccGGAGTTGCCAAAGAGTTGAACAG Reverse Intron 17 caggaaacagctatgacc
18 ATAACTTGAACTTGCTCTCTTGTGATTC Forward Intron 17 ATAACTTGAACTTGCTCTCTTGTGATTC
GCAGAGGGTAGAGGCTACAGTGA Reverse Intron 18 AAAAGACCACCTTGGGATGAGA
19 tgtaaaacgacggccagtTTAGCACACTGGGCTTCAACAT Forward Intron 18 tgtaaaacgacggccagt
caggaaacagctatgaccAAAAAGCAGATTAGAAAACTAAGATTGAGA Reverse Intron 19 caggaaacagctatgacc
20-21 tgtaaaacgacggccagtTTGATTCATGTTTTCACTGGGAAT Forward Intron 19 tgtaaaacgacggccagt
caggaaacagctatgaccCAGTTTTGTGCCCTCTGGACAT Reverse 3’ UTR caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
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Supplemental Table 6. Primers used for JARID2 sequencing
Exon PCR primer (5’ to 3’)
Forward/
Reverse
Location Sequence primer  (5’ to 3’)
1 tgtaaaacgacggccagtTTCCCAATTTCGGATTTATTTCAAG Forward 5’UTR tgtaaaacgacggccagt
 caggaaacagctatgaccCAACCAAACTAGGCAGACACCAC Reverse Intron 1 caggaaacagctatgacc
Alt 1* tgtaaaacgacggccagtTGGAATAGTCTCTGGGCTGG Forward 5’UTR tgtaaaacgacggccagt
 caggaaacagctatgaccGCCCCAAAATCAAATACGTTC Reverse Intron 1 caggaaacagctatgacc
2 tgtaaaacgacggccagtGGTCGTGGTCACACAGTACG Forward Intron 1 tgtaaaacgacggccagt
 caggaaacagctatgaccGTGCCTAGACCAGGAAGCAC Reverse Intron 2 caggaaacagctatgacc
3 tgtaaaacgacggccagtTTCATCAGCGTTGTGTAGGG Forward Intron 2 tgtaaaacgacggccagt
 caggaaacagctatgaccGGTGAAAACTGGCACCTGAG Reverse Intron 3 caggaaacagctatgacc
4 tgtaaaacgacggccagtATTTTATTGCCGCACGTAGG Forward Intron 3 tgtaaaacgacggccagt
 caggaaacagctatgaccCATGGCAGAGAGTAAAGCTAAGG Reverse Intron 4 caggaaacagctatgacc
5 tgtaaaacgacggccagtTCGGTTTTGTTTCATTGTGG Forward Intron 4 tgtaaaacgacggccagt
 caggaaacagctatgaccCAGCAGAGGCTCTCTTCCAG Reverse Intron 5 caggaaacagctatgacc
6 tgtaaaacgacggccagtCATGGGGATTACAGTTGGAC Forward Intron 5 tgtaaaacgacggccagt
 caggaaacagctatgaccTCACCTCCTGCTTCTTGAGC Reverse Intron 6 caggaaacagctatgacc
7a tgtaaaacgacggccagtCATCCAGGGTCCTTTCTCAC Forward Intron 6 tgtaaaacgacggccagt
 caggaaacagctatgaccCTCCGGCACTTCCTTCTTC Reverse Exon 7 caggaaacagctatgacc
7b tgtaaaacgacggccagtCCAAGAAGATGAAAGGGGC Forward Exon 7 tgtaaaacgacggccagt
 caggaaacagctatgaccTGAAGACTGTGAGGGAACTGC Reverse Intron 7 caggaaacagctatgacc
8 tgtaaaacgacggccagtAAGAAGTACAGGTTGAATGAGGAAC Forward Intron 7 tgtaaaacgacggccagt
 caggaaacagctatgaccAGTGCATAGCACGCTCCAC Reverse Intron 8 caggaaacagctatgacc
9 tgtaaaacgacggccagtCAGGTGTCTGGCCTCATTTG Forward Intron 8 tgtaaaacgacggccagt
 caggaaacagctatgaccGGACAGGATGTCCTCCAGC Reverse Intron 9 caggaaacagctatgacc
10-11 tgtaaaacgacggccagtTTGGGTTGAACTGTGCTCTG Forward Intron 9 tgtaaaacgacggccagt
 caggaaacagctatgaccTTAGAAGGGATTTCCCAGCC Reverse Intron 11 caggaaacagctatgacc
12 tgtaaaacgacggccagtTTCCTTCTTGTTTTAGCGGAAG Forward Intron 11 tgtaaaacgacggccagt
 caggaaacagctatgaccAAGAAGTTACCCACAGGCCC Reverse Intron 12 caggaaacagctatgacc
13 tgtaaaacgacggccagtGTCCCTGAGGGTGACGG Forward Intron 12 tgtaaaacgacggccagt
 caggaaacagctatgaccTGGGAAACCATGTTCAAGTG Reverse Intron 13 caggaaacagctatgacc
14 tgtaaaacgacggccagtGTGCGCATACGTCACCTG Forward Intron 13 tgtaaaacgacggccagt
 caggaaacagctatgaccGCAGGGATGCTTCTGTGTG Reverse Intron 14 caggaaacagctatgacc
15 tgtaaaacgacggccagtGCCCCCTCCACCAAGAAG Forward Intron 14 tgtaaaacgacggccagt
 caggaaacagctatgaccGCAGACACACCCTCCTGTCA Reverse Intron 15 caggaaacagctatgacc
16 tgtaaaacgacggccagtGTGTCCCCTCTGCTGGTG Forward Intron 15 tgtaaaacgacggccagt
 caggaaacagctatgaccCTCCTGGGCAGAGAGCG Reverse Intron 16 caggaaacagctatgacc
17 tgtaaaacgacggccagtTCCTACCTTACCCTCCCAGG Forward Intron 16 tgtaaaacgacggccagt
 caggaaacagctatgaccGGAGTGCCTACATCCAGCC Reverse Intron 17 caggaaacagctatgacc
18 tgtaaaacgacggccagtTGCATGGCTCTCAGGGAC Forward Intron 17 tgtaaaacgacggccagt
 caggaaacagctatgaccTGCAAAGACAGCTTGAATCC Reverse 3’ UTR caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
*Based on transcript ENST00000397311
PRC2 defects in myeloid malignancies
45
2EED SUZ12
EZH1/2
JARID2
AEBP2
RbAp46/48
PCL
SET
A
B
Supplemental Figure 1. Genetic defects in the PRC2 complex. (A) The PRC2 complex consists of three core 
components (indicated in color) and several additional regulatory components (indicated in gray). SET indicates 
the catalytic domain of EZH2. (B) SNP array profile of chromosome 6 of an MDS patient (UPN064) showing a 5-Mb 
deletion at 6p22.3 in the neoplastic MDS cells, which is absent in the T cells. The deletion encompasses a total of 15 
annotated genes, among which JARID2. The deletion starts within intron 1 of JARID2 leading to a deletion of almost 
the entire gene. UPN indicates unique patient number.
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Abstract
We assessed the prognostic impact of TET2 mutations and mRNA expression in a prospective 
cohort of 357 adult AML patients <60 years of age enrolled in the European Organization 
for Research and Treatment of Cancer (EORTC)/Gruppo Italiano Malattie Ematologiche 
dell’Adulto (GIMEMA) AML-12 06991 clinical trial. In addition, the co-occurrence with other 
genetic defects and the functional consequences of TET2 mutations were investigated. 
TET2 mutations occurred in 7.6% of the patients and were an independent marker of poor 
prognosis (p=0.024). TET2 and IDH1/2 mutations strongly associated with aberrations in the 
DNA methyltransferase DNMT3A. Functional studies confirmed previous work that neither 
nonsense nor missense TET2 mutations induced 5-hydroxymethylcytosine formation. In 
addition, we now show that mutant TET2 forms did not act in a dominant-negative manner 
when co-expressed with the wild-type protein. Finally, as loss-of-function TET2 mutations 
predicted poor outcome, we questioned whether low TET2 mRNA expression in cases of AML 
without TET2 mutations would affect overall survival. Notably, also AML patients with low 
TET2 mRNA expression levels showed inferior overall survival.
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Introduction
Recently, a number of novel recurrent alterations have been described in adult AML, 
among which a group of epigenetic modifiers including TET2, ASXL1, BCOR, DNMT3A, IDH1 
and IDH2.1,2 Verifying the relevance of these new genes as prognostic markers is crucial 
before they can be implemented into clinical practice to improve risk-adapted treatment. 
Understanding the molecular biological consequences of genetic mutations allows the 
development and application of targeted forms of therapy, aiming at the impaired proteins 
or the biological pathways they are involved in. TET2 aberrations occur in various myeloid 
neoplasms. Mutations were found in 20-25% of myelodysplastic syndromes,3,4 10-15% 
of myeloproliferative neoplasms,5 and up to 50% of chronic myelomonocytic leukemias.6 
In AML, TET2 mutations affect 7-10% of the adulthood cases3-5 and 1.5-4% of pediatric 
cases.7,8 The impact of TET2 mutations on clinical outcome in AML is still controversial. In 
some studies, TET2 mutations correlated with inferior survival, particularly in the subgroup 
of cytogenetically normal AML, whereas in other studies no prognostic impact of TET2 
mutations was observed.9-15 So far, few prospectively collected cohorts have been analyzed 
for the impact of TET2 mutations using multivariate analysis, and including the currently 
established genetic and other prognostic parameters.10-12,14
Several studies based on mouse models have shown that inactivation of TET2 in myeloid 
cells induces a myeloproliferative syndrome, confirming the role of TET2 mutations in the 
pathogenesis of myeloid malignancies.16-18 The TET protein family comprising TET1, TET2 and 
TET3, belongs to the group of 2-oxoglutarate (2OG)- and Fe(II)-dependent dioxygenases, and 
is involved in a novel epigenetic modification, namely the conversion of 5-methylcytosine 
(5mC) into 5-hydroxymethylcytosine (5hmC).19 TET proteins further oxidize 5hmC to 
formyl- and carboxylcytosine (5fC and 5caC). 5fC and 5caC are recognized by the thymine-
DNA glycosylase (TDG), and replaced by unmodified cytosines through the DNA repair 
machinery.20,21 Mapping of TET protein binding sites and 5hmC on the genome has shown 
that they localize to the transcription start sites of genes, suggesting a role for the TETs in the 
regulation of gene expression through modification of chromatin at promoter regions.22-24
In this study, we assessed the incidence and clinical impact of TET2 mutations in a 
prospective cohort of 357 AML patients who were treated uniformly according to the EORTC/
GIMEMA AML-12 06991 clinical trial protocol. We determined the co-occurrence of TET2 
mutations with other molecular markers. In addition, the function of different TET2 isoforms 
and TET2 mutants was tested in cell line models. Finally, mRNA levels of TET2 were measured 
and correlated to survival.
Materials and methods
Patients
Bone marrow samples from 357 patients included in the EORTC/GIMEMA 06991 AML-1225 
clinical trial NCT0004128 (1999-2009) were obtained at diagnosis. Informed consent was 
obtained from all patients included in the study. To avoid bias, consecutive patients from the 
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larger participating centers were included in the analysis. Median age was 46 years (range 15-
60 years) and median follow-up was 5.63 years. The study was approved by the Institutional 
Review Board of the Radboud University Nijmegen Medical Centre and all aspects of this 
study abided by the principles laid out in the declaration of Helsinki. All patients had untreated 
newly diagnosed AML, ≥30% blast cells in bone marrow smears, and represented all AML FAB 
subtypes, except AML-M3. Briefly, the AML-12 trial assessed the value of high vs. standard 
dose Ara-C during induction, as well as IL-2 after intensive consolidation/autologous stem cell 
transplantation.
qPCR and mutational analysis
For qPCR analysis RNA was isolated from healthy donor-derived G-CSF-mobilized CD34+ cells, 
or patient-derived bone marrow or peripheral blood mononuclear cells. mRNA levels of 
TET2 isoform 1 and isoform 2, TET1 and TET3, were determined as previously described.3,4 
DNA sequencing of TET2 isoform 1 (NM_001127208.2) was performed as described.3 
cDNA sequencing primers are listed in Supplemental Table 1. EVI1, IDH1 R132, IDH2 R140 
and R172 detection was performed as described.26,27 Direct DNA sequencing of DNMT3A 
(ENST00000264709) was performed on exons 7-23 either by Sanger sequencing (primer 
sequences listed in Supplemental Table 2) or 454-based next generation sequencing (NGS; 
454 Life Sciences, Branford, CT, USA).28 NGS data were analyzed using R453Plus1Toolbox, 
GS Variant Analyzer Software 2.6 (454 Life Sciences) and Sequence Pilot version 3.5.2 
(JSI Medical Systems, Kippenheim, Germany).29 NPM1 and FLT3 mutation analyses were 
developed previously.30,31
Statistical analysis
Overall survival (OS) was computed from the date of registration in the EORTC 06991 study 
until death (by any cause) or until last follow-up (censored observation). Survival distribution 
of OS was estimated according to the Kaplan-Meier technique. The Cox Proportional Hazards 
Model was used to determine the prognostic importance of each factor analyzed and to 
obtain hazard ratio (HR) estimates as well as corresponding 95% confidence intervals (95% 
CI). All statistical analyses were performed according to the intention-to-treat principle. Being 
a prognostic factor analysis, only eligible patients were included. For contingency tables, the 
significance of a relationship between 2 categorical variables, the Fisher exact test was used. 
Statistical analyses were performed by using SAS® (Cary, USA).
Plasmids used for overexpression in cell line models
N-terminally tagged eGFP-TET2 isoform 1 plasmid was kindly provided by Dr. O. Bernard. 
TET2 isoform 1 (NM_001127208.2), TET2 isoform 2 (NM_017628.4), TET2 catalytic domain 
(a.a. 1104 - a.a. 2002), TET2 box 2 (a.a. 1789 - a.a. 2002) sequences were cloned into 
pDONR201 using the Gateway cloning technology (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. The entry vectors were further transferred into 
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a Gateway-based pDest733 destination vector32 to create N-terminal mRFP fusion proteins. 
TET2 mutant sequences were generated using the QuikChange XL site-directed mutagenesis 
kit (Stratagene, Agilent technologies, CA, USA) as recommended by the manufacturers 
and cloned into pDONR201. The entry vectors were used for transfer into pDest733 and 
pDest501 Gateway-based expression plasmids to create N-terminal mRFP and eCFP fusions, 
respectively.
Cell culture, transfection and immunofluorescence
COS-1 cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM; Life technologies) 
supplemented with 10% fetal calf serum and penicillin and streptomycin. Cells were 
transfected with Lipofectamin 2000 reagent (Life technologies). Proteins were expressed for 
20-24h. Subsequently, cells were fixed with 4% PFA for 20 min, washed extensively with PBS 
and permeabilized with 0.5% Triton X-100 in PBS for 5 min. To allow detection of 5hmC, cells 
were treated with 2M HCl for 20-25 min. HCl was neutralized with 100mM Tris-HCl (pH=8) for 
10 min, followed by extensive washing with PBS. A blocking step was performed with 5% BSA 
in PBS/Tween for 30 min. Afterwards, samples were incubated with a primary antibody against 
5hmC (Active motif, CA, USA; 1:500 dilution) for 2h at room temperature and subsequently 
washed with PBS. To allow primary antibody detection, the following secondary antibodies 
were used: Alexa 488 (Life technologies; 1:500 dilution) or Alexa 350 (Life technologies; 
1:50 dilution). Samples were mounted with Vectashield with DAPI or Antifade Prolong Gold 
(in the case of Alexa 350). Samples were analyzed with a Leica DMBRE (type 301-371.011) 
microscope. Images were taken at 40x or 100x magnification using a DC350F (10447116) 
camera and Leica FW4000 acquisition software (Leica Microsystems, Wetzlar, Germany).
Results
TET2 mutations correlate with poor overall survival in AML in univariate analysis
Bidirectional Sanger sequencing of the entire TET2 coding region, and the splice donor and 
acceptor sites, revealed mutations in 27/357 (7.6%) of the patients (for detailed patient 
characteristics see Table 1; localization of mutations is depicted in Supplemental Figure 1). In 
19 of the cases, mutations affected one allele, whereas in 8 patients two TET2 aberrations co-
existed, suggesting bi-allelic inactivation (for detailed patient characteristics of TET2-mutated 
patients see Table 2). In univariate analysis, the various cytogenetic subtypes showed the 
expected correlations with overall survival, with the t(8;21) and inv(16) translocations 
correlating with a good prognosis, and -5, -7, and complex karyotypes signifying poor outcome 
(Supplemental Figure 2A). NPM1 mutations did, however, not have prognostic impact 
(Supplemental Figure 2B). In line with published data, the presence of a FLT3-ITD mutation 
correlated with inferior clinical outcome (p<0.0001), whereas a FLT3-TKD mutation associated 
with intermediate or slightly better survival (Supplemental Figure 2C-D). Furthermore, EVI1 
overexpression was strongly associated with inferior prognosis (p=0.0004; Supplemental 
Figure 2E).
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Table 1. Clinical and molecular characteristics according to TET2 mutation status in 357 adult 
AML patients
TET2 mutation Correlation to 
TET2 mutation 
(p-value)
Hazard ratio 
(95% CI)
p-value 
(Wald test)No (n=330) Yes (n=27)
N (%) N (%)
Type of AML De novo 311 (94.2) 27 (100) 0.38
Secondary 19 (5.8) 0 (0.0) 
Sex Male 160 (48.5) 13 (48.1) 0.97
Female 170 (51.5) 14 (51.9)
Age (years) at Median 45.0 54.0
diagnosis Range 15.0  - 60.0 24.0  - 59.0
15-25 36 (10.9) 1 (3.7) 0.015 1.0 0.05 
26-45 133 (40.3) 6 (22.2) 1.33 (0.79, 2.25)
46-60 161 (48.8) 20 (74.1) 1.71 (1.03, 2.85)
WHO-ECOG perfor- PS 0 181 (54.8) 13 (48.1) 0.65 1.0 0.11
mance status PS 1 119 (36.1) 12 (44.4) 0.89 (0.66, 1.19)
PS 2 22 (6.7) 1 (3.7) 1.30 (0.76, 2.23)
PS 3-4 8 (2.4) 1 (3.7) 2.03 (0.99, 4.17)
WBC (x109/l) at Median 21.5 32.1
diagnosis Range 0.5  - 319.6 1.1 - 240.8
< 25 183 (55.5) 13 (48.1) 0.69 1.0 0.44
25-99.9 105 (31.8) 10 (37.0) 1.16 (0.86, 1.56)
>= 100 42 (12.7) 4 (14.8) 1.09 (0.72, 1.64)
FAB subtype M0 13 (3.9) 1 (3.7) 0.06 1.0 0.16
M1 87 (26.4) 2 (7.4) 1.21 (0.55, 2.65)
M2 93 (28.2) 9 (33.3) 1.18 (0.54, 2.59)
M4 60 (18.2) 3 (11.1) 0.91 (0.40, 2.08)
M5 65 (19.7) 11 (40.7) 1.53 (0.69, 3.37)
M6 6 (1.8) 1 (3.7) 2.23 (0.75, 6.64)
M7 1 (0.3) 0 (0.0) 4.72 (0.58, 38.64)
Unknown 5 (1.5) 0 (0.0) -
Cytogenetic risk Good 41 (12.4) 0 (0.0) 0.004 1.0 <0.0001
group Intermediate 
(NN,-Y)
111 (33.6) 15 (55.6) 2.63 (1.40, 4.97)
Others 73 (22.1) 1 (3.7) 3.17 (1.65, 6.11)
Poor (-5/5q-,-
7/7q-, Complex)
29 (8.8) 1 (3.7) 6.16 (3.01, 12.60)
UNK/ND/
Failure
76 (23.0) 10 (37.0) -
NPM1 mutation No 224 (67.9) 13 (48.1) 0.03 1.0 0.67
Yes 102 (30.9) 14 (51.9) 0.94 (0.70, 1.25)
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Unknown 4 (1.2) 0 (0.0) -
FLT3-ITD No 254 (77.0) 19 (70.4) 0.48 1.0 <0.0001
Yes 73 (22.1) 8 (29.6) 2.39 (1.78, 3.20)
Unknown 3 (0.9) 0 (0.0) -
FLT3-TKD No 294 (89.1) 22 (81.5) 0.31 1.0 0.19
Yes 30 (9.1) 4 (14.8) 0.73 (0.46, 1.17)
Unknown 6 (1.8) 1 (3.7) -
IDH1 mutation No 288 (87.3) 24 (88.9) 0.24 1.0 0.08
Yes 28 (8.5) 0 (0.0) 1.50 (0.96, 2.36)
Unknown 14 (4.2) 3 (11.1) -
IDH2 mutation No 278 (84.2) 22 (81.5) 1.0 1.0 0.49
Yes 36 (10.9) 2 (7.4) 0.86 (0.55, 1.33)
Unknown 16 (4.8) 3 (11.1) -
IDH mutation No 254 (77.0) 22 (81.5) 0.28 1.0
Yes 62 (18.8) 2 (7.4) 1.07 (0.76, 1.51) 0.69
Unknown 14 (4.2) 3 (11.1) -
EVI1 overexpres- No 103 (31.2) 7 (25.9) 1.0 1.0 0.0004
sion Yes 7 (2.1) 0 (0.0) 3.94 (1.75, 8.88)
Unknown 220 (66.7) 20 (74.1) -
DNMT3A mutation No 50 (15.2) 6 (22.2) 0.02 1.0 0.04
Yes 18 (5.5) 9 (33.3) 1.73 (1.01, 2.99)
Unknown 262 (79.4) 12 (44.4) -
CI indicates confidence interval; WBC, white blood cell count; PS, performance status; ITD, internal tandem dupli-
cation; TKD, tyrosine kinase domain.
The presence of a TET2 mutation correlated with poor overall survival (p=0.025; Figure 
1A). IDH2 mutations did not show a significant effect on overall survival (Figure 1C), whereas 
a trend towards poor prognosis was present in patients with an IDH1 mutation (p=0.075; 
Figure 1D). Finally, DNMT3A mutations also predicted unfavorable outcome (p=0.04; Figure 
1B).
Association of TET2 mutations with other prognostic features including molecular 
and cytogenetic markers
TET2 mutations correlated with older age, and were almost exclusively present in the group 
of cytogenetically normal AML (Table 1). We found no association between TET2 mutations 
and performance status or WBC at diagnosis. There was, however, an association between 
TET2 mutations and FAB subtype (p=0.06). TET2 mutations were less frequent in AML-M1, 
and enriched in AML-M5 patients. NPM1 and TET2 defects were significantly correlated 
(p=0.03), whereas FLT3-ITD and FLT3-TKD aberrations were often present together with 
TET2 mutations but their co-occurrence did not reach statistical significance. TET2 and IDH 
mutations seldom co-existed in the same patient as may be expected since IDH mutations
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Table 2. Characteristics of TET2 mutated patients
UPN TET2 mutation by sequencing Cytogenetics FLT3-ITD, FLT3-TKD, IDH1, 
IDH2, DNMT3A, NPM1, EVI1 
overexpression
Non-
sense
Frameshift/
In-frame deletion
Missense/
Splice site
36
p.S1039L 46,XX IDH2 p.R172L, DNMT3A 
p.F640Y
98 p.R1359H 46,XY NPM1
171 p.A31T 46,XX -
329 p.P1115LfsX2 46,XX NPM1, FLT3-ITD, DNMT3A 
IVS9-1G>T
356 p.N275IfsX18 46,XX FLT3-ITD, DNMT3A p.R882C
362* p.R1896M 46,XX,t(4;7)(q24;q21) 
[19]/46,XX [1] 
NPM1, FLT3-TKD
379 p.Q255X Failure -
404 p.Q414X Unknown -
729 p.S358R 46,XY NPM1
791 p.I1873N 45,XY,-7,del(20)(q11) -
806* p.P929LfsX24
p.S137VfsX8
46,XY NPM1, FLT3-ITD, DNMT3A 
p.D252X
858 p.L956V Failure NPM1, FLT3-ITD
879 p.Q742K Unknown NPM1, FLT3-ITD
893 p.I750_K753 46,XY -
1062 p.I1873N 46,XY -
1266* p.G1869E
IVS2-2A>G
46,XX NPM1, FLT3-TKD, DNMT3A 
p.N501S, DNMT3A p.R882H
1398 p.H850R 46,XY NPM1, FLT3-ITD, DNMT3A 
p.R882H
1456 p.Q831TfsX15 46,XX FLT3-ITD, DNMT3A p.R882H
1552* p.Q917X Failure -
1612* p.C1378R
p.P1419R
Failure
-
1744 p.R1572W Failure -
1832 p.T621SfsX13 46,XX NPM1, FLT3-TKD
1879 p.T1397I 46,XX NPM1
1915* p.S1758X p.T1554SfsX16 Failure NPM1, FLT3-TKD
1928* p.Q749X p.D1384N 46,XY NPM1, DNMT3A IVS9del 
-18_+1
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1965 p.S1246L Failure NPM1, FLT3-ITD, DNMT3A 
p.R882H, IDH2 p.R140Q
2112* p.R1261H
p.R1359S
Failure -> FISH: MLL 
(11q23) rearrange-
ment negative; 1 
extra MLL signal 
[44/150] and 2 extra 
MLL signals [74/150]
-
Additional molecular markers that were assessed: FLT3-ITD, FLT3-TKD, IDH1, IDH2, DNMT3A, NPM1 mutation, and 
EVI-1 overexpression. UPN indicates unique patient number. *Patients with more than one affected TET2 allele, 
based on the occurence of two seperate TET2 mutations, or a homozygous mutation as observed in the Sanger-se-
quencing results, pointing to LOH by (micro) deletions or uniparental disomy.
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Figure 1. Univariate analysis assessing the effect of mutations in genes implicated in the DNA (hydroxy)
methylation pathway. (A) TET2 (B) DNMT3A (C) IDH1 and (D) IDH2.
abrogate the activity of TET2.33 Notably, both TET2 and IDH mutations strongly correlated 
with the presence of a DNMT3A mutation (p=0.02 and p=0.004, respectively). Patients who 
carried DNMT3A aberrations together with either a TET2 or an IDH mutation, very frequently 
had an additional FLT3-ITD.
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TET2 mutations represent an independent marker of poor prognosis in AML
Cox regression analysis was performed to determine whether TET2 mutations represent an 
independent marker of poor prognosis. In multivariate analysis, adjusted for age, cytogenetic/
FLT3-ITD risk group, NPM1 mutation, AML type, institution, and stratified by treatment arm, 
TET2 mutations remained an independent predictor of inferior survival (p=0.01, HR=1.86, 
95% CI: 1.15-3.00). Within the poor-risk group of patients carrying a FLT3-ITD and/or a high-
risk cytogenetic profile (-5, -7, complex), which conferred the expected poor overall survival, 
the presence of an additional TET2 mutation defined a subgroup of patients with an even 
more dismal prognosis (p=0.033; Figure 2A). NPM1 mutations had only a minor effect towards 
favorable outcome in the cytogenetically normal subgroup without FLT3-ITD (Supplemental 
Figure 2B). Also within the NPM1-mutated group, TET2 mutations conferred a trend towards 
worse survival (p=0.061; Figure 2B). Finally, as DNMT3A and TET2 mutations frequently co-
occurred (Table 1), and DNMT3A mutations correlated with inferior survival (Figure 1B), we 
tested what the effect of TET2 mutations would be in the context of a concomitant DNMT3A 
mutation. Also in the DNMT3A-mutated subgroup, the presence of a TET2 mutation further 
exacerbated the poor prognosis of patients (p=0.066; Figure 2C). Treatment with standard or 
high dose Ara-C did not alter the effect of TET2 mutations, as these mutations remained a 
poor indicator of prognosis in both patient groups (Supplemental Figure 3).
Figure 2. Kaplan-Meier survival curves of cytogenetic and genetic subgroups. An unfavorable effect of TET2 
mutations on overall survival was observed within the cytogenetic high risk and/or FLT3-ITD-positive patients (A), 
NPM1-mutated (B), and DNMT3A-mutated patients (C).
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Figure 3. TET2 mutant proteins show impaired catalytic activity, but do not exhibit dominant-negative features 
when co-expressed with wild-type protein. (A) Localization of TET2 mutations found in patients with myeloid 
malignancies used for functional testing. Two of the mutants result in truncated proteins lacking either both 
conserved boxes within the catalytic region, or only the second conserved box, whereas the rest of the mutants 
result in missense substitutions in the conserved boxes. All aberrations leading to amino acid changes have been 
confirmed, either by us or others, as true acquired somatic mutations. The H1881Q mutation targets an Fe(II)-
binding site in the catalytic domain of TET2. (B) Mutant forms of TET2 found in patients are unable to produce 5hmC 
unlike wild-type protein. Constructs contain an N-terminal mRFP tag. Images were taken at 40x magnification. (C) 
mRFP-tagged mutant forms of TET2 do not act in a dominant-negative manner over wild-type GFP-TET2. Images 
were taken at 100x magnification.
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Functionality of different TET2 splice and truncation variants
Although studies so far have always focused on the longest isoform of TET2 (isoform 1), there 
are three major TET2 transcripts that may be expressed in cells, as we previously showed 
(Supplemental Figure 4A).3 The shorter isoforms lack the catalytic domain and their function 
remains unknown. The expression levels of isoform 1, and of the shorter form, isoform 2, 
are comparable. Furthermore, isoform 2 is reminiscent of some of the truncation mutants 
found in patients.3 To investigate whether isoform 2 exhibits dominant-negative features, we 
tested its effect on the capacity of isoform 1 to generate 5hmC. Several expression constructs 
were created that contained TET2 isoform 1, TET2 isoform 2, the catalytic domain (CD), 
and the second conserved region of the catalytic domain (box 2; Supplemental Figure 4B). 
To monitor expression, all proteins were N-terminally fused to monomeric red fluorescent 
protein (mRFP). COS-1 cells were transiently transfected with each of the expression vectors 
and immunostaining was performed using an antibody specific for 5-hydroxymethylcytosine. 
Expression of isoform 1 and the isolated catalytic domain resulted in a clear formation 
of 5hmC. Isoform 2 and the isolated, conserved box 2 showed no enzymatic activity 
(Supplemental Figure 4C). Importantly, co-expression of isoform 2 with isoform 1 did not 
inhibit the generation of 5hmC (Supplemental Figure 4D), implying that isoform 2 does not 
exhibit dominant-negative properties.
TET2 mutations result in loss of function and are not dominant-negative
Mutations in TET2 are scattered throughout the entire coding region of the gene and may 
result in the production of truncated proteins, as well as single amino acid substitutions. 
In vitro studies and mouse models have suggested that likely all TET2 mutations lead to 
loss of function. Moreover, in patients, despite the presence of a wild-type allele, DNA 
hydroxymethylation is strongly reduced.34 It remains, however, possible that the mutant 
protein inhibits the function of the wild-type allele in a dominant-negative fashion. To test 
this, six mutant TET2 sequences were cloned into expression vectors, each N-terminally 
fused to mRFP. Two nonsense mutations were selected that either delete both conserved 
boxes (R506X) - hence the whole catalytic domain - or yield a protein containing only the 
first conserved box (box 1), causing a partial deletion of the catalytic domain (S1758X). 
Additionally, four missense substitutions were generated, two in box 1 (R1214W and R1261L) 
and two in box 2 (I1873T and H1881Q; Figure 3A). All six mutants, including the single 
amino acid substitutions, lost the capability to generate 5hmC (Figure 3B). Furthermore, co-
expression of GFP-tagged wild-type TET2 with each of the mutant proteins did not result 
in loss of hydroxymethylation, indicating that, with respect to the formation of 5hmC, the 
mutants are not dominant-negative (Figure 3C).
Effect of wild-type TET2 on survival of AML patients
As diminished TET2 function appears to be the mechanism through which mutations in this 
gene contribute to oncogenesis, and patients who carry TET2 mutations show a significantly 
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Figure 4. Effect of aberrant TET2 expression on survival. Aberrant expression of the wild-type TET2 isoform 1 has a 
negative impact on overall survival (A), whereas the TET2 isoform 2 expression has no effect on survival (B).
worse overall survival, we tested whether the expression levels of isoforms 1 and 2 of TET2 
may impact clinical outcome in patients without a TET2 or IDH mutation. The mRNA levels 
of both isoforms varied between different patients. No significant differences in expression 
were observed between patients with and without a TET2 mutation (Supplemental Figure 
5A). When compared to mRNA levels of TET2 in CD34+ cells, AML patients showed expression 
levels that were distributed in a wider range (Supplemental Figure 5B). The median levels of 
TET2 expression in patients were similar to those measured in healthy CD34+ control cells. 
There was no difference in overall survival when TET2 isoform 2 expression was considered 
(Figure 4B). In contrast, overall survival analysis showed that low TET2 isoform 1 expressers 
had an inferior clinical outcome (p=0.05; Figure 4A).
Discussion
The prognostic significance of TET2 mutations in AML patients has been controversial. 
Initially, Abdel-Wahab et al.9 showed an association with poor OS in a smaller, retrospective 
study, whereas Nibourel et al.13 reported no correlation between TET2 mutational status and 
clinical outcome, albeit in a pre-selected group of de novo AML patients achieving complete 
remission. Consequently, studies involving larger cohorts of patients were explored. Shen 
et al.14 found no prognostic significance for TET2 mutations in 605 de novo AML patients 
who had no other recognizable karyotypic abnormalities except 11q23, and Metzeler et al.12 
identified TET2 mutations as a predictor of inferior survival in favorable risk cytogenetically 
normal primary AML patients, as defined by the European LeukemiaNet (ELN) guidelines. 
Chou et al.10 defined TET2 aberrations as a marker of poor prognosis in AML patients of 
intermediate risk, and Weismann et al.15 also showed a negative impact of TET2 mutations 
on survival in favorable risk AML patients with normal cytogenetics. Most recently, Gaidzik 
et al.11 did not find a prognostic impact of TET2 mutations in 330 cytogenetically normal 
AML patients. In the current study, we show a negative prognostic impact of TET2 mutations 
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in a sizeable, prospectively studied cohort of adult AML patients <60 years of age. The 
negative effect of TET2 mutations on overall survival was present in various risk groups. In 
accordance with previous reports, TET2 mutations were significantly associated with older 
age. In addition, TET2 alterations were reported in normal elderly individuals with clonal 
hematopoiesis35 and TET2 mutations were shown to be present in a pre-leukemic stage of 
leukemia evolution.36 Furthermore, TET2 mutations are found in many different subtypes 
of myeloid malignancies. This suggests that cells carrying TET2 defects may clonally expand, 
but that additionally acquired mutations mostly determine the subtype and severity of the 
disease that eventually causes clinical problems.
It has previously been noted that TET2 and DNMT3A mutations co-occur in T-cell 
lymphomas.37 In AML, a correlation between IDH and DNMT3A mutations has been 
observed.14 In the present study, we show that both TET2 and IDH mutations were enriched 
in patients who also carried a DNMT3A defect. Although DNMT3A mutations conferred poor 
prognosis (in line with previous work38), the additional presence of TET2 alterations in these 
patients defined a subgroup with a particularly unfavorable outcome. As established earlier, 
TET2 and IDH mutations were mutually exclusive since both groups of mutations perturb a 
common biological pathway.33,39,40 The high incidence of DNMT3A mutations in both of these 
groups is highly indicative of a cooperative mechanism through which mutations impairing 
DNA hydroxymethylation and DNA methylation contribute to leukemogenesis. Further 
functional characterization of this interaction in in vivo models is necessary and may provide 
important insights into targeted therapies aimed at the DNA (de)methylation pathway within 
patients with this particular genetic profile.
Testing of TET2 mutations in vitro34 as well as in mouse models consistently points to a 
loss-of-function phenotype.16-18,41 This is further supported in this manuscript. In addition, we 
show that TET2 mutants do not suppress the function of the wild-type protein, and hence 
do not show dominant-negative traits. As mRNA levels of TET2 in AML patients varied over a 
wide range compared to normal hematopoietic cells, this raised the possibility that the level 
of TET2 mRNA expression could be relevant in patients who do not carry loss-of-function 
mutations of the TET2 gene. Analysis of the effect of wild-type TET2 expression on clinical 
outcome in patients without TET2 or IDH mutations demonstrated that patients with low 
levels of TET2 expression had a worse overall survival. We conclude that both loss-of-function 
mutations and low expression of TET2 are markers of poor prognosis in AML indicating that 
the development of therapies targeting the DNA hydroxymethylation pathway could be 
beneficial for these patients.
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Supplemental data
Supplemental Table 1. Primers used for cDNA sequencing of TET2
Exon Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
3 CAGTTTGCTATGTCTAGGTATTCCGA TGTGCGTTTTATTCCTCCATTTT
3 CAGAATAGTCGTGTGAGTCCTGAC GCAATGGAAACACAATCTGGA
3 GAACACACACATGGTGAACTCC AATTGTGATGGTGGTGGTGG
3 TCCAGGGAACCACAAAGCTAG GCTTGAGGTGTTCTGACATTGG
3 ACATGTATGCAGCCCTTCTCC GGGAATCTGCTCTTTGTTGAAA
3 ACCAACATCTCCAGTTCCAA ATGCACTTGATTTCATGGTCT
3 CAAATGGGACTGGAGGAAGT GTTTGCTGCTGTTCTTGCTT
3 CAGAAGGACACTCAAAAGCATG TTGCTGCTCTAAAGCTGGG
3 GAGAATCCACCTGCAAGCTG TTTCACAAGACACAAGCATCG
3-6 GAGCAGGTCCTAA TAAGCTGCTTGGGGATGACC
6-9 TGTACTACAATGGATGTAAGTTTGCC GACTTGCCGACAAAGGAAACTAGA
9-10 AAGTCAGGATGTTAGCAGAGCCA GGCTTTTGAATCAGAATACCCAA
10 CCAGCCCTATGAACTTCTATTC CCATAACTACAGTGCAGCTCCG
10 CAAACATGGACTATAAAAATGGTGAAC CACCAGGATCTCCCTCGTCTT
10 GCCGTGGCTCCAACTCAT GGCAGTGGGGAAAGGTCAC
Supplemental Table 2. Primers used for Sanger sequencing of DNMT3A exon 7 till 23
Exon Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
7 CTAATTCCTGGAGAGGTCAAGGTG AGATGGAGAGAGGAGAGCAGGAC
8 TCTTGCCTCATTCAGATGGAGC CCTGGGATCAAGAACCTTCCC
9 GTGCTTGCAAGTGTAAGCCTCG CCTGCACTCCAACTTCCAGG
10 GCCTTCCAGCCTGTCCTGA CCAACTCTACGGTTCTAGCCAAC
10-11 GCCTTCCAGCCTGTCCTGA GTACACCAGCCGCTCTGCA
11-12 GTTGGCTAGAACCGTAGAGTTGG CTAAGTGCCTCTGCTACTCTGCC
13 GTTCGAGACTGGGGTCACAGT AGAAGCGGTGGACACAGTCAG
14 GGTCATGTCTTCAGGGCTTAGG TGCTACCTGGAATGGAAAGACC
15 TTTCCATTCCAGGTAGCACACC AGGCTCCTAGACCCACACACC
16 AGGGTGTGTGGGTCTAGGAGC GCTGTGAAGCTAACCATCATTTCG
17 GTGGGGTAGAATTGTAGCAGGA ATGAACAAAATGAAAGGAGGCAA
18-19 TTCCTGTCTGCCTCTGTCCCT CAGCAGTCCAAGGTAGAAGCCA
20 ATTAACCATTCAGCTCCTCAATCAC TGCAGTCCCAGCCCACAG
21 GTTATGACGTGTGTGCGTGATT CCTGCACCGTCTCCTAAATTG
22 GTTTGGCGAGTACCTGGCATATT GGAAAACAAGTCAGGTGGGAAAG
23 CTGCTGTGTGGTTAGACGGCTT TGCAATAACCTTCTTGTTTCAGTCA
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Supplemental Figure 1. Schematic representation of the position of TET2 mutations found in 357 patients with 
AML. A total of 33 mutations was found in 27 patients. Indicated are missense mutations leading to amino acid 
substitutions (dark boxes) and nonsense and frameshift mutations leading to stop codons (light boxes). The splice 
site defect in subject 1266 is shown in the beginning of the protein since it affects the first coding exon of the 
gene (exon 3). The catalytic domain of TET2, including the highly, cross-species conserved domains (box 1 and 2), is 
indicated. Ruler denotes amino acid number, UPN indicates unique patient number.
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Supplemental Figure 2. Univariate analysis indicating the effect of various cytogenetic (A) and molecular markers 
(B-E) on overall survival in 357 patients with AML. FLT3-ITD and overexpression of EVI1 correlated with significantly 
inferior overall survival, whereas FLT3-TKD and NPM1 mutations did not significantly affect clinical outcome.
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Supplemental Figure 3. Overall survival of patients treated with standard dose Ara-C (A), or high-dose Ara-C (B).
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Supplemental Figure 4. Enzymatic activity (conversion of 5mC to 5hmC) of various TET2 isoforms and truncation 
mutants. (A) Schematic representation of the three major TET2 transcripts. (B) Schematic representation of TET2 
isoform 1 (TET2 iso1); TET2 isoform 2 (TET2 iso2); Catalytic Domain (CD) of TET2 isoform 1 (a.a. 1104 – a.a. 2002); 
and second conserved region of TET2 isoform 1 (box2, a.a. 1789 – a.a. 2002).
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Supplemental Figure 4 (continued). Enzymatic activity (conversion of 5mC to 5hmC) of various TET2 isoforms 
and truncation mutants. (C) Upon overexpression in COS-1 cells both the full length TET2 isoform 1 and the isolated 
catalytic domain (box 1 and 2) are able to generate 5hmC. TET2 isoform 2, as well as the isolated conserved box 
2, lack this ability. (D) Co-expression of isoform 1 together with isoform 2 does not inhibit the formation of 5hmC.
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Supplemental Figure 5. (A) Expression of TET2 isoform 1 and isoform 2 relative to GAPDH in TET2 wild-type AML 
patients (isoform 1 n=164; isoform 2 n=162) vs. TET2-mutated individuals (n=13). Filled triangles indicate single TET2 
mutation; empty triangles indicate two TET2 mutations. (B) Expression of TET2 isoform 1 and isoform 2 relative to 
GAPDH in cells from AML patients (including non AML-12; n=218) vs. donor derived CD34+ cells (n=9).
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Abstract
Patients with acute myeloid leukemia (AML) frequently harbor mutations in genes involved 
in the DNA (hydroxy)methylation pathway (DNMT3A, TET2, IDH1 and IDH2). In this study, 
we measured 5-hydroxymethylcytosine (5hmC) levels in 206 clinically and molecularly well-
characterized younger adult AML patients (≤60 years) included in the European Organization 
for Research and Treatment of Cancer/Gruppo Italiano Malattie EMatologiche dell’Adulto 
(EORTC/GIMEMA) AML-12 06991 clinical trial and correlated the 5hmC levels with mutational 
status and overall survival (OS). In healthy control cells, 5hmC levels were confined to a 
narrow range (1.5-fold difference), whereas in AML cells, a much wider range was detected 
(15-fold difference). We identified three 5hmC subpopulations in our patient cohort (low, 
intermediate, and high). The low 5hmC group consisted almost entirely of patients with 
TET2 or IDH mutations. As expected, TET2- and IDH-mutated patients had significantly 
lower levels of 5hmC compared to patients without mutated TET2 and IDH1/2 (both 
p<0.001). Interestingly, high 5hmC levels correlated with inferior OS (high vs intermediate 
5hmC: p=0.047, hazard ratio [HR]=1.81). Multivariate analysis revealed that high 5hmC is an 
independent poor prognostic indicator for OS (high vs intermediate 5hmC: p=0.01, HR=2.10). 
This trial was registered at www.clinicaltrials.gov as NCT00004128.
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Introduction
Alterations in DNA methylation occur in many types of cancer, including hematological 
malignancies. Global hypomethylation as well as promoter hypermethylation leading to 
silencing of various tumor suppressor genes have been described.1,2 Because DNA methylation 
is reversible, it represents a promising target for therapy. In several clinical trials, the effect 
of hypomethylating agents (azacitidine and decitabine) on the treatment of patients with 
myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) has been assessed,3-6 
which may result in the reactivation of silenced genes. These trials showed promising 
results for intermediate-1 to high-risk MDS and elderly AML patients by improving complete 
remission rates, event-free survival, and overall survival (OS).
In the last few years, our knowledge of DNA (de)methylation has grown extensively. It 
has been known for a few decades that DNA methyltransferases (DNMTs) are responsible 
for the conversion of cytosine into methylcytosine. DNMT3A and DNMT3B are de novo 
DNMTs, whereas DNMT1 is mainly implicated in maintaining methylcytosine marks 
during DNA replication.7 DNA demethylation can take place as a passive process when the 
5-methylcytosine (5mC) mark is not sustained during DNA replication. Only recently, evidence 
for an active DNA demethylation process has been presented. In 2009 it was discovered 
that the Ten-Eleven-Translocation (TET) protein family, consisting of TET1, TET2, and TET3, 
mediates the conversion of 5mC into 5-hydroxymethylcytosine (5hmC).8 5hmC can be further 
oxidized by TET proteins to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), which 
are both recognized by thymine DNA glycosylase. Subsequently, thymine DNA glycosylase 
activates the base excision repair pathway, which replaces the modified cytosine with an 
unmodified cytosine, thereby completing the active demethylation process.9-11 Neuronal cells 
and stem cells display remarkably high levels of 5hmC, suggesting that 5hmC may be a rather 
stable mark with a more versatile function besides being an intermediate in the active DNA 
demethylation process.8,12 TET proteins belong to the group of α-ketoglutarate (α-KG) and 
iron (Fe(II))-dependent dioxygenases. The co-substrate α-KG is produced by the isocitrate 
dehydrogenase (IDH) proteins, which catalyze the conversion of isocitrate into α-KG.13
Intriguingly, four genes (TET2, IDH1, IDH2, and DNMT3A) important for regulating 
DNA (hydroxy)methylation are frequently mutated in myeloid malignancies (Supplemental 
Figure 1). Loss-of-function mutations in TET2 have been described in various hematological 
malignancies,14-17 including 7% to 10% of AML patients.18-20 Heterozygous mutations in 
IDH1 and IDH2 occur in 10% to 20% of AML patients and are mutually exclusive with TET2 
mutations.19 Mutant IDH proteins are unable to catalyze the formation of α-KG but gain the 
function to convert α-KG into the oncometabolite 2-hydroxyglutarate (2HG).21 In vitro studies 
have shown that 2HG is a competitive inhibitor of the TET proteins.22,23 This implies that both 
TET2 and IDH1/2 mutations can impair 5hmC generation, which may explain why mutations 
in these genes are mutually exclusive. Indeed, AML patients with TET2 or IDH mutations 
showed decreased 5hmC levels.24-27 Recently, mutations affecting the methyltransferase 
DNMT3A were described in 20% to 25% of AML patients.19,28,29 Interestingly, DNMT3A 
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mutations frequently co-occurred with TET2 or IDH1/2 mutations,18 suggesting that an 
additive effect may result from the combination of these mutations. In most AML studies 
DNMT3A mutations have been associated with a poor prognosis18,19,28-30 except for a recent 
study by Gaidzik et al.31 Also TET2 mutations were associated with a poor prognosis in most 
studies,18,19,32-34 whereas the effect of IDH mutations is less clear. In several studies IDH1 
mutations correlated with a poor survival in cytogenetically normal AML patients, whereas 
the impact of IDH2 mutations on survival remains inconclusive.18,35-37
Several studies have assessed the effect of these mutations on DNA methylation. AML 
patients harboring IDH1/2 mutations showed a promoter hypermethylation phenotype 
and clustered together based on their common DNA methylation profile.38 The effect of 
TET2 mutations on overall DNA methylation remains controversial. In some studies TET2-
mutated patients displayed a hypermethylation signature overlapping with IDH1/2-mutated 
patients,23 whereas others described no major effect on global methylation or even 
hypomethylation.24,39 In vitro, most DNMT3A mutations led to a decreased capability of the 
protein to produce 5mC,29,40 although global 5mC levels in patients with DNMT3A mutations 
were not decreased.28 Methylated DNA immunoprecipitation experiments showed several 
differentially methylated regions between patients with and without DNMT3A mutations.28,29 
No information is available concerning the consequences of DNMT3A mutations on 5hmC 
levels.
The impact of 5hmC levels on survival of AML patients has not been addressed so far. 
In this study, we measured 5-(hydroxy)methylcytosine (5(h)mC) levels in a prospectively 
collected cohort of 206 AML patients included in the European Organization for Research and 
Treatment of Cancer/Gruppo Italiano Malattie Ematologiche dell’Adulto (EORTC/GIMEMA) 
AML-12 clinical trial and assessed whether 5hmC levels in AML correlated with clinical and 
molecular parameters.
Materials and methods
Patient samples
Bone marrow (BM) and peripheral blood (PB) from AML patients (n=206) included in the 
EORTC/GIMEMA AML-12 06991 clinical trial (NCT0004128, 1999-2009)41 were obtained after 
informed consent. To avoid bias, only patients from participating centers where DNA was 
collected from all consecutive cases were included. In total we obtained DNA from 206 AML 
patients. After DNA collection, we performed the 5hmC analysis. A consort diagram of the 
trial and an overview of the patients included and excluded in our study is presented in 
Supplemental Tables 1-2 and Supplemental Figures 2-3. The observed OS rate was slightly 
lower in the included cohort of patients compared with the non-included group (38.6% vs 
41.9% 5-year OS rate; p=0.22). The study was conducted in accordance with the Declaration 
of Helsinki and was approved by the Institutional Review Board of the Radboud University 
Nijmegen Medical Centre. The cohort of AML patients (age 16 to 60 years) contained samples 
of all French-American-British classification subtypes, except for AML M3. The median follow-
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up at the time of analysis was 6.4 years. PB and BM mononuclear cells, as well as G-CSF-
mobilized CD34-positive cells, were obtained from healthy donors (age 18 to 60 years for PB 
and BM donors and 44 to 67 years for donors of CD34-positive cells).
DNA and RNA isolation
For genomic sequencing and 5(h)mC measurements, DNA was isolated from whole PB or BM 
of AML patients (at diagnosis or in remission) using salt extraction. We compared the 5hmC 
values in PB and BM and observed that the levels were comparable (Supplemental Figure 
4). RNA for expression analysis was isolated using RNA-Bee (Tel-Test, inc., Friendswood, TX, 
USA). DNA from G-CSF-mobilized CD34-positive cells was isolated using salt extraction and 
DNA from PB and BM mononuclear cells of healthy donors was isolated using the NucleoSpin 
Blood QuickPure kit (Macherey Nagel, Düren, Germany).
Sequence analysis
Sanger sequencing was performed on polymerase chain reaction (PCR)-amplified genomic 
DNA fragments spanning the entire coding region of TET2 (NM_001127208.2) as previously 
described.14 For IDH1 (ENST00000345146) and IDH2 (ENST00000330062) the mutational 
hotspot regions were sequenced. DNMT3A exons 7 to 23 (ENST00000264709) were sequenced 
using Sanger sequencing or Roche 454-based next generation sequencing (NGS) (454 Life 
Sciences, Branford, CT, USA). Primers used for IDH1, IDH2 and DNMT3A Sanger sequencing 
can be found in Supplemental Tables 3 and 4. DNMT3A NGS was performed as previously 
described.42 In short, this encompasses PCR-based amplicon-library preparation followed 
by emulsion PCR and pyrosequencing. NGS data were analyzed using R453Plus1Toolbox,43 
GS Variant Analyzer Software 2.6 (454 Life Sciences), and Sequence Pilot, version 3.5.2 (JSI 
Medical Systems, Kippenheim, Germany). For TET2 and DNMT3A, all intron-exon boundaries 
were included to identify possible splice site mutations. The variations were compared 
with the single nucleotide polymorphism database (dbSNP) to determine whether they 
represented known single nucleotide polymorphisms.
TET expression analysis
Messenger RNA (mRNA) levels of TET2 isoform 1 and isoform 2, TET1, and TET3 were 
determined using quantitative PCR. Specific PCR primers and probes were designed to 
discriminate between the different TET2 isoforms (Supplemental Table 5). Taqman assays 
Hs00286756_m1 and Hs00379125_m1 (Life Technologies, Carlsbad, CA, USA) were used 
to determine TET1 and TET3 expression. Quantitative PCR was conducted using an Applied 
Biosystems Taqman 7900HT Fast Real-Time PCR system (Life Technologies). Expression levels 
were normalized to GAPDH and calculated using the 2ΔCT method.
5mC and 5hmC HPLC-MS/MS measurement
For each patient, 2 µg of DNA (isolated from ~1 x 106 cells) was degraded into individual 
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nucleosides using DNA degradase plus (Zymo Research, Irvine, CA, USA). The individual 
nucleosides were measured using a high-performance liquid chromatography-tandem 
mass spectrometry (HPLC-MS/MS) system consisting of an Acquity UPLC (Waters, Milford, 
MA, USA) containing a Waters Atlantis Hilic column (2.1mm x 100mm, 3µm) connected to 
a Micromass Quattro Premier XE (Waters). Quantification was performed using area-based 
linear regression curves derived from calibration standards containing internal standard 
solutions. The 5mC and 5hmC levels were calculated as a concentration percentage ratio 
of %5-methyl-2’-deoxycytidine/2’-deoxyguanosine (%mdC/dG) and %5-hydroxymethyl-2’-
deoxycytidine/2’-deoxyguanosine (%hmdC/dG), respectively. The inter-assay coefficient 
of variation over a one-year period was 2% for 5mC and 5% for 5hmC (n=49). A detailed 
description is presented in the supplemental data.
2HG HPLC-MS/MS measurement
A detailed description is presented in the supplemental data.
Bisulfite sequencing
Bisulfite conversion of 500 ng of DNA was performed using the Methyldetector kit (Active 
motif, Carlsbad, CA, USA), according to the manufacturer’s protocol. A semi-nested PCR on the 
converted DNA was carried out to amplify a CpG-rich promoter region in 2 genes frequently 
hypermethylated in AML: P15 and MyoD. Primer sequences are listed in Supplemental Table 
6. PCR products were cloned into the pDrive vector (Qiagen, Valencia, CA, USA), transformed 
in competent DH12α cells, and plated on a Luria-Bertani agar plate containing 50 µg/ml 
ampicillin. Per patient, DNA was isolated from 10 colonies and sequenced using Sanger 
sequencing.
Statistical analysis
5(h)mC differences between two patient groups were statistically tested by performing unpaired 
t-tests or Mann-Whitney U tests. More than two groups were compared using a 1-way analysis 
of variance or Kruskal Wallis test. Pearson and Spearman correlation coefficients were used 
to calculate correlations between two continuous variables. Two-sided p-values are reported. 
For negative results that may be scientifically relevant, we determined minimal detectable 
differences with a power of 80% (http://biomath.info/power/ttest.htm). To divide the AML 
patients in subgroups based on their 5hmC level, we fitted a normal mixture model to the data 
using the mixtools R package.44 The optimal number of components was determined using the 
Akaike information criterion (AIC).45 The results of the OS analysis have been presented in a 
Kaplan-Meier curve. OS was computed from the date of registration in the EORTC 06991 study 
until death (by any cause) or until last follow-up (censored observation). The Cox Proportional 
Hazards Model was used to determine the prognostic importance of each factor analyzed and to 
obtain hazard ratio (HR) estimates as well as corresponding 95% confidence intervals (95% CIs). 
The following variables were considered: 5hmC levels as continuous or categorical variable, 
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cytogenetic/FLT3-ITD risk group (good = inv16, t(8;21); poor = -5/5q-, -7/7q-, complex, FLT3-
ITD; Intermediate = NN, -Y; others = other cytogenetic abnormalities), white blood cell count 
(<25, 25 to <100, >100), percent of BM blasts (20 to <40%, 40 to <60%, 60 to <80%, >80%) 
and age (<30, 30 to <40, 40 to <50, 50-60 years). Statistical analyses were performed using SAS 
(SAS, Cary, NC, USA), R (R Development Core Team, www.r-project.org), and SPSS software (IBM 
Corporation, Armonk, NY, USA).
Results
Wide distribution of 5hmC levels in AML patients
5hmC levels were measured in 206 AML patients (see Table 1 for patient characteristics), in 
healthy purified CD34-positive progenitor cells, and healthy BM and PB cells using HPLC-MS/
MS. In CD34-positive cells (Figure 1A, range 0.037 to 0.045%; mean 0.041%), and in healthy 
control cells from BM and PB (Figure 1B, range 0.024 to 0.033%; mean 0.029%) 5hmC levels 
were tightly clustered, whereas in AML cells a wide range of 5hmC levels was detected 
(Figure 1A, range 0.006 to 0.091%; mean 0.039%). To determine whether these aberrant 
5hmC levels were normalized in remission, we measured 5hmC levels in paired samples at 
diagnosis and remission from 25 AML patients. For 19/25 patients, the type of material (BM 
or PB) at remission was matched to the material used at diagnosis. In all cases, the remission 
samples showed 5hmC levels comparable with the levels in healthy BM and PB (Figure 1B). In 
addition, from 5 patients 5hmC was measured at diagnosis, during remission, and at relapse. 
For all 5 patients, 5hmC levels in remission were comparable with healthy controls (Figure 
1C). At relapse, 5hmC returned to the levels obtained at diagnosis in all but one patient 
(UPN128). We found that this patient harbored an IDH1 mutation at diagnosis that was 
absent at relapse, which may explain the difference in 5hmC levels between diagnosis and 
relapse (see next paragraph). For patients with similar 5hmC levels at diagnosis and relapse, 
the same mutations were present at both time points (Supplemental Table 7).
Decreased global 5hmC levels in patients with TET2 or IDH1/2 mutations
The entire TET2 gene and the mutational hotspot regions in IDH1 and IDH2 were sequenced 
in 206 AML patients using Sanger sequencing.18 TET2 mutations were present in 7% of the 
patients (n=15), IDH1 R132 in 10% (n=21), IDH2 R140 in 11% (n=22), and IDH2 R172 in 2% 
(n=4) of the patients. In most cases TET2, IDH1 and IDH2 mutations were mutually exclusive, 
except for one patient with an IDH1 and subclonal IDH2 mutation (Supplemental Table 8).
Using HPLC-MS/MS, we confirmed that patients with IDH mutations produce 2HG, 
which is known to inhibit TET proteins (Figure 2A and Supplemental Table 9).22,23 Patients 
with IDH mutations had up to 150 times higher plasma 2HG levels compared with IDH 
wild-type patients (p=0.03). Because a reduced function of TET2, either by mutations or by 
2HG-mediated inhibition, may affect both 5mC and 5hmC levels, we compared these levels 
in patients with and without TET2 or IDH mutations. We observed small but statistically 
significant differences in 5mC levels between the different patient groups (Figure 2B). Patients
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Table 1. Patient characteristics
Overall population (n=206)
No. %
Age (years) at diagnosis
   Median (range) 48.0 (16.0-60.0)
   <30 21 10.2
   30 to <40 36 17.5
   40 to <50 59 28.6
   50-60 90 43.7
Sex
   Male 101 49.0
   Female 105 51.0
WHO-ECOG performance status
   0 122 59.2
   1 74 35.9
   2 7 3.4
   3-4 3 1.5
WBC (x109/l) at diagnosis
   Median (range) 24.7 (0.5-312.5)
   <25 104 50.5
   25-99.9 69 33.5
   ≥100 33 16.0
FAB subtype
   M0 11 5.3
   M1 45 21.8
   M2 65 31.6
   M4 25 12.1
   M5 48 23.3
   M6 6 2.9
   M7 1 0.5
   Unknown 5 2.4
Cytogenetic/FLT3-ITD risk group
   Good 24 11.7
   Intermediate (NN,-Y) 62 30.1
   Poor (-5/5q-,-7/7q-,complex, FLT3-ITD) 67 32.5
   Others 46 22.3
   UNK/ND/Failure 7 3.4
No. indicates number; WHO-ECOG, World Health Organization-Eastern Cooperative Oncology 
Group; WBC, white blood cell count; FAB, French-American-British classification; UNK, 
unknown; ND, not determined.
with IDH mutations displayed slightly increased 5mC values compared with TET2/IDH wild-
type and TET2-mutated patients (p=0.02 and p=0.001, respectively). In contrast, substantial 
differences in 5hmC levels were found. Patients with TET2 mutations had significantly lower 
5hmC levels compared with patients without TET2 or IDH mutations (p<0.0001; Figure 2C). 
Patients with two TET2 aberrations showed a significantly lower 5hmC than patients with 
a single affected allele (p=0.003; Figure 2D). Furthermore, 5hmC values were decreased in 
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Figure 1. Aberrant 5hmC levels in AML. (A) In AML cells, a broad range of 5hmC levels was detected at diagnosis 
when compared with healthy CD34-positive cells. (B) Aberrant 5hmC levels at diagnosis were restored to normal 
levels in remission. (C) For five AML patients, 5hmC levels were measured at diagnosis, remission, and relapse. The 
5hmC levels were in 4 out of 5 cases comparable at diagnosis and relapse. For unique patient number (UPN) 128, the 
5hmC level at relapse was remarkably higher than at diagnosis due to an IDH1 mutation at diagnosis that was absent 
at relapse. Dashed lines indicate the range of 5hmC values measured in healthy BM and healthy PB.
patients with IDH1/2 mutations compared with TET2/IDH wild-type patients (p<0.001; Figure 
2C). Comparison of the 3 different IDH mutational hotspots revealed a slightly lower 5hmC in 
the subgroup of patients with IDH2 R172 mutations (n=4, Figure 2D).
Effect of DNMT3A mutations on global 5mC and 5hmC levels
Because the DNMT3A protein forms 5mC, we investigated whether mutations in DNMT3A 
would affect global 5mC and 5hmC levels. DNMT3A exons 7 to 23 were sequenced in 79 
patients (Supplemental Table 8). Interestingly, DNMT3A mutations frequently co-occurred 
with TET2 or IDH mutations; 64% of TET2-mutated and 63% of IDH-mutated patients harbored 
a DNMT3A mutation. The frequent co-occurrence suggests that an additive oncogenic effect 
may result from the combination of these mutations. When patients were divided into 
different subgroups based on co-occurring mutations, mutant DNMT3A alone had no strong 
effect on global 5mC levels (Figure 2E). The detected difference between means (DNMT3A/
TET2/IDH wild-type vs. DNMT3A mutant group) was 0.03 and was not significant 
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Figure 2. 5hmC levels are decreased in TET2- and IDH-mutated patients. (A) Plasma 2HG levels measured by LC-
MS/MS were up to 150 times higher in patients with IDH mutations compared with IDH wild-type patients. (B) Small 
differences in 5mC values were present between AML patients. Patients with IDH mutations showed higher 5mC 
levels than TET2-mutated and TET2/IDH wild-type patients. (C) Patients with TET2 or IDH1/2 mutations showed 
significantly lower 5hmC levels than TET2/IDH wild-type patients. (D) Patients with two affected TET2 alleles showed 
lower 5hmC values than patients with only one affected allele. All types of IDH mutations led to decreased 5hmC 
levels. The 4 patients with an IDH2 R172 mutation had slightly lower 5hmC values than most patients with an IDH1 
R132 or IDH2 R140 mutation. (E) DNMT3A mutations frequently co-occurred with TET2 or IDH mutations. DNMT3A 
mutations did not significantly affect global 5mC levels. (F) Mutant DNMT3A also did not strongly affect 5hmC values, 
but the levels were influenced by the presence or absence of accompanying TET2 or IDH mutations. Mut indicates 
mutated; wt, wild-type. Symbols indicate unpaired t-test (*), Mann-Whitney U test (†), 1-way analysis of variance (‡) 
and Kruskal Wallis test (§).
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(the minimal detectable difference in our cohort was 0.29 %5mC/G with a power of 80%). In 
addition, DNMT3A mutations also did not significantly affect global 5hmC values (Figure 2F). 
The observed difference between means was 0.0056 (the minimal detectable difference with 
a power of 80% was 0.016 %5hmC/G). 
High 5hmC levels confer poor prognosis in AML
In AML, a wide range of 5hmC levels was observed when compared with healthy control cells 
(Figure 1A). As the 5hmC values were not normally distributed, we used a mixture model 
analysis to divide the patient cohort in subgroups. Three subpopulations were identified; 
low 5hmC (0.006 to <0.023), intermediate 5hmC (0.023 to <0.070) and high 5hmC (0.070-
0.091) (see Supplemental Table 10 for patient characteristics). We questioned whether 5hmC 
levels correlated with OS by examining the survival of these three groups. Univariate analysis 
showed that the low and intermediate 5hmC groups had comparable 5-year OS rates (38.3% 
vs 40.7%; Figure 3). Interestingly, the high 5hmC group showed a considerably lower 5-year 
OS rate when compared with the intermediate group (18.9% vs 40.7%; Figure 3) resulting 
in a significant difference in OS (p=0.047, HR=1.81, 95%CI=1.01-3.24). A similar trend was 
observed when event-free survival was analyzed (Supplemental Table 11). Multivariate Cox 
regression analysis showed that, when adjusted for cytogenetic/FLT3-ITD features, high 
5hmC levels independently predicted poor OS (high vs intermediate 5hmC: p=0.01, HR=2.10, 
95%CI=1.16-3.80; Table 2).
Compared groups p-value HR 95%CI
low vs intermediate p=0.65 1.10 0.73-1.66
high vs intermediate p=0.047 1.81 1.01-3.24
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Figure 3. OS according to 5hmC level. Patients were divided into three groups based on a mixture model analysis. 
Univariate analysis indicates that patients with high 5hmC levels (0.070-0.091) showed a poor OS compared with 
patients with low (<0.023) and intermediate (0.023 to <0.070) 5hmC.
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Table 2. Multivariate Cox regression analysis
95% HR
Parameter p-value HR Confidence limits
5hmC: <0.023 vs 0.023 to <0.070 0.44 1.18 0.77 1.81
5hmC: ≥0.070 vs 0.023 to <0.070 0.01 2.10 1.16 3.80
Cytogenetics/FLT3-ITD: good vs. intermediate 0.21 0.60 0.25 1.36
Cytogenetics/FLT3-ITD: others vs. intermediate 0.17 1.44 0.86 2.39
Cytogenetics/FLT3-ITD: poor vs. intermediate <0.0001 3.00 1.90 4.68
Cytogenetics/FLT3-ITD: unknown vs. intermediate 0.02 2.96 1.21 7.21
AIC for this model=1238
Addition of age, treatment arm (data not shown), and/or percentage BM blasts (Supplemental Table 12) in the model 
did not improve its prognostic discrimination value. Considering 5hmC as a continuous variable in the model (linear 
and quadratic effect), and adjusting for cytogenetic/FLT3-ITD risk groups, provided similar results as the model 
indicated above (Supplemental Table 12).
Correlation of 5hmC levels with clinical and molecular parameters
As shown in Figure 2C, low 5hmC levels could in many patients be explained by TET or IDH 
mutations. In patients without TET2 or IDH mutations, 5hmC levels still varied considerably. 
Therefore, we examined whether the range of 5hmC values in patients without TET2 or IDH 
mutations correlated with specific clinical or molecular parameters. There was no significant 
correlation between 5hmC levels and sex, age, initial performance status, white blood cell 
count, or cytogenetic categories (Supplemental Figure 5). Furthermore, we assessed whether 
5hmC levels correlated with the percentage of blasts at diagnosis, because it has been shown 
that stem cells may contain more 5hmC than differentiated cells.46 A positive correlation was 
present between 5hmC levels and the percentage of blasts in BM (p=0.003) and PB (p=0.02) 
at diagnosis (Supplemental Figure 6). The percentage of BM blasts did, however, not appear 
to be of prognostic importance for OS, neither in uni- nor in multivariate analysis. When 
blast percentage was included in the multivariate model (Supplemental Table 12, model 2), 
high 5hmC remained an independent poor prognostic factor, thereby showing that 5hmC 
is not a surrogate marker for percentage of BM blasts. To investigate whether the level of 
TET expression affected the level of 5hmC in AML, we measured mRNA expression of TET1 
(n=31), TET2 (isoform 1 and 2, n=109) and TET3 (n=31) in patients without TET2 or IDH 
mutations. For all TET family members, no strong correlation was found with the level of 5hmC 
(Supplemental Figure 7). Finally, we considered whether 5hmC levels correlated with other 
specific molecular aberrations. Interestingly, MLL aberrations and AML1-ETO translocations 
were enriched in patients with high levels of 5hmC (Figure 4). Of note, there was one patient 
who carried an IDH2 mutation together with an MLL translocation. Of all patients with MLL 
aberrations, this patient showed the lowest value of 5hmC, possibly indicating that the effect 
of IDH mutations (correlating with low 5hmC) overrides the effect of MLL translocations 
(correlating with high 5hmC).
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Increased P15 promoter methylation in patients with low 5hmC levels
We examined the methylation status of 2 genes that are frequently hypermethylated in 
AML (P15 and MyoD)47 in 10 patients with low and 10 with high 5hmC levels. The majority 
of patients with low 5hmC (8/10) showed considerable methylation on the P15 promoter 
compared with only 2/10 patients with high 5hmC levels (at least 1 CpG >50% methylated; 
Figure 5A), which suggests that demethylation of the P15 promoter is altered in most 
patients with low 5hmC. In contrast, for MyoD no difference in promoter methylation was 
observed between the low and high 5hmC groups (Figure 5B), indicating that this correlation 
is promoter specific. Therefore, genome-wide analysis should be performed to determine 
which genes are differentially methylated between the low and high 5hmC groups.
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Figure 5. P15 and MyoD promoter methylation. P15 (A) and MyoD (B) promoter methylation were determined in 
10 patients with low and 10 with high 5hmC levels. For each CpG, the methylation status is indicated with shaded 
boxes. Patients with low 5hmC show more P15 promoter methylation than patients with high 5hmC levels, whereas 
there is no difference in MyoD promoter methylation. UPN indicates unique patient number.
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Discussion
In this study, we correlated global 5(h)mC levels with various clinical and molecular parameters 
in a large, prospectively collected cohort of younger adult AML patients (age ≤60) included 
in the EORTC/GIMEMA AML-12 clinical trial. No major differences in global 5mC levels were 
observed between patients, but 5hmC levels were distributed over a wide range. In remission, 
5hmC values were normalized to levels comparable with healthy BM and PB, indicating that 
the aberrant 5hmC levels at diagnosis were an intrinsic property of the leukemic cells. In 
line with previous reports, mutations in TET2 and IDH1/2 were mutually exclusive,19,23 and 
patients with these mutations displayed significantly decreased 5hmC levels.24-27 Among the 
patients that did not harbor TET2 or IDH mutations, a wide variation in 5hmC levels was still 
observed.
Remarkably, IDH or TET2 mutations co-occurred frequently with mutations in DNMT3A, 
indicating that they may co-operate during malignant transformation. The majority of 
DNMT3A mutations are heterozygous missense mutations affecting one specific amino 
acid (R882), but nonsense and frameshift mutations have also been described.48 We did 
not observe significant effects of DNMT3A mutations on global 5mC levels in patients with 
either mono- or bi-allelic mutations. This suggests that there is still enough remaining DNMT 
protein (DNMT3B, DNMT1 and in most cases a remaining DNMT3A allele) to form most of the 
5mC marks. In addition, we did not find strong correlations between global 5mC levels and 
survival (Supplemental Figure 8). This lack of correlation does not necessarily mean that 5mC 
levels are not relevant, but may rather point to the fact that global DNA methylation patterns 
obscure local effects at specific genes. To identify the important loci for (deregulated) 5mC 
levels, more targeted strategies, such as MeDIP, should be used.
TET2 and IDH mutations both lead to defective conversion of 5mC into 5hmC, which 
may result in impaired demethylation of DNA, contributing to the malignant transformation 
of cells. Using bisulfite sequencing, we showed a high level of P15 promoter methylation in 
patients with low 5hmC. However, no difference was observed for the MyoD gene, indicating 
that the correlation is locus specific. Genome-wide methylation and hydroxymethylation 
patterns should be determined to see which genes are differentially (hydroxy)methylated 
between patients with low and high 5hmC levels. Apart from affecting the methylation status 
of the DNA, other processes might be influenced by 5hmC as well. Several studies showed 
that the 5hmC mark may attract specific proteins like MECP2 and UHRF2.49,50 The role of these 
interactions is not clear yet, but protein complexes that recognize the 5hmC mark might 
serve as “readers” of the local epigenetic DNA code and induce further chromatin alterations.
After excluding patients with mutations in TET2 or IDH, 5hmC levels still varied 
considerably in the remaining patients. The cause of this broad range of 5hmC levels could 
not be attributed to differences in TET expression, as no strong correlation was found 
between TET1, 2 or 3 mRNA expression and 5hmC levels. A positive correlation was, however, 
observed between blast count at diagnosis and 5hmC levels. As it has been shown that stem 
cells contain more 5hmC than differentiated cells, this might explain the correlation.46
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We assessed whether 5hmC levels correlated with OS by comparing the survival of the 
three 5hmC subpopulations present in our cohort (Figure 1A). We showed that high 5hmC 
levels conferred a poor prognosis in both uni- and multivariate analysis. On the other hand, 
low 5hmC levels did not affect survival. The low 5hmC group mainly consists of patients with 
TET2 or IDH1/2 mutations (45 out of 47 patients). TET2 mutations in AML are often associated 
with a poor prognosis,32-34 as was also observed in our study.18 The impact of IDH mutations 
on OS was less pronounced, with IDH1 mutations showing a trend towards a poor prognosis, 
whereas IDH2 mutations had no effect.18 The differences in OS between these 3 types of 
mutations indicates that low 5hmC is not the only variable that affects survival in these 
patients. Interestingly, AML1-ETO and MLL translocations were more frequently present in 
patient cells with high 5hmC levels. These findings remain to be confirmed in future studies.
Finally, it would be particularly interesting to investigate how patients with aberrant 
5hmC respond to hypomethylating agents, such as decitabine and azacitidine, as these 
compounds have shown promising results in MDS and elderly AML.3-6 If a correlation between 
5hmC levels and response to these therapeutics could be shown, this would allow a more 
tailored therapeutic approach.
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Supplemental data
5mC and 5hmC HPLC-MS/MS measurement
For each patient, 2 µg of DNA was degraded into individual nucleosides by mixing the DNA 
with 1x DNA degradase reaction buffer and 5U DNA degradase plus (Zymo Research, Irvine, 
CA, USA), followed by incubation at 37°C for 5 hours and 70°C for 20 minutes. Hydrolyzed 
DNA was used for HPLC-MS/MS analysis. Nucleoside calibration standards corresponding to 
0.025, 0.05, 0.1, 0.2, 0.5, 1 and 2 µg of DNA, containing 5.3% 5-methyl-2’-deoxycytidine/2’-
deoxyguanosine (mdC/dG) and 0.02% 5-hydroxymethyl-2’-deoxycytidine/2’-deoxyguanosine 
(hmdC/dG), were prepared in deionized water (dH2O). In addition, an internal standard 
solution was prepared containing 0.02 µM D
2
hmdC, 0.27µM 13C4-mdC (kindly provided 
by Prof. Dr. H. Blom) and U-15N
5
-dG (Cambridge Isotopes Laboratories, Andover, MA, USA) 
in dH2O. 25 µl dH2O was added to the 25 µl of DNA hydrolysate, and 25 µl 1x degradase 
reaction buffer to the calibration standards. Subsequently, 25 µl of internal standard solution, 
50 µl of methanol (Merck, Darmstadt, Germany) and 500 µl acetonitrile (ACN, Merck) were 
added to both samples and calibrators. After centrifugation, the eluates were dried under 
an N
2
 flow and dissolved in 75 µl 95% ACN. 5 µl of the calibrators and samples were injected 
into the HPLC-MS/MS system consisting of an Acquity UPLC (Waters, Milford, MA, USA) 
containing a Waters Atlantis Hilic column (2.1mm*100mm, 3µm) connected to a Micromass 
Quattro Premier XE (Waters). The mobile phase was made up by ACN and 20 mM ammonium 
acetate (Sigma-Aldrich, St. Louis, MO, USA) in dH2O. The initial flow rate was set to 400 µl/
min. The UPLC flow was directed to the Quattro Premier fitted with an electrospray ionization 
probe operated in positive mode at unit resolution. The capillary voltage was set at 3 kV. The 
temperature settings for the source and ion block were 400 ˚C and 100 ˚C respectively. As a 
drying gas, nitrogen was used at a flow rate of 1100 L/h. The collision cell was operated with 
argon as the collision gas at a pressure of 0.8 Pa. The cone voltage and collision energy voltage 
were individually set for the different nucleosides to obtain a maximum response for their 
deoxyribose loss. Quantification was performed using area-based linear regression curves 
derived from the prepared calibration standards. The 5mC and 5hmC levels were calculated 
as a concentration percentage ratio of %mdC/dG and %hmdC/dG, respectively.
In each run, granulocyte DNA, with 5mC and 5hmC levels of 3.9 and 0.027 respectively, 
was included to monitor inter-assay reproducibility. The inter-assay CV over a one-year 
period was 2% for 5mC and 5% for 5hmC (n=49). To test the reproducibility of the 5hmC 
measurements at the extremes, three patient samples with 5hmC values of 0.014 (low), 
0.044 (intermediate) and 0.096 (high) were measured 5 times leading to CV values of 5.7%, 
2.9% and 1.1%, respectively. The accuracy of the assay was determined by measuring a 
range of 5hmC values from 2% to 0.0032% with 5-fold steps, resulting in a R2 of 0.9866, see 
graph below. All measurements were performed blinded to clinical and molecular data of the 
patients.
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2HG HPLC-MS/MS measurement
2HG (Sigma-Aldrich) calibration standards of 0.15, 0.3, 0.6, 1.2, 2.5, 5 and 10 µM, and an 
internal standard solution of 10 µM U-13C
5
-l-2hg (Chiralex, Nijmegen, the Netherlands) 
were prepared in dH2O. 100 µl sample was diluted with 50 µl internal standard solution 
and passed through a Microcon 30 kD ultrafilter (Millipore, Billerica, MA, USA). The filtrate 
was acidified with 10 µl 4% formic acid (Merck) and 5 µl was injected into the HPLC-MS/
MS system consisting of a 232 XL autosampler (Gilson, Middleton, WI, USA) connected to 
an HP1100 HPLC (Agilent, Palo Alto, CA, USA) with an PFP column (2.1mm*100mm, 3µm, 
Phenomenex, Torrance, CA, USA), and a Micromass Quattro LC (Waters). The mobile phase 
consisted of dH2O and methanol (Merck) containing 0.3% formic acid (Merck) and was run 
at a flow rate of 250 µl/min. By running a gradient, 2HG was eluted completely separated 
from its structural isomers 3-hydroxyglutarate and 2-hydroxy-2-methylsuccinate (the optical 
D- and L-isomers do still co-elute). The HPLC flow was directed to a Quattro LC tandem mass 
spectrometer fitted with an electrospray ionization probe operating in the negative mode at 
unit resolution. The capillary voltage was set at 3 kV, and a cone voltage of 20 V was used. 
The temperature settings for the source and ion block were 400 ˚C and 100 ˚C respectively. 
As a drying gas nitrogen was used at a flow rate of 650L/h. The collision cell was operated at 
9 eV with argon as the collision gas at a pressure of 0.2 Pa. The mass spectrometer was set to 
monitor the water loss of both 2HG and U-13C
5
-I-2hg; recording the mass transitions of m/z 
147 to m/z 129 and m/z 152 to m/z 134, respectively.
Quantification was performed using an area-based linear regression curve derived from 
the prepared calibration standards containing internal standard solution. The inter-assay (3 
months period) CV of a plasma containing 1.0 µM of 2HG was 4% (n=20). All measurements 
were performed blinded to clinical and molecular data of the patients.
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Supplemental Table 1. Patient characteristics
Patient characteristics AML-12 study
Parameter Excluded (n=1736) Included (n=206)
N (%) N (%)
Age (years) at diagnosis
   <30 290 (16.7) 21 (10.2)
   30-<40 332 (19.1) 36 (17.5)
   40-<50 476 (27.4) 59 (28.6)
   50-60 638 (36.8) 90 (43.7)
Sex
   Male 911 (52.5) 101 (49.0)
   Female 818 (47.1) 105 (51.0)
   Missing 7 (0.4) 0 (0.0)
WHO-ECOG performance status (PS)
   PS 0 805 (46.4) 122 (59.2)
   PS 1 740 (42.6) 74 (35.9)
   PS 2 160 (9.2) 7 (3.4)
   PS 3-4 27 (1.6) 3 (1.5)
   Missing 4 (0.2) 0 (0.0)
WBC (x109/l) at diagnosis
   <25 1037 (59.7) 104 (50.5)
   25-99.9 499 (28.7) 69 (33.5)
   >=100 191 (11.0) 33 (16.0)
   Missing 9 (0.5) 0 (0.0)
FAB subtype
   M0 98 (5.6) 11 (5.3)
   M1 435 (25.1) 45 (21.8)
   M2 445 (25.6) 65 (31.6)
   M3 4 (0.2) 0 (0.0)
   M4 346 (19.9) 25 (12.1)
   M5 321 (18.5) 48 (23.3)
   M6 57 (3.3) 6 (2.9)
   M7 3 (0.2) 1 (0.5)
   Unknown 27 (1.6) 5 (2.4)
Cytogenetic/FLT3-ITD risk group
   Good 165 (9.5) 24 (11.7)
   Intermediate (NN,-Y) 578 (33.3) 62 (30.1)
   Poor (-5/5q-,-7/7q-,complex,FLT3-ITD) 144 (8.3) 67 (32.5)
   Others 240 (13.8) 46 (22.3)
   UNK/ND/Failure 609 (35.1) 7 (3.4)
Treatment randomized
   SD-AraC 859 (49.5) 110 (53.4)
   HD-AraC 877 (50.5) 96 (46.6)
SCT in CR
   Auto-SCT 484 (27.9) 62 (30.1)
   Allo-SCT 347 (20.0) 53 (25.7)
Response after induction
   CR 1280 (73.7) 152 (73.8)
   NoCR 456 (26.3) 54 (26.2)
EFS status
   NoCR 413 (23.8) 53 (25.7)
   CCR 570 (32.8) 61 (29.6)
   Relapse 567 (32.7) 69 (33.5)
   Death in CR 143 (8.2) 22 (10.7)
   Not evaluated 43 (2.5) 1 (0.5)
Survival status
   Alive 752 (43.3) 76 (36.9)
   Dead 984 (56.7) 130 (63.1)
WHO-ECOG indicates World Health Organization-Eastern Cooperative Oncology Group; WBC, white blood cell count; 
FAB, French-American-British classification; UNK, unknown; ND, not determined; SD, standard dose; HD, high dose; 
SCT, stem cell transplantation; CR, complete remission; EFS, event-free survival; CCR, continuous complete remission.
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Supplemental Table 2. Duration of survival
Study population Patients Observed Hazard Ratio P-Value Median (95% CI)
(N) deaths (O) (95% CI) (Log-Rank) (Years)
Excluded 1736 984 1 0.2164 2.12 (1.85, 2.48)
Included 206 130 1.12 (0.93, 1.35) 1.68 (1.20, 2.96)
% at 5 year(s) Time used Std error Min AML-12: Max AML-12:
(95% CI) (Years) Duration of survival Duration of survival
41.91 (39.50, 44.30) 4.97 1.227 0 10.91
38.57 (31.85, 45.25) 4.35 3.437 0 11.64
95% CI indicates 95% confidence interval
Supplemental Table 3. Primers used for IDH1 and IDH2 sequencing
Gene position Forward/Reverse Primer sequence (5’ to 3’)
IDH1 R132 Forward tgtaaaacgacggccagtGGCACGGTCTTCAGAGAAGC
Reverse caggaaacagctatgaccCAAAATCACATTATTGCCAAGATG
IDH2 R140 and R172 Forward tgtaaaacgacggccagtCGTCTGGCTGTGTTGTTGCTT
Reverse caggaaacagctatgaccAGGATGGCTAGGCGAGGAG
M13 seq primer Forward tgtaaaacgacggccagt
Reverse caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
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Supplemental Table 4. Primers used for sequencing DNMT3A exon 7 till 23
Exon Forward/Reverse Primer sequence (5’ to 3’)
7 Forward tgtaaaacgacggccagtCTAATTCCTGGAGAGGTCAAGGTG
Reverse caggaaacagctatgaccAGATGGAGAGAGGAGAGCAGGAC
8 Forward tgtaaaacgacggccagtTCTTGCCTCATTCAGATGGAGC
Reverse caggaaacagctatgaccCCTGGGATCAAGAACCTTCCC
9 Forward tgtaaaacgacggccagtGTGCTTGCAAGTGTAAGCCTCG
Reverse  caggaaacagctatgaccCCTGCACTCCAACTTCCAGG 
10 Forward tgtaaaacgacggccagtGCCTTCCAGCCTGTCCTGA
Reverse caggaaacagctatgaccCCAACTCTACGGTTCTAGCCAAC
10-11 Forward tgtaaaacgacggccagtGCCTTCCAGCCTGTCCTGA
Reverse caggaaacagctatgaccGTACACCAGCCGCTCTGCA
11-12 Forward tgtaaaacgacggccagtGTTGGCTAGAACCGTAGAGTTGG
Reverse caggaaacagctatgaccCTAAGTGCCTCTGCTACTCTGCC
13 Forward tgtaaaacgacggccagtGTTCGAGACTGGGGTCACAGT
Reverse caggaaacagctatgaccAGAAGCGGTGGACACAGTCAG
14 Forward tgtaaaacgacggccagtGGTCATGTCTTCAGGGCTTAGG
Reverse caggaaacagctatgaccTGCTACCTGGAATGGAAAGACC
15 Forward tgtaaaacgacggccagtTTTCCATTCCAGGTAGCACACC
Reverse caggaaacagctatgaccAGGCTCCTAGACCCACACACC
16 Forward tgtaaaacgacggccagtAGGGTGTGTGGGTCTAGGAGC
Reverse caggaaacagctatgaccGCTGTGAAGCTAACCATCATTTCG
17 Forward tgtaaaacgacggccagtGTGGGGTAGAATTGTAGCAGGA
Reverse caggaaacagctatgaccATGAACAAAATGAAAGGAGGCAA
18-19 Forward tgtaaaacgacggccagtTTCCTGTCTGCCTCTGTCCCT
Reverse caggaaacagctatgaccCAGCAGTCCAAGGTAGAAGCCA
20 Forward tgtaaaacgacggccagtATTAACCATTCAGCTCCTCAATCAC
 Reverse caggaaacagctatgaccTGCAGTCCCAGCCCACAG
21 Forward tgtaaaacgacggccagtGTTATGACGTGTGTGCGTGATT
Reverse caggaaacagctatgaccCCTGCACCGTCTCCTAAATTG
22 Forward tgtaaaacgacggccagtGTTTGGCGAGTACCTGGCATATT
Reverse caggaaacagctatgaccGGAAAACAAGTCAGGTGGGAAAG
23 Forward tgtaaaacgacggccagtCTGCTGTGTGGTTAGACGGCTT
Reverse caggaaacagctatgaccTGCAATAACCTTCTTGTTTCAGTCA
M13 seq primer Forward tgtaaaacgacggccagt
Reverse caggaaacagctatgacc
M13 sequence primers are indicated by lower-case letters
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Supplemental Table 5. Primers and probes for quantitative PCR
Gene/isoform Primer/probe Primer/probe sequence (5’ to 3’)
TET2 Forward primer AATTTATTGGATACACCTGTCAAGACTC
TET2 isoform 1 Reverse primer ACCTGCTCCTAGATGGGTATAAAAAG 
TET2 isoform 2 Reverse primer GATAAACGCCATGTGTCTCAGTACA 
TET2 Probe TATGATTTCCCATCTTGC
TET1 Primer/probe mix Hs00286756_m1 (TaqMan)
TET3 Primer/probe mix Hs00379125_m1 (TaqMan)
Supplemental Table 6. Primers bisulfite sequencing
Gene Forward/Reverse Primer sequence (5’ to 3’)
P15 Forward_1 TTTAAAATATTAGTTTTGGTTTTATTGGAT
Forward_2 TTTTAGTATTTTTGGGTAGGTTTTTT
Reverse_1/2 ACCTAAACTCAACTTCATTACCCTC
MyoD Forward_1 GTTTTAAGTTTTTTGTTTTTTG
Forward_2 GGGATAGAGGAGTATTGAAAGTTAGTTTAG
Reverse_1/2 AAAACTTCCTCACCCCTAACTTCT
M13 seq primer Forward gtaaaacgacggccagt
Reverse caggaaacagctatgac
Supplemental Table 7. Mutations at diagnosis and relapse
UPN Genetic defects diagnosis Present at relapse
128 FLT3-ITD yes*
IDH1 no
140 FLT3-ITD yes
IDH2 yes
DNMT3A yes
256 FLT3-ITD yes
NPM1 yes
DNMT3A yes
282 FLT3-ITD yes
NPM1 yes
IDH1 yes
1530 AML1-ETO yes
* Different FLT3-ITD variants at diagnosis and relapse
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Supplemental Table 8. Mutations in genes involved in DNA (hydroxy)methylation
UPN DNMT3A TET2 IDH1 IDH2 5mC level 5hmC level
6 N/A - p.R132H - 4.0 0.018
35 p.S714C - - p.R140Q 3.9 0.019
36 p.F640Y - - p.R172L 4.1 0.008
50 p.R882H - - p.R172L 4.0 0.013
80 N/A - - p.R140Q 3.8 0.028
88 p.V563M* - - p.R140Q 4.1 0.019
98 - p.R1359H - - 3.8 0.023
128 - - p.R132H - 4.1 0.023
140 p.R882C - - p.R140Q 4.1 0.016
256 p.R882H - - - 3.7 0.035
265 N/A - - p.R140Q 4.2 0.036
282 N/A - p.R132H - 4.0 0.014
290 N/A - p.R132H - 3.4 0.026
328 N/A - p.R132L - 4.2 0.013
329 p.IVS9-1G>T p.P1115LfsX2 - - 3.9 0.035
356 p.R882C p.N275IfsX18 - - 3.5 0.021
360 N/A - p.R132H - 3.4 0.013
362 N/A p.R1896M* - - 3.6 0.013
378 N/A p.R1993W - - 3.6 0.024
397 p.R882H - p.R132H - 4.0 0.013
405 p.S714C - - - 4.0 0.050
438 N/A - p.R132C p.R140Q† 4.0 0.013
463 p.R326H - - - 4.2 0.052
484 p.R882C - - p.R140Q 4.1 0.019
566 N/A - p.R132C - 3.7 0.007
573 N/A - p.R132C - 3.8 0.006
582 N/A - p.R132C - 3.4 0.010
596 p.R882H - - - 3.9 0.050
627 p.R882H - - - 3.8 0.034
630 p.G543C - - - 4.0 0.034
671 p.R882H - p.R132H - 4.2 0.024
690 - - p.R132C - 4.2 0.012
746 N/A - - p.R140Q 4.2 0.013
791 - p.I1873N - - 3.9 0.029
806 p.D252X* p.S137VfsX8 - - 3.8 0.013
p.P929LfsX24  
824 N/A - p.R132L - 4.0 0.016
907 N/A - p.R132H - 3.8 0.021
910 N/A - - p.R140Q 3.9 0.014
935 N/A p.L615AfsX23 - - 3.2 0.014
p.T229NfsX25  
970 N/A - - p.R140Q 3.8 0.017
977 N/A - - p.R140Q 3.9 0.017
1012 - - - p.R140Q 4.2 0.007
1031 p.R635W - - p.R140Q 4.1 0.020
1079 p.R882H - - - 3.6 0.056
1095 N/A - - p.R140Q 4.1 0.017
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1174 N/A - - p.R140Q 3.9 0.012
1176 - - p.R132H - 4.1 0.024
1178 - - - p.R140Q 3.9 0.024
1253 N/A - p.R132C - 3.7 0.013
1266 p.R882H p.IVS2-2A>G - - 3.8 0.016
p.N501S p.G1869E  
1269 p.R882H - - p.R140Q 4.0 0.020
1398 p.R882H p.H850R - - 3.9 0.043
1399 N/A - - p.R140Q 4.0 0.013
1433 N/A - - p.R172L 3.9 0.008
1456 p.R882H p.Q831TfsX15 - - 3.7 0.031
1546 - - p.R132H - 3.9 0.023
1575 N/A - - p.R140Q 3.9 0.008
1622 N/A - p.R132G - 3.7 0.013
1626 N/A - - p.R140Q 3.9 0.021
1652 p.C517R - - - 3.8 0.054
1663 N/A - - p.R140Q 3.8 0.022
1704 N/A - p.R132H - 3.7 0.019
1763 N/A - - p.R172L 4.1 0.006
1799 N/A - p.R132H - 4.2 0.015
1879 N/A p.T1397I - - 3.8 0.032
1915 - p.S1758X - - 3.7 0.029
p.T1554SfsX16
1928 p.IVS9del-18_+1 p.Q749X - - 3.9 0.021
p.D1384N
2085 p.R882H - - - 3.8 0.038
2111 N/A - - p.R140Q 4.2 0.015
2112 - p.R1261H - - 3.8 0.006
p.R1359S
UPN indicates unique patient number; N/A, not analyzed;  - , wild-type.
*Homozygous mutation
† Subclonal IDH2 mutation
Supplemental Table 9. Plasma 2HG levels in IDH wild-type and IDH mutant AML patients
Sample IDH mutation TET2 mutation 2HG (µM)
1 IDH1 R132H - 3.9
2 IDH1 R132C - 10
3 IDH1 R132C - 14
4 IDH2 R140Q - 11
5 IDH2 R140Q - 32
6 IDH1 R132C + subclonal IDH2 R140Q - 6.3
7 - Q847X+S128fsX15 0.39
8 - R1261H+R1359S 1.3
9 - - 0.22
10 - - 0.30
11 - - 0.35
12 - - 0.55
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Supplemental Table 10. Patient characteristics per 5hmC group
5hmC groups Total cohort
<0.023 (n=47) 0.023-<0.070 (n=142) 0.070-0.091 (n=17) (n=206)
No. (%) No. (%) No. (%) No. (%)
Age (years) at diagnosis
   Median (range) 53 (35-60) 46 (16-60) 42 (16-59) 48 (16-60)
   <30 0 (0.0) 18 (12.7) 3 (17.6) 21 (10.2)
   30-40 1 (2.1) 31 (21.8) 4 (23.5) 36 (17.5)
   40-50 14 (29.8) 40 (28.2) 5 (29.4) 59 (28.6)
   50-60 32 (68.1) 53 (37.3) 5 (29.4) 90 (43.7)
Sex
   Male 18 (38.3) 77 (54.2) 6 (35.3) 101 (49.0)
   Female 29 (61.7) 65 (45.8) 11 (64.7) 105 (51.0)
WHO-ECOG performance status
   PS 0 27 (57.4) 86 (60.6) 9 (52.9) 122 (59.2)
   PS 1 19 (40.4) 48 (33.8) 7 (41.2) 74 (35.9)
   PS 2 1 (2.1) 5 (3.5) 1 (5.9) 7 (3.4)
   PS 3-4 0 (0.0) 3 (2.1) 0 (0.0) 3 (1.5)
WBC (x109/l) at diagnosis
   Median (range) 16.9 (0.5-291.0) 25.8 (0.6-312.5) 18.2 (1.0-196.4) 24.7 (0.5-312.5)
   <25 25 (53.2) 69 (48.6) 10 (58.8) 104 (50.5)
   25-99.9 11 (23.4) 53 (37.3) 5 (29.4) 69 (33.5)
   ≥100 11 (23.4) 20 (14.1) 2 (11.8) 33 (16.0)
FAB subtype
   M0 4 (8.5) 6 (4.2) 1 (5.9) 11 (5.3)
   M1 14 (29.8) 25 (17.6) 6 (35.3) 45 (21.8)
   M2 8 (17.0) 51 (35.9) 6 (35.3) 65 (31.6)
   M4 2 (4.3) 22 (15.5) 1 (5.9) 25 (12.1)
   M5 17 (36.2) 29 (20.4) 2 (11.8) 48 (23.3)
   M6 1 (2.1) 5 (3.5) 0 (0.0) 6 (2.9)
   M7 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.5)
   Unknown 1 (2.1) 3 (2.1) 1 (5.9) 5 (2.4)
Cytogenetic/FLT3-ITD risk group
   Good 0 (0.0) 22 (15.5) 2 (11.8) 24 (11.7)
   Intermediate (NN,-Y) 25 (53.2) 33 (23.2) 4 (23.5) 62 (30.1)
   Poor (-5/5q-,-7/7q-,complex, FLT3-ITD) 11 (23.4) 28 (19.7) 7 (41.2) 46 (22.3)
   Others 10 (21.3) 53 (37.3) 4 (23.5) 67 (32.5)
   UNK/ND/Failure 1 (2.1) 6 (4.2) 0 (0.0) 7 (3.4)
Percentage BM blasts
   Median (range) 76 (30-98) 64 (20-96) 68 (33-95) 67 (20-98)
   <40% 1 (2.1) 23 (16.2) 2 (11.8) 26 (12.6)
   40 to <60% 11 (23.4) 35 (24.6) 3 (17.6) 49 (23.8)
   60 to <80% 12 (25.5) 41 (28.9) 6 (35.3) 59 (28.6)
   80 to ≤100% 23 (48.9) 43 (30.3) 6 (35.3) 72 (35.0)
No. indicates number; WHO-ECOG, World Health Organization-Eastern Cooperative Oncology Group; WBC, white 
blood cell count; FAB, French-American-British classification; UNK, unknown; ND, not determined; BM, bone marrow.
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Supplemental Table 11. Event-free survival status according to 5hmC level
Non-parametric Cox model
Patients Observed Median (years) % at 5 Years P-value Hazard ratio P-Value
Parameter (N) events (O) (95% CI) (95% CI) (Log-Rank) (95% CI) (Score test)
5hmC: <0.023 47 33
0.83 
(0.43, 1.54)
31.9 
(19.3, 45.3)
0.159 (df=2) 1.00
0.197 
(df=2)
5hmC: 0.023-
            <0.070
141 96
0.92 
(0.57, 1.21)
31.4 
(23.8, 39.2)
0.96 
(0.65, 1.43)
5hmC: ≥0.070 17 15
0.44 
(0.00, 1.63)
6.4 
(0.4, 25.2)
1.58 
(0.85, 2.91)
95% CI indicates 95% confidence interval
Supplemental Table 12. Multivariate Cox regression analysis for overall survival
95% Hazard ratio
Parameter P-value Hazard ratio Confidence limits
Model 1 (5hmC as categorical variable, including WBC)*
5hmC: <0.023 vs. 0.023 to <0.070 0.18 1.35 0.87 2.10
5hmC: ≥0.070 vs. 0.023 to <0.070 0.004 2.50 1.35 4.17
Cytogenetics/FLT3-ITD: Good vs. Intermediate 0.26 0.62 0.27 1.43
Cytogenetics/FLT3-ITD: Others vs. Intermediate 0.13 1.48 0.89 2.47
Cytogenetics/FLT3-ITD: Poor vs. Intermediate <0.0001 3.51 2.18 5.65
Cytogenetics/FLT3-ITD: Unknown vs. Intermediate 0.05 2.96 1.01 6.22
WBC: 25 to <100 vs. <25 0.04 1.51 1.01 2.24
WBC: ≥100 vs. <25 0.17 0.69 0.41 1.17
Model 2 (5hmC as categorical variable, including BM blasts)
5hmC: <0.023 vs. 0.023 to <0.070 0.39 1.21 0.79 1.87
5hmC: ≥0.070 vs. 0.023 to <0.070 0.01 2.15 1.18 3.93
Cytogenetics/FLT3-ITD: Good vs. Intermediate 0.17 0.56 0.24 1.29
Cytogenetics/FLT3-ITD: Others vs. Intermediate 0.15 1.46 0.88 2.44
Cytogenetics/FLT3-ITD: Poor vs. Intermediate <.0001 3.17 2.01 5.03
Cytogenetics/FLT3-ITD: Unknown vs. Intermediate 0.01 3.19 1.28 7.99
BM blasts: 40 to <60% vs. <40% 0.73 1.12 0.60 2.09
BM blasts: 60 to <80% vs. <40% 0.35 1.33 0.74 2.41
BM blasts: ≥80 % vs. <40% 0.74 0.91 0.51 1.62
Model 3 (5hmC as continuous variable)
5hmC x 100: Linear effect 0.10 0.42 0.18 0.96
5hmC100 x 5hmC100: Quadratic effect 0.06 1.10 1.01 1.18
Cytogenetics/FLT3-ITD: Good vs. Intermediate 0.21 0.58 0.25 1.35
Cytogenetics/FLT3-ITD: Others vs. Intermediate 0.19 1.41 0.84 2.36
Cytogenetics/FLT3-ITD: Poor vs. Intermediate <0.0001 2.96 1.89 4.64
Cytogenetics/FLT3-ITD: Unknown vs. Intermediate 0.02 2.94 1.21 7.14
Model 1: AIC=1234
Model 2: AIC=1241
Model 3: AIC=1240
*WBC was excluded from table 2 (main manuscript) because the HR corresponding to the comparison in OS 
between WBC 25 to <100 and WBC <25 is around 1.5, whereas the HR for the comparison in OS between WBC 
≥100 and WBC <25 is 0.7, which is unexpected as outcome generally decreases with increasing WBC. Since more 
patients in the WBC ≥100 have poor cytogenetic/FLT3-ITD features than in the other WBC groups, such a low HR (+/- 
0.7) counterbalances the HR of 3.51 (model 1 above) corresponding to the comparison poor cytogenetic/FLT3-ITD 
features vs. intermediate risk group.
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Supplemental Figure 1. DNA (hydroxy)methylation pathway. Schematic overview of the DNA (hydroxy)methylation 
pathway, showing the link between DNMT proteins, TET proteins and wild-type and mutated IDH proteins.
Assessed for 5hmC (n=206)
       TET2 or IDH mutated  
                    (n= 61)
TET2 and IDH wild-type 
(n=145)
Did not reach CR (n=13)
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Supplemental Figure 2. Consort diagram
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Supplemental Figure 3. Overall survival AML-12 cohort. The OS rate for the 206 AML-12 patients included in our 
study was slightly lower than for the non-included AML-12 patients.
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Supplemental Figure 4. 5hmC levels in peripheral blood and bone marrow are comparable. For 15 patients 5hmC 
levels were measured in peripheral blood (PB) and bone marrow (BM). These measurements showed comparable 
levels using both sources. The Pearson correlation coefficient (r) was determined.
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Supplemental Figure 5. Correlation of 5hmC levels with clinical and molecular parameters in TET2/IDH wild-type 
patients. No significant correlation was found between 5hmC levels and sex (A), age (B), initial performance status 
(PS) (C), WBC (D)  or cytogenetics (FLT3-ITD status not considered) (E). WBC indicates white blood cell count; Int, 
intermediate. Symbols indicate Mann-Whitney U test (*), Kruskal Wallis test (†), and Spearman correlation coefficient 
(rs, ‡).
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Supplemental Figure 6. Blast count correlates with 5hmC levels in TET2/IDH wild-type patients. 5hmC values in 
TET2/IDH wild-type patients correlated with the percentage of blasts in PB (A) and BM (B). Pearson correlation 
coefficients (r) were determined.
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Supplemental Figure 7. Correlation between TET expression and global 5hmC values. 5hmC levels in AML patients 
without TET2 or IDH mutations were correlated with the mRNA levels of TET1 (A), TET2 isoform 1 (B), TET2 isoform 2 
(C) and TET3 (D). Expression levels were normalized to GAPDH. No significant correlation could be observed between 
TET expression and 5hmC levels. Spearman correlation coefficients were determined. Iso indicates isoform.
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global 5mC levels and overall survival. 

5
5-Hydroxymethylcytosine: An epigenetic 
mark frequently deregulated in cancer
Kroeze LI, van der Reijden BA, Jansen JH
Biochim Biophys Acta. 2015 Apr;1855(2):144-154 
Chapter 5
106
Abstract
The epigenetic mark 5-hydroxymethylcytosine (5hmC) has gained interest since 2009, when 
it was discovered that Ten-Eleven-Translocation (TET) proteins catalyze the conversion of 
5-methylcytosine (5mC) into 5hmC. This conversion appears to be an intermediate step in 
the active DNA demethylation pathway. Factors that regulate DNA hydroxymethylation are 
frequently affected in cancer, leading to deregulated 5hmC levels. In this review, we will 
discuss the regulation of DNA hydroxymethylation, defects in this pathway in cancer, and 
novel therapies that may correct deregulated (hydroxy)methylation of DNA.
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Introduction
DNA methylation is essential for normal development and plays an important role in many 
processes, including X-chromosome inactivation, imprinting and transcriptional regulation. 
Methylation of promoter regions is associated with transcriptional repression, while 
actively transcribed genes may contain high levels of gene body methylation (from the 
transcription start site to the end of the transcript).1 DNA methylation is mediated by DNA 
methyltransferases (DNMTs) and predominantly occurs on cytosine residues present in CpG 
context. DNMT3A and DNMT3B are responsible for de novo methylation, while DNMT1 is 
mainly involved in maintaining methylcytosine marks during DNA replication (Figure 1).2
DNA demethylation may take place as a passive process due to lack of maintenance 
methylation during DNA replication. In addition, recent studies presented evidence for an 
active DNA demethylation pathway initiated by the Ten-Eleven Translocation (TET) protein 
family. The TET proteins are responsible for the conversion of 5-methylcytosine (5mC) into 
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) 
through three consecutive oxidation reactions.3,4 5fC and 5caC marks are recognized by 
thymine DNA glycosylase (TDG). TDG activates the base excision repair pathway (BER), which 
replaces the modified cytosine with an unmodified cytosine (Figure 1).5
Many proteins and cofactors control the balance between methylation and demethylation. F\WRVLQHE E, ,E,ϮK ,
PHWK\OF\WRVLQHE E, ,E,ϮK K\GUR[\PHWK\OF\WRVLQHE E, ,E,Ϯ2,ϯ ,ϮK,'107$% 7(7Į.*)HYLWDPLQ& 7(7 IRUP\OF\WRVLQHE E, ,E,ϮK
FDUER[\OF\WRVLQHE E, ,E,ϮKK\GUR[\PHWK\OXUDFLOE E, ,K Į.*)HYLWDPLQ& ,K
KK,,ϮK,
3DVVLYHGHPHWK\ODWLRQ $FWLYHGHPHWK\ODWLRQ
7(77'*7'*%DVHH[FLVLRQUHSDLU $,'$32%(&K, Į.*)HYLWDPLQ&'1$UHSOLFDWLRQPDUNQRWFRSLHGE\'107
Figure 1. DNA methylation and demethylation pathways. DNMT proteins are responsible for the methylation of 
cytosines in the DNA. DNMT3A/B are the most important regulators of de novo methylation, while DNMT1 is mainly 
involved in maintaining the 5mC mark during DNA replication. When DNMT1 is not able to copy the mark, this can 
lead to passive demethylation during cell division. Recently, two pathways of active demethylation have been 
described. Most evidence exists for a pathway in which TET proteins convert 5mC into 5hmC, 5fC and 5caC through 
three consecutive oxidation reactions. Subsequently, 5fC and 5caC are recognized by TDG proteins which activate 
the base excision repair pathway. In addition, evidence exists for a pathway in which AID/APOBEC proteins deaminate 
5hmC to 5hmU followed by TDG-mediated base excision repair.149
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In cancer, this balance is frequently deregulated, leading to altered methylation patterns. 
These changes in methylation can lead to repression of tumor suppressor genes or activation 
of oncogenes. Recently, it has been shown that hydroxymethylation levels are also altered in 
various types of cancer.6-9 Key events that contributed to the elucidation of the link between 
deregulated 5hmC levels and cancer are summarized in Figure 2. Several mechanisms have 
been described that may be involved in these changes in 5hmC, which will be the focus of this 
review. Insights into these mechanisms may open new possibilities for treatment.
DNA hydroxymethylation and its regulation 
5hmC was initially found in the DNA of bacteriophages,10 and was first reported to be 
present in mammalian DNA in 1972.11 After 1972, the interest for this cytosine modification 
was lost until 2009, when it was shown that TET proteins catalyze the conversion of 5mC to 
5hmC.3 Currently, 5hmC is well-accepted as an intermediate in demethylation. In addition, 
several studies suggest that it has additional functions as well. First of all, various tissues 
accumulate substantial levels of 5hmC, which is unexpected if 5hmC would only be a 
transient intermediate.12 The levels differ considerably between tissues, with the highest 
levels observed in neuronal and adult liver cells.13,14 Secondly, proteins have been described 
that specifically bind to 5hmC.15  Our knowledge about these proteins is still limited, but they 
may function as so-called 5hmC ‘readers’.
The regulation of DNA hydroxymethylation is mediated by several factors. As mentioned, 
the TET protein family, consisting of TET1, TET2 and TET3, is responsible for the formation of 
5hmC marks. TET proteins belong to the family of α-ketoglutarate- (αKG) and Fe2+-dependent 
dioxygenases, and require αKG as a co-substrate and Fe2+ and ascorbate as co-factors.3,16 The 
availability of these 3 factors may influence the activity of the TET proteins. The co-substrate 
αKG is produced by the isocitrate dehydrogenase (IDH) protein family, consisting of IDH1, 
IDH2 and IDH3. IDH proteins catalyze the oxidative decarboxylation of isocitrate to αKG, 
which is an intermediate step in the tricarboxylic acid (TCA) cycle (Figure 3).
TET1 and TET3 contain a CXXC domain which is implicated in DNA binding. Due to a 
chromosomal inversion event during evolution, the ancestral CXXC domain of TET2 is located 
upstream of the TET2 gene and transcribed in the opposite direction. This CXXC domain 
currently functions as a separate gene, called CXXC4 (or IDAX).17 Recently Ko et al.18 showed 
that CXXC4, and another CXXC protein called CXXC5 (or RINF), are able to downregulate TET2 
protein levels in a dose-dependent manner, with a concomitant decrease in 5hmC levels. 
They showed that CXXC4 binds to unmethylated DNA and recruits TET2 to the genome to 
exert its function. At the same time, DNA-bound CXXC4 triggers degradation of TET2 in a 
caspase-dependent manner. A similar autoregulatory function was observed for the CXXC 
domain present in the TET3 protein.
5hmC levels are also partly regulated by microRNAs (miRNAs). Recently, several miRNAs 
were found to target the TET proteins and other components of the demethylation pathway 
(Table 1). So overall, the 5hmC mark is regulated on many levels.
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Figure 2. Timeline illustrating the key events that contributed to elucidation of the link between deregulated 
5hmC levels and cancer. 
Figure 3. Effect of TET2, IDH1, IDH2, SDH and FH mutations on the generation of 5hmC. Schematic overview 
of a cell, with the Krebs cycle and DNA (de)methylation pathway indicated. In red, five genes are highlighted that 
are frequently mutated in cancer. TET2 mutations disturb the catalytic activity of the TET2 protein, resulting in 
decreased generation of 5hmC. Mutations in IDH, SDH and FH proteins result in accumulation of the metabolites 
2-hydroxyglutarate, succinate and fumarate respectively. All three metabolites are able to inhibit αKG-dependent 
enzymes, including the TET protein family, which leads to a decreased formation of 5hmC.
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Deregulation of DNA hydroxymethylation in cancer 
Several genes that influence hydroxymethylation are mutated in cancer. First of all, one 
of the TET genes, TET2, is affected by mutations in different hematological malignancies. 
Furthermore, four genes that play a role in the Krebs cycle, namely IDH1, IDH2, SDH and FH, 
are mutated in hematological malignancies and various types of solid cancers. These 4 genes 
are able to affect the activity of the TET proteins by changing the levels of metabolites that 
compete with the TET co-factor αKG. In addition, changes in expression of TET, IDH and CXXC 
genes are linked to altered 5hmC levels in cancer. All these individual factors will be discussed 
in the next sections.
Table 1. Human TET- and TDG-targeting miRNAs
miRNA*,† Target(s)‡ References
miR-7 TET2 78
miR-22 TET1,2,3 79,80
miR-26 TET1,2,3 and TDG 78,110
miR-29 TET1,2,3 and TDG 78,81,111
miR-30 TET2 78
miR-33 TET2 78
miR-101 TET2 78
miR-125 TET2 78
miR-202 TET2 78
miR-335 TET2 78
miR-339 TET2 78
miR-520d TET2 78
miR-550-2 TET2 78
miR-767 TET2 78
*Most miRNA family members have a similar effect
†From Cheng et al.78 only miRNAs included with more than 25% repressive effect
‡Not the same targets tested for each miRNA
TET2 mutations 
In 2009, TET2 aberrations were discovered in different hematological malignancies (Table 
2).19,20 The TET2 gene can be affected by deletions as well as by splice site, missense, and 
nonsense mutations. The majority of the missense mutations target the C-terminal catalytic 
domain of the protein. The frequency of TET2 mutations depends on the type of disease (Table 
2), with the highest frequencies observed in chronic myelomonocytic leukemia (CMML) and a 
subtype of T-cell lymphomas called angio-immunoblastic T-cell lymphoma (AITL).21,22 In most 
hematological malignancies, TET2 mutations did not significantly affect prognosis, but several 
studies reported an association with poor prognosis in acute myeloid leukemia (AML).23-25 In 
vitro studies have shown that TET2 mutations result in loss-of-function. Cells transfected with 
wild-type TET2 produced high levels of 5hmC, while 5hmC could hardly be detected in cells 
transfected with a TET2 mutant.7,25 Recently, several studies reported decreased 5hmC levels 
in TET2 knock-out (KO) mice26 and patients with TET2 mutations.7,9,27,28 Importantly, TET2 
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KO mice showed an increase in hematopoietic progenitor cells and a bias towards myeloid 
differentiation, and ultimately developed a CMML-like disease.29,30 The discovery of loss-
of-function TET2 mutations in hematological malignancies provided the first link between 
deregulated 5hmC levels and cancer (Figures 2-3). Interestingly, TET2 mutations have not 
been reported, or are very rare, in other malignancies where 5hmC levels are affected, 
including brain tumors and melanoma.31-33
Table 2. Mutated genes that influence 5hmC levels
Disease/cancer type Frequency   Prognostic impact Reference
TET2 mutations
Chronic myelomonocytic leukemia 44-58% Intermediate/poor 21,112,113
Myelodysplastic syndrome 21-33% Intermediate 19,114,115
Myeloproliferative neoplasms  12-15% Intermediate 20,116,117
T-cell lymphoma 12% ND 29
      Angioimmunoblastic T-cell lymphoma 47-76% Intermediate 22,29,118
Acute myeloid leukemia 7-13% Intermediate/poor 9,23,24,119
B-cell lymphoma 2% ND 29
IDH1/2 mutations
Secondary glioblastoma 73-95% Favorable 120-122
Glioma (grade II and III) 68-85% Favorable 120,123,124
Angioimmunoblastic T-cell lymphoma 20-45% Intermediate 118,125
Acute myeloid leukemia 15-23% IDH1 R132 Intermediate/poor 9,35,119,126,127
IDH2 R172 Intermediate/poor
IDH2 R140 favorable
Myelodysplastic syndrome 4-12% Intermediate/poor 114,115,128,129
Chronic myelomonocytic leukemia 3-6% Intermediate 112,130,131
Ollier disease and Maffucci syndrome 77-93% ND 50,51
Chondrosarcoma and enchondroma 43-56% Intermediate 49,51,132,133
Intrahepatic cholangiocarcinoma 10-28% Favorable 52,53,134
Melanoma 10% ND 56
Thyroid cancer* 8-16% ND 55,135
Prostate cancer 3% ND 54
SDH mutations
Paraganglioma/pheochromocytoma 12-15% (SDHA,B,C,D) Poor 64,136,137
Gastrointestinal stromal tumors 3-8% (SDHA,B,C,D) Favorable 59,138-140
Renal cell carcinoma 1-4% (SDHB) ND 141,142
FH mutations
Multiple cutaneous and uterine 
leiomyomata 
100% ND 143,144
Hereditary leiomyomatosis and renal 
cell cancer
71-93% ND 145-147
Papillary renal cell cancer 17% ND 145
Leydig cell tumors 7% ND 148
Paraganglioma/pheochromocytoma <1% ND 61,64
ND indicates not determined
*IDH1 mutations outside hotspot region; no 2HG production
Chapter 5
112
IDH mutations and elevated 2HG
Two genes of the IDH family, IDH1 and IDH2, are frequently mutated in hematological 
malignancies as well as in certain solid tumors (Table 2).34 IDH mutations are always 
heterozygous and occur at hotspot regions; mutations in IDH1 target arginine 132, and 
mutations in IDH2 target the arginines at position 140 and 172 of the protein.35 In vitro studies 
have shown that mutant IDH proteins gain the function to convert the TET co-substrate αKG 
into R-2-hydroxyglutarate (R-2HG).36 Importantly, 2HG can act as a competitive inhibitor of 
αKG-dependent enzymes, including the TET protein family.37,38
IDH1(R132H) knock-in mice had several hematological defects. They showed increased 
numbers of early hematopoietic progenitors, and developed splenomegaly and anemia with 
extramedullary hematopoiesis.39 In IDH-mutated AML patients, elevated 2HG levels could be 
measured in myeloblasts, bone marrow aspirates, urine and serum.40 Several reports showed 
the potential of using serum 2HG (often 50-100 fold elevated) as a biomarker to detect IDH-
mutated AML.40,41 2HG-mediated inhibition of TET proteins resulted in decreased 5hmC levels 
in these AML patients.9,27 As both TET2 and IDH mutations affect 5hmC levels in AML, this may 
explain why mutations in these genes are mutually exclusive. However, given that αKG is a 
co-substrate for more than 70 αKG-dependent dioxygenases, the effect of IDH mutations may 
be broader than only inhibiting TET proteins.
The first IDH mutations were discovered in 2008 in gliomas.42 Additional studies in 
various central nervous system tumors revealed IDH1 and IDH2 mutations in 75% of grade II 
to III gliomas and secondary glioblastomas (Table 2). As in hematological malignancies, IDH 
mutations in glioma are heterozygous and restricted to specific positions: arginine 132 in 
IDH1 (90% of the cases) and arginine 172 in IDH2 (10% of the cases). In contrast to AML, IDH2 
R140 mutations are absent. The reason why IDH2 R140 mutations are found in hematological 
malignancies but not in brain tumors is currently unknown. As expected, IDH mutant 
glioma cells had elevated 2HG levels (~100 fold).36 In line with 2HG-mediated inhibition of 
TET proteins, IDH-mutated gliomas showed a hypermethylation phenotype; an increased 
prevalence of CpG island hypermethylation in promoter regions.43 5hmC levels were strongly 
decreased in brain tumors when compared to healthy brain tissue; however, the decreased 
5hmC did not always correlate with IDH mutations. Several studies reported decreased 5hmC 
levels in IDH mutant tumors compared to IDH wild-type tumors,8,37,44 while other studies could 
not confirm this difference.45-47 This discrepancy might be caused by the area where biopsies 
were taken from, the specific types of brain tumors that were investigated or the techniques 
that were used to measure 5hmC. 5hmC levels in brain tumors negatively correlated with 
tumor grade, and low 5hmC correlated with a poor prognosis.8,47 In contrast, IDH mutations 
in brain tumors are associated with a relatively favorable prognosis.42,48 Additional studies 
should be performed to clarify this inconsistency.
IDH1 R132 and IDH2 R172 mutations have also been identified in cartilaginous 
tumors, which range from benign enchondromas to highly malignant chondrosarcomas.49 
IDH mutations are found in 56-70% of central chondrosarcomas and enchondromas.50 In 
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addition, somatic mosaic IDH1 and IDH2 mutations have been detected in 77-91% of patients 
with Ollier disease and Maffucci syndrome, two syndromes characterized by multiple benign 
enchondromas. Elevated 2HG levels and hypermethylation were detected in these IDH-
mutated tumor tissues.50,51
IDH1 R132 and IDH2 R172 mutations also occur in 10-23% of intrahepatic 
cholangiocarcinomas, tumors composed of epithelial cells from the bile duct. These IDH-
mutated tumors are characterized by elevated 2HG levels, decreased 5hmC levels, increased 
5mC levels and a hypermethylation signature.52,53 In this disease, IDH1/2 mutations are an 
independent favorable prognostic factor.52
In addition, IDH mutations have been detected at lower frequencies in prostate cancer 
(3%), thyroid cancer (8-16%) and melanoma (10%) (Table 2).54-56 Of note, most IDH mutations 
in thyroid cancer are located outside the hotspot regions and do not produce 2HG, and 
therefore 5hmC levels will presumably not be affected.57 Future research is required to 
determine how relevant these mutations are  for the pathogenesis of thyroid cancer.
A recent study described elevated 2HG levels in a subset of breast cancer tumors 
with predominantly basal-like and mesenchymal origin.58 Although the 2HG levels were 
comparable to those found in IDH-mutated leukemia or glioma samples, no IDH mutations 
were present in these breast tumors. The exact mechanism leading to this elevated 2HG 
is not yet known; however, MYC pathway activation and increased glutamine metabolism 
were linked to elevated 2HG levels in these patients. These tumors were associated with 
a hypermethylation phenotype and poor clinical outcome. Although 5hmC levels were not 
measured in this study, an increase in 2HG will most likely lead to decreased generation of 
5hmC by TET proteins.
SDH and FH mutations
Fumarate hydratase (FH) and succinate dehydrogenase (SDH) are mutated in a subset of 
human cancers (Table 2). Both enzymes play an important role in the Krebs cycle (Figure 3). 
FH catalyzes the conversion of fumarate to malate, and SDH, which is composed of 5 subunits 
(SDHA, SDHB, SDHC, SDHD and SDHAF2), catalyzes the oxidation of succinate to fumarate. 
Mutations targeting the FH gene are found in multiple cutaneous and uterine leiomyomata 
(MCUL, ~100%), hereditary leiomyomatosis and renal cell cancer (HLRCC, 71-93%), papillary 
renal cell cancer (17%), Leydig cell tumors (7%), and paraganglioma and  pheochromocytoma 
(<1%). SDH genes are mutated in renal cell carcinoma (1-4%), gastrointestinal stromal tumors 
(3-8%), and paraganglioma and pheochromocytoma (12-15%).59-61 In most cases this are 
germline mutations, but also some somatic mutations have been described.62 Mutations in 
FH and SDH lead to a reduction of enzymatic activity, which results in an accumulation of 
fumarate and succinate, respectively.63 Structurally, both fumarate and succinate are similar 
to αKG and 2HG. In vitro and in vivo studies have shown that fumarate and succinate are able 
to inhibit multiple αKG-dependent dioxygenases, including the TET family. Indeed, knockdown 
of Fh or Sdha in mouse liver cells led to a decrease in 5hmC, which could be rescued by 
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transfecting with wild-type but not with mutant FH or SDHA constructs.62 Genome-wide 
methylation studies revealed a hypermethylation phenotype in pheochromocytoma and 
paraganglioma samples with SDH or FH mutations. In addition, 5hmC levels were decreased 
in these patients, providing in vivo evidence for the effect of SDH and FH mutations on 5hmC 
levels. SDH and FH mutations were associated with poor prognosis in pheochromocytoma 
and paraganglioma.61,64
Other TET abnormalities that may influence 5hmC levels
TET1 was first identified as a gene fused to MLL in an AML patient with a ten-eleven 
translocation.65 This translocation does not occur very frequently with only 13 cases reported 
in the literature to date: 11 AML and 2 ALL patients.66 5hmC measurements have not yet been 
reported in these patients.
In glioma, TET2 mutations have not been described; however, TET2 promoter 
methylation has been detected in 14% of low-grade glioma patients without IDH mutation.32 
Since promoter methylation is associated with transcriptional repression, this suggests 
a decreased TET2 expression in these patients, possibly leading to decreased levels of 
5hmC. More research is required to determine the consequences and importance of this 
observation. In addition, Mϋller et al.46 showed a strong correlation between nuclear 
exclusion of TET1 and decreased 5hmC levels in glioma. In their study, 61% of the tumor 
samples had decreased 5hmC levels; however, there was no correlation between 5hmC and 
IDH mutations. Of the 5hmC negative tumors, 70% showed nuclear exclusion of TET1, or no 
detectable TET1 protein, thereby demonstrating an additional mechanism that may lead to 
decreased 5hmC in glioma.
Altered TET/IDH/TDG expression
In several types of cancer, deregulated 5hmC was accompanied by changes in TET or IDH 
expression. Diminished expression of IDH2 and TET1/2/3 was reported in melanoma, and 
therefore may represent one of the molecular mechanisms underlying global 5hmC loss in 
these tumors.31 5hmC levels were decreased in melanoma but not in benign nevi, showing 
the potential of 5hmC levels to be used as a biomarker to discriminate between benign and 
malignant lesions.67 5mC levels did not differ significantly between melanoma and benign 
nevi.68 Loss of 5hmC correlated with melanoma progression, increasing nuclear diameter 
and decreased tumor-free survival.31,69 Rebuilding the 5hmC landscape in melanoma by 
reintroducing active TET2 or IDH2, suppressed melanoma growth and increased tumor-free 
survival in animal models.31
Also in breast and liver cancer the expression of all three TET proteins was reduced 
when compared to matched healthy tissues.70 In gastric cancer all three TET proteins, IDH2, 
and TDG were downregulated; however, the loss of 5hmC was mainly correlated with the 
downregulation of TET1.71 In colorectal cancer TET1 expression was found to be reduced,72 
while in oral squamous cell carcinoma reduced 5hmC levels were accompanied by decreased 
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TET2 expression levels.73 In gastric cancer and hepatocellular carcinoma, 5hmC levels 
negatively correlated with tumor size and tumor stage, and reduced 5hmC predicted a poor 
overall survival.74,75
In addition, several genes involved in regulating the levels of 5hmC were differentially 
expressed between glioblastoma subtypes. mRNA expression of all three TET proteins was 
decreased in the aggressive mesenchymal subtype of glioblastoma. Moreover, the expression 
of several genes involved in the active demethylation pathway, including TDG, was increased 
in this glioblastoma subtype. Reduced TET1 or TET3 expression was associated with inferior 
overall survival. The expression levels of TDG and TET genes were not directly correlated with 
5hmC levels; however, decreased TET expression and increased expression of genes involved 
in demethylation (e.g. TDG), both suggest a reduction in 5hmC levels.47
Huang et al. observed increased TET1 expression in leukemia patients with MLL-
rearrangements. They described an oncogenic role for TET1 in MLL-rearranged leukemia. 
Knockdown of TET1 inhibited MLL-AF9-induced leukemogenesis in mice, and led to a 
significant downregulation of HOXA9, MEIS1 and PBX3, three genes frequently overexpressed 
in MLL-rearranged leukemia.76 In accordance with high TET1 expression, we found that most 
AML patients with MLL rearrangements had high 5hmC levels.9
Altered 5hmC levels have also been described in some benign tumors. In uterine 
leiomyoma, the most common benign tumor of the female reproductive tract, 5hmC levels 
were found to be increased, which was associated with an elevated protein expression of 
TET1 and TET3.77
MicroRNA expression
Several TET-targeting microRNAs have recently been described (Table 1). Changes in the 
expression of these miRNAs may account for the altered TET expression observed in several 
types of cancer. Cheng et al.78 discovered a complete network of more than 30 miRNAs 
that inhibited TET2 expression. The top 10 most effective human TET2-targeting miRNAs 
were miR-26a-1, -26a-2, -29b-1, -520d, -26b, -7-3, -125b-1, -7-1, -125a, -30d. Overexpression 
of these miRNAs in cell lines resulted in decreased TET2 mRNA and protein expression, 
and decreased levels of 5hmC. Some TET2-targeting miRNAs, including miR-26 and -29 
family members, also regulated TET1 and TET3 expression levels. Transplantation of bone 
marrow cells transduced with TET2-targeting miRNAs into lethally irradiated mice resulted 
in a disturbed hematopoiesis with hematopoietic expansion and/or a myeloid differentiation 
bias, whereas co-expression of TET2 corrected these phenotypes. Importantly, several of 
these TET2-targeting miRNAs, including miR-125b, miR-29b, miR-29c, miR-101 and miR-7, 
were predominantly overexpressed in TET2 wild-type AML, which suggests that TET2 activity 
can be affected by either TET2 mutations or deregulated TET expression in AML patients.
In a study by Song et al., TET2 was predicted to be a target of miR-22.79 Transgenic 
mice overexpressing miR-22 in the hematopoietic compartment developed a myelodysplastic 
syndrome (MDS)-like disease which, in 70% of the mice, resulted in myeloid leukemia. 
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The phenotype developed in these mice closely resembled the inactivation of TET2 in the 
hematopoietic compartment. TET2 mRNA and protein levels were reduced in peripheral 
blood and bone marrow of miR-22 overexpressing mice, as well as the expression of TET2 
target genes. 5hmC levels were reduced more than 2-fold in bone marrow with a concomitant 
increase in 5mC levels. Micro-array data showed upregulated miR-22 expression in patients 
with MDS and AML. Around 60% of the MDS patients had decreased TET2 expression which 
anti-correlated with miR-22 expression levels. These findings show that changes in miR-22 
may affect 5hmC levels in hematological malignancies.
miR-22 also represses TET1, TET2 and TET3 in breast cancer.80 Overexpression of miR-22 
in the mammary glands of mice resulted in decreased 5hmC levels. Targeting of TET proteins 
by miR-22 inhibited the demethylation of the miR-200 promoter, leading to silencing of anti-
metastatic miR-200 family members. miR-200 family members are known to be important 
regulators of epithelial-to-mesenchymal transition and mammary stem cell function. miR-22 
was highly expressed in non-triple-negative breast cancer samples when compared to normal 
breast tissue, and high expression correlated with silencing of the TET-miR-200 axis and poor 
clinical outcome. This study shows that a reduced expression of TET enzymes, caused by miR-
22 overexpression, may promote breast cancer metastasis.
Analysis of miRNA-targets across 10 cancer types (see Table 3, last row) led to the 
discovery of miR-29 as an important regulator of TET1 and TDG.81 TET1 expression was strongly 
negatively correlated with expression of miR-29 family members in all 10 tested cancer types 
and of TDG in all but one cancer type. miR-29a was generally downregulated and TET1 and 
TDG were upregulated as compared with representative normal samples. In line with this, 
the majority of TDG-associated promoters were hypomethylated in 9/10 cancer types. These 
results are opposite to the decreased TET1 expression reported in melanoma, hepatocellular 
carcinoma, gastric cancer and the mesenchymal subtype of glioblastoma. It would be of 
interest to determine 5hmC levels in the analyzed tumor samples, since upregulated TET1 
suggests elevated 5hmC levels, while most papers describe decreased 5hmC levels in cancer.
CXXC4/5 expression
As explained above, CXXC4/5 proteins are able to influence 5hmC levels by modulating TET 
protein levels. In line with this, Ko et al. showed that CXXC overexpression may play a role 
in hematological malignancies, since CXXC4 overexpression mimicked TET2 deficiency by 
skewing differentiation of murine bone marrow hematopoietic stem/progenitor cells towards 
the myeloid lineage.18 Importantly, deletions of chromosome 5 or the long arm of chromosome 
5 (-5/del(5q)), including CXXC5,  are frequently observed in leukemia. In addition, decreased 
CXXC5 expression was recently reported in a subset of leukemia patients, particularly cases 
with -5/del(5q), MLL rearrangements and AML1-ETO translocations.82,83 In line with this, we 
found that most patients with AML1-ETO and MLL rearrangements have high 5hmC levels.9
Aberrant CXXC4 or CXXC5 expression has also been observed in several other types 
of cancer. CXXC5 is overexpressed in a number of solid cancers (breast cancer, melanoma, 
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Table 3. Mechanisms deregulating 5hmC in each cancer type
Type of cancer Defects possibly influencing 5hmC levels Effect on 5hmC level
Brain tumors IDH1/2 mutations Decreased/No effect
Nuclear exclusion of TET1 Decreased
TET2 promoter methylation ND
Possibly: Aberrant expression of genes involved in 
demethylation
ND
Breast cancer Increased miR-22 expression Decreased
 Decreased TET1/2/3 expression Decreased
 Increased 2HG production ND
 CXXC5 overexpression ND
Colon cancer Decreased TET1 expression Decreased
 CXXC4 overexpression ND
Gastric cancer Decreased IDH2, TDG, TET1/2/3 expression Decreased (TET1)
 Decreased CXXC4 expression ND
Gastrointestinal stromal tumors SDH mutations ND
Hematological malignancies TET2 mutations Decreased
IDH1/2 mutations Decreased
Increased expression of TET-targeting miRNAs Decreased
TET1 overexpression Increased
Decreased CXXC5 expression ND
Possibly: MLL-TET1 translocation ND
Liver cancer Decreased TET1/2/3 expression Decreased
Melanoma IDH1/2 mutations ND
 Decreased IDH2, TET1/2/3 expression Decreased
 CXXC5 overexpression ND
Oral squamous cell carcinoma Decreased TET2 expression Decreased
Paraganglioma/pheochromocytoma SDH mutations Decreased
 FH mutations Decreased
Renal cell carcinoma SDH mutations ND
 FH mutations ND
Thyroid cancer CXXC5 overexpression ND
Uterine leiomyoma TET1 and TET3 overexpression Increased
Cartilaginous tumors IDH1/2 mutations ND
Intrahepatic cholangiocarcinoma  Decreased 
Prostate cancer  ND
Hereditary leiomyomatosis and renal cell cancer FH mutations ND
Leydig cell tumors   
Multiple cutaneous and uterine 
leiomyomata
 
Bladder urothelial carcinoma Decreased miR-29 expression ND
Breast invasive carcinoma  
Colon and rectum adenocarcinoma  
Glioblastoma multiforme  
Head and neck squamous-cell carcinoma   
Kidney renal clear-cell carcinoma  
Lung adenocarcinoma
Lung squamous-cell carcinoma   
Ovarian serous cystadenocarcinoma  
Uterine corpus endometrioid carcinoma   
ND indicates not determined
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thyroid cancer) and correlated with poor prognosis in breast cancer.84 Furthermore, 
CXXC4 overexpression has been described in adenomas of the colon,85 whereas CXXC4 
downregulation has been described in gastric carcinoma, where it associated with poor 
prognosis.86 Future studies should examine whether overexpression or downregulation of 
CXXC4/5 proteins influences 5hmC levels in these types of cancer.
Potential 5hmC regulating factors
TET proteins belong to the family of αKG- and Fe2+-dependent dioxygenases, and therefore 
require αKG as a co-substrate and iron (Fe2+) as a co-factor for their activity.3 Recently, in vitro 
studies revealed an additional co-factor, ascorbate, which enhances TET-mediated generation 
of 5hmC.16 Ascorbate is required to maintain iron in the active state by reducing inactive Fe3+ 
to active Fe2+. A disbalance in co-substrates and co-factors might affect the activity of the 
TET proteins and consequently the levels of 5hmC. Therefore, it will be interesting to explore 
whether the levels of αKG, iron and ascorbate are altered in cancer.
TET proteins utilize molecular oxygen to oxidize 5mC, which suggests that altered oxygen 
levels in the tumor microenvironment may influence TET activity. In the past few years, several 
studies reported an effect of altered oxygen levels on TET expression or activity. It has been 
shown that hypoxia leads to an increased IDH-dependent carboxylation of glutamine-derived 
αKG, which is associated with an increased synthesis of 2HG in cells with wild-type IDH1 
and IDH2 proteins.87 Elevated 2HG levels could lead to enhanced inhibition of TET activity 
and decreased 5hmC levels in these cells. On the contrary, it has been shown that hypoxia 
induces an HIF1-dependent increase in TET1 expression in neuroblastoma cell lines, followed 
by an increase in 5hmC.88 Finally, it has been reported that reactive oxygen species (ROS), 
induced by the drug 5-fluorouracil, upregulated TET1 expression and function in colorectal 
cancer, whereas antioxidants had the opposite effect.89 More research should therefore be 
performed to clarify the effects of altered oxygen levels on 5hmC levels in cancer.
Several proteins have been discovered that bind to 5hmC, like MECP2, WDR76, UHRF1 
and UHRF2.15 It may be possible that these 5hmC readers block further oxidation of 5hmC 
into 5fC and 5caC or, in contrast, promote active demethylation. In line with the latter, Spruijt 
et al. showed that overexpression of UHRF2 in vitro increased the levels of 5hmC, 5fC and 
5caC, which suggests that UHRF2 stimulates TET-mediated oxidation.15
Possibilities for treatment
Although the causes and consequences of deregulated 5hmC levels are still under 
investigation, several opportunities for targeting the underlying mechanisms have already 
been explored.
A number of specific inhibitors for IDH1 and IDH2 mutations have been developed and 
tested in in vitro and in vivo settings. Inhibitors for IDH1 R132 (AGI-5198,90 HMS-101,91 AG1-
14100,92 ML30993) were shown to specifically inhibit the ability of the mutant enzyme to 
produce 2HG in leukemia and glioma xenograft models. In addition, treatment with these 
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inhibitors resulted in growth inhibition and induction of cellular differentiation.91,92 Recently, 
the IDH1 inhibitor AGI-14100 was tested in combination with Ara-C in a xenograft model, 
which resulted in a stronger decrease of bone marrow tumor burden than either treatment 
alone.92 Specific inhibitors for IDH2 R140 have also been developed; AGI-678094 and AG-
221.95 Both compounds reduce 2HG production and induce cellular differentiation. AG-221 
was also shown to reverse histone and DNA hypermethylation in vitro. The AG-221 inhibitor 
is currently being tested in vivo in a phase 1 dose-escalation study.
In addition, changes in DNA methylation are interesting targets for therapy, because 
epigenetic modifications are reversible. Several clinical trials investigated the treatment 
of MDS and AML patients with hypomethylating agents (azacitidine and decitabine), 
which may result in reactivation of silenced tumor suppressor genes. These trials showed 
promising results, including improved complete remission, event-free survival and overall 
survival rates.96,97 Azacitidine and decitabine have therefore been approved by the Food and 
Drug Administration (FDA) for treatment of MDS patients, and AML patients with 20-30% 
blasts (previously classified as RAEB-T by the French-American-British MDS classification). 
In addition, decitabine has been approved by the European Medicines Agency (EMA) for 
treatment of AML patients aged 65 years and older who are not eligible for initial standard 
induction chemotherapy. Because TET2- and IDH-mutated AML patients are characterized by 
a hypermethylation phenotype, hypomethylating agents were hypothesized to be particularly 
beneficial for these patients. Studies by Itzykson et al.,98 Traina et al.99 and Bejar et al.100 reported 
an increased response rate to azacitidine for patients with a TET2 mutation; however, other 
recent reports did not show a preferential benefit for TET2- or IDH-mutated patients.101-103 
Future large prospective studies are required to unravel the biomarkers that predict response 
to hypomethylating agents in hematological malignancies. The hypomethylating agent 
decitabine was also tested in an IDH1-mutant glioma xenograft model. Decitabine treatment 
resulted in decreased cell growth and induction of differentiation. In addition, genome-
wide DNA demethylation and upregulation of several differentiation-associated genes were 
observed.104  More research is necessary to determine the effectiveness of hypomethylating 
agents in IDH-mutated glioma patients. Despite the successes achieved by these nucleoside 
analogs, there is still room for improvement since the specificity of these compounds is quite 
low and cellular toxicity has been observed. In an attempt to overcome these problems 
several non-nucleoside DNMT inhibitors have been explored, including hydralazine, RG108, 
SGI-1027, procaine, procainamide, and MG98.105 To date, none of these compounds has yet 
been approved for use as DNMT inhibitor in the clinic. In addition to the reported beneficial 
effects of hypomethylating agents, these drugs might also reactivate oncogenes and, in solid 
tumors like breast cancer, prometastatic genes, indicating that caution is needed when using 
these drugs.106,107
Based on recent discoveries, several new treatment options might be investigated. In 
patients where 5hmC is decreased due to elevated miRNA or CXXC expression, TET proteins are 
still functional, which suggests that increasing TET expression or TET activity may be beneficial 
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for these patients. In vitro studies have already demonstrated that TET overexpression is able 
to rescue the phenotype caused by overexpression of TET-targeting miRNAs.78,80 In addition, 
modulating the activity of the TET proteins by changing the availability of co-substrates and 
co-factors (αKG, iron and ascorbate) warrants investigation.
5hmC
TET2 mutations
TET expression
CXXC4/5 
expression
TET-targeting 
miRNAs
TET2 hyper-
methylation
TET activity
TET1 nuclear
exclusion
IDH1/2 
mutations
TET co-factors
5hmC binding 
proteins
SDH/FH
mutations
Expression of 
genes involved 
in demethylation
+
+ +
+ +
Figure 4. Factors (potentially) influencing 5hmC levels in cancer. In cancer, 5hmC levels are mainly influenced by 
changes in TET expression or TET activity. In addition, changes in the expression of genes that bind 5hmC or genes 
that are implicated in demethylation may affect the levels of 5hmC (indicated in yellow). Several factors have been 
described that are able to influence the expression or activity of TET proteins (indicated in purple). + indicates 
positive effect, – negative effect.
Concluding remarks and perspectives 
Deregulated 5hmC levels have been observed in many types of cancer, both in solid cancers 
as well as in hematological malignancies. Several mechanisms can be responsible for the 
altered 5hmC levels, ranging from mutations to deregulated miRNA expression (Table 3, 
Figure 4). The fact that altered 5hmC levels are frequently observed in cancer suggests that 
the (de)methylation pathway might be an important target for cancer therapy, however, 
several unanswered questions still need to be addressed.
First of all, it is still unclear whether deregulated 5hmC levels are a cause or a 
consequence of cancer. In hematological malignancies, TET2 mutations seem to play an 
important role in transformation, since TET2 KO mice develop a CMML-like disease, and TET2 
mutations are often early events.29,30 Also IDH mutations are often early events,108 but a sole 
IDH mutation in mice is insufficient to cause glioma or leukemia, suggesting that additional 
hits are required for full transformation.39 On the other hand, in some solid cancers 5hmC 
levels seem to correlate with the stage of the disease,31,74,75 which suggests that 5hmC levels 
either change as a consequence of cancer progression, or promote cancer progression. This 
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suggests that the role of deregulated 5hmC in pathogenesis may differ per cancer type, 
with mutations more likely to be involved in the initiation of cancer, while other ways of 
deregulating 5hmC (e.g. changes in TET expression) may be associated with progression of 
the disease. More research should be performed to clarify the involvement of 5hmC changes 
in the pathogenesis of different cancer types.
Secondly, it is important to unravel how altered 5hmC levels contribute to pathogenesis. 
A decrease or increase in global 5hmC suggests a defect in the balance of methylation and 
demethylation, which may lead to silencing of tumor suppressor genes or activation of 
oncogenes. Genome-wide (hydroxy)methylation studies should be performed to determine 
which genes are differentially (hydroxy)methylated between healthy and cancer tissues. This 
will give insights into the genes that might play a role in the pathogenesis or progression 
of the disease, and thereby point towards new targets for therapy. At the moment, several 
techniques are available to determine genome-wide 5mC distribution, however, not all 
techniques are able to discriminate between 5mC and 5hmC marks. Techniques suitable for 
specific detection of 5mC are for example methylated DNA immunoprecipitation (MeDIP) and 
methyl binding domain (MBD)-based techniques. Determining the genome-wide distribution 
of 5hmC is still challenging due to the low levels, however, with the rapidly improving 
techniques this should be possible in the future.
Finally, it will be very interesting to determine whether the levels of the other 
demethylation intermediates, 5-formyl- and 5-carboxylcytosine, are also altered in cancer. 
Genome-wide techniques to determine 5fC and 5caC have only recently been developed and 
might be used in the future to answer this question.109
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Abstract
Cancer development is a dynamic process during which the successive accumulation of 
mutations results in transformed cells with increasing malignant characteristics. To assess 
the precise evolutionary pattern of malignant transformation, we performed an in-depth 
genetic analysis of 11 myelodysplastic syndrome (MDS) patients receiving supportive care, 
with (n=5) or without (n=6) lenalidomide (follow-up time 2.5-11 years). Whole exome and 
targeted deep sequencing of blood and bone marrow samples at multiple time points during 
the disease course revealed marked differences in clonal evolution between patients. This 
varied from patients with a single clone remaining stable for many years (>8 years) to patients 
with dynamic changes in clonal composition. This study shows that 1) genetic evolution, 
according to both linear and branched evolutionary patterns, occurs in MDS with and without 
disease-modifying treatment, 2) the application of disease-modifying therapy may create an 
evolutionary bottleneck after which more complex MDS, but also non-MDS related clones of 
hematopoietic cells may emerge, and 3) that subclones that acquired an additional mutation 
associated with treatment resistance (TP53) or disease progression (NRAS, KRAS) may be 
detected months before clinical changes become apparent.
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Introduction
Myelodysplastic syndromes (MDSs) are a heterogeneous group of hematopoietic neoplasms 
characterized by bone marrow dysplasia and peripheral blood cytopenias. In approximately 
30% of MDS patients, progression towards acute myeloid leukemia (AML) occurs. Various 
genetic mutations underlying the pathogenesis of MDS have been identified. Most of the 
recurrently affected genes can be classified as transcription factors, signal transduction 
proteins, epigenetic modifiers, proteins involved in RNA splicing and proteins of the cohesin 
complex involved in cell division.1-3
Typically, in a given MDS patient, several mutations can be detected simultaneously. 
Genes that are recurrently mutated in different individuals with MDS likely play a role in the 
pathogenesis of the disease (driver mutations), but also non-pathogenic mutations that are 
acquired in individual cells during life (passenger mutations) are found, as these are clonally 
expanded together with the pathogenic mutations during the development of the disease.4 
Oncogenesis is thought to be a multistep evolutionary process. The successive acquisition 
of several mutations that confer a selective advantage may result in the emergence of 
populations of cells that harbor the same set of mutations.5,6 Both linear and branching 
patterns of evolution have been described. During linear evolution subclones that acquired 
additional mutations completely overgrow the ancestral clone from which they originate, 
whereas branched evolution results in the emergence of subclones with a divergent set 
of mutations, which exist simultaneously.7,8 Apart from the evolution of the overall growth 
characteristics of the disease, the genetic diversity amongst co-existing subclones may result 
in a more difficult to treat type of disease, as some of the subclones may be resistant to 
specific types of therapy. Consequently, eradication of all subclones may be hard to achieve. 
In several studies the genetic changes during transformation from MDS towards AML 
have been documented.5,9,10 Evolutionary patterns in MDS patients before or without leukemic 
transformation are, however, much less documented, and are often derived from imputations 
based on a limited number of analyses per patient.11-13 In this study, we performed an in-
depth analysis of clonal evolution in MDS patients who were followed for a prolonged period 
of time. Six patients were studied who were treated solely with supportive care (transfusions, 
growth factors, folic acid), as well as five patients who were treated with lenalidomide. Whole 
exome sequencing (WES) was performed at multiple time points during the disease course. 
Subsequently, targeted deep sequencing, tailored to the identified acquired mutations at 
various time points, was used to quantify the mutational burden of all mutations at high 
sensitivity. Clonal composition and evolutionary patterns were reconstructed on the basis 
of the observed mutational burdens. Subsequently, the clonal evolution patterns were 
correlated to therapy response and other clinical parameters. Clonal evolution was observed 
both in patients treated with supportive care only and in patients treated with disease- 
modifying therapy.
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Materials and methods
Patient samples
Eleven lower risk MDS patients were selected based on a long disease course and many 
sampling moments. The patients were diagnosed between 1996 and 2006. Bone marrow 
(BM) and peripheral blood (PB) from these patients were obtained after informed consent. 
The study was conducted in accordance with the Declaration of Helsinki and institutional 
guidelines and regulations (CMO 2013/064). The patient characteristics are listed in Table 
1. Morphology and cytogenetic analysis (karyotype analysis and fluorescence in situ 
hybridization) were performed according to standard procedures.
DNA isolation and amplification
DNA was isolated from PB or BM of MDS patients using the NucleoSpin Blood QuickPure kit 
(Macherey Nagel, Düren, Germany) according to the manufacturer’s protocol. In addition, 
BM and PB mononuclear cells (MNCs) and PB granulocytes were obtained after ficoll-1077 
density gradient separation, after which DNA was isolated. When the extraction yield was 
insufficient, 80 ng of DNA was amplified using the Qiagen REPLI-g kit (Qiagen, Hilden, Germany) 
in 4 parallel reactions (20 ng per reaction), according to the manufacturer’s protocol.
T cell culture
Pure T cells were obtained from each patient by in vitro expansion of T cells from peripheral 
blood. Myeloid cells were first depleted by adherence to tissue culture flasks. The remaining 
cells were cultured for 14 to 21 days in IMDM medium (Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% human serum (PAA Laboratories GmbH, Pasching, Austria), IL-2 (100 
IU/ml) and CD3/CD28 coated Dynabeads (Thermo Fisher Scientific, Waltham, MA, USA). The 
purity of the T cells was measured by flowcytometric analysis using the CD3 surface marker. 
When the purity of the T cells exceeded 95%, DNA was isolated using the NucleoSpin Blood 
QuickPure kit.
Mesenchymal stem cell (MSC) culture
Bone marrow MNCs were obtained by ficoll-1077 density gradient separation. BM-MNCs 
were seeded at a density of 8 to 23 x 104 cells/cm2 in α-MEM medium (Sigma-Aldrich, St 
Louis, MO, USA) supplemented with heparin (3.5 iU/ml) and 5% platelet lysate. Platelet lysate 
was prepared by freeze-thawing platelets (>0.8x109 platelets/ml), followed by centrifugation 
at 4700xg and collection of the supernatant. Seven days after seeding, the culture medium 
was refreshed. Subsequently, cells were passed when 80% confluency was reached. After 
approximately 7 days of culture all blood cells died and/or were washed away and a layer with 
MSCs remained. MSCs were cultured up to 5 passages.
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Sorting of myeloid progenitors
Viably frozen bone marrow MNCs were thawed in the presence of DNAse I and incubated for 
10 minutes in a solution of fetal calf serum, heparin and MgSO4. Subsequently, the myeloid 
progenitor cells were sorted according to a protocol adapted from Pang et al., with minor 
modifications.14 The cells were washed and stained with CD34-APC (Beckman Coulter, Brea, 
CA, USA), CD38-PE-Cy7 (BioLegend, San Diego, CA, USA), CD123-PE (BioLegend) and CD45RA-
PB (BioLegend) monoclonal antibodies. Cells were analyzed and sorted using a FACS Aria 
SORP flow cytometer and DIVA software (Becton Dickinson, Franklin Lakes, NJ, USA). Viable 
cells were selected based on forward scatter (FSC) and side scatter (SSC) profiles, and doublets 
were discriminated using FSC area vs. width and SSC area vs. width. The hematopoietic stem 
cell (HSC) population was defined as CD34+CD38-. Within the CD34+CD38+ fraction, the 
common myeloid progenitor (CMP) cells (CD123+CD45RA−), the granulocyte-macrophage 
progenitor (GMP) cells (CD123+CD45RA+) and the megakaryocyte-erythroid progenitor (MEP) 
cells (CD123−CD45RA−) were selected. DNA isolation from these cell fractions, followed by 
DNA amplification, was carried out using the Qiagen REPLI-g single cell kit (Qiagen, Venlo, The 
Netherlands) according to the manufacturer’s protocol.
Whole exome sequencing
Whole exome sequencing was performed on sequential BM-MNC (n=43) and PB-MNC 
samples (n=2) taken at regular time intervals. For all patients, DNA isolated from cultured T 
cells was used as a reference to exclude germline variants. In addition, for 5 patients MSCs 
were used as additional germline control to ensure that no variants acquired in multipotent 
HSCs (and therefore also affecting T cells), were incorrectly marked as germline variants 
and excluded. Exome capture was performed using SureSelect Human All Exon V5 (Agilent 
Technologies, Santa Clara, CA, USA). Enriched exome fragments were then subjected to 
massively parallel sequencing using the HiSeq 2500 platform (Illumina, San Diego, CA, USA). 
Sequence alignment and mutation calling were performed using our in-house pipelines, as 
previously described,15 with minor modifications. Candidate mutations with (I) Fisher’s exact 
p≤0.001 and (II) a variant allele frequency (VAF) in tumor samples ≥0.07 were selected, and 
further filtered by excluding (I) synonymous single nucleotide variants (SNVs), (II) SNVs in 
genes whose structure is not correctly annotated and (III) known variants listed in the 1000 
Genomes Project (Nov 2010 release), dbSNP131 or our in-house SNP database.
Targeted-capture sequencing
We analyzed 2 samples after allogeneic stem cell transplantation (allo-SCT) using SureSelect 
(Agilent)-based targeted-capture sequencing for 72 known driver genes (Supplemental Table 
1) in MDS. Mutation calling was performed as previously described,3 with minor modifications. 
Germline SNVs were removed using whole exome sequencing data of paired germline control 
samples. Finally, we only selected definitely oncogenic mutations.2
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Targeted amplicon-based deep sequencing
The variants detected by WES were validated and sequenced with high depth (~10.000x 
coverage) in all available PB and BM samples from each patient. Fragments with lengths of 
approximately 200 base pairs were amplified in two consecutive PCR reactions. In the first PCR 
the target fragments were amplified and in the second PCR Ion Xpress barcodes and adapters 
were added (Primer sequences see Supplemental Tables 2-4). After pooling and purifying, the 
PCR fragment libraries were bidirectionally sequenced on an Ion Torrent Personal Genome 
Machine system (Thermo Fisher Scientific). The sequencing data were mapped to the 
GRCh37 (hg19) reference genome build and variants were called with the SeqNext module 
of Sequence Pilot software, version 4.2.2 (JSI medical systems, Ettenheim, Germany). Besides 
the automatic calling of variants, all locations where variants were detected by WES were 
manually inspected. A detailed description of the experimental set-up is presented in the 
supplemental data. In addition, a FLT3-ITD and JAK2 V617F mutation were detected using 
in-house GeneScan and qPCR techniques, respectively.
Microarray-based genomic profiling (SNP array)
Microarray-based genomic profiling was carried out using the CytoScan HD array platform 
(Affymetrix, Inc., Santa Clara, CA, USA). Hybridizations were performed according to the 
manufacturer’s protocols. The data were analyzed using the Chromosome Analysis Suite 
software package (Affymetrix), using the annotations of reference genome build GRCh37 
(hg19). For a comprehensive analysis of the microarray-based genomic profiling data we 
used a previously developed filtering pipeline, and its interpretation was performed using 
criteria adapted from Simons et al.16 and Schoumans et al.17 as follows: (I) All aberrations 
affecting segments larger than 5 Mb (resolution of conventional karyotyping), regardless 
of gene content, were denoted as true aberrations. (II) All aberrations affecting segments 
smaller than 5 Mb that coincided with known cancer genes (http://cancer.sanger.ac.uk/
cancergenome/projects/census/ date of accession November 2012) were included. (III) 
Since paired control DNA was not used, alterations that coincided with established normal 
genomic variants were excluded. For this approach, we used the publicly available database 
‘Database of Genomic Variants’ (http://projects.tcag.ca/variation) and, in addition, in-house 
databases of copy number alterations (CNAs) detected in ~1,000 healthy individuals studied 
with the CytoScan HD platform. (IV) Regions of copy-neutral loss of heterozygosity (CN-LOH), 
also known as acquired uniparental disomy (UPD), were only considered if they were >10 Mb 
in size and if they extended towards the telomeres of the involved chromosomes, as reported 
in Heinrichs et al.18 (V) Focal CNAs in the immunoglobulin genes were excluded from this 
study, as these lesions generally represent the B cell clones with rearranged immunoglobulin 
genes. All the data were also visually inspected to define alterations present in smaller 
proportions of cells, and to eliminate alterations reported in regions with low probe density. 
Only aberrations fulfilling the above criteria were included in the genomic profiles, and were 
described according to the standardized ISCN 2013 nomenclature system.19
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Reconstructing clonal composition and evolution patterns
For clonal reconstruction, all variants detected with a VAF of 0.2% or higher were considered. 
Mutations were clustered based on the VAFs (corrected for ploidy) from all sequenced 
samples (PB and BM) at all different time points. The sequential order of mutational events 
and the most probable clonal evolution pattern were derived from these mutation clusters 
and their behavior in time. In UPN05, the clonal evolution pattern was calculated for the 
myeloid fraction, rather than for the total BM-MNC fraction, as this patient developed bone 
marrow fibrosis and peripheral blood lymphocytosis, resulting in non-comparable sampling 
before and during romiplostim treatment. In all other patients, lymphocyte counts were 
stable over time.
Results
Genetic analysis of MDS patients
We assessed clonal evolution patterns in 11 lower risk MDS patients (7 males, 4 females) 
with a long disease follow-up (2.5-11 years, median 7) of whom multiple bone marrow 
and peripheral blood samples (5-31, median 7) were available (Table 1). Two categories of 
patients can be defined; patients who received supportive treatment only (n=6), and patients 
who were treated with lenalidomide (n=5). Two patients of the latter group also received 
azacitidine. To identify acquired mutations, WES was performed on sequentially acquired bone 
marrow samples taken at regular time intervals. DNA from autologous T cells was used as a 
constitutive reference to exclude germline variants. High density SNP arrays were performed 
on DNA extracted from bone marrow cells at several time points, allowing to correct VAFs 
for local copy number variations. In total, 45 BM (n=43) and PB (n=2) samples were used for 
WES (2 to 8 samples per patient), to an average depth of 110x. To validate and quantify the 
presence of all mutations with high accuracy, specific assays were developed for amplicon-
based deep sequencing (with a coverage of ~10,000x). Using this approach, mutational 
burdens were measured in all the samples available for each patient. In total, 175 different 
acquired somatic mutations were identified in 157 different genes (Supplemental Table 5). 
The median number of acquired gene mutations per patient was 17 (range 8-27). Of these, a 
median of four mutations per patient (range 0-6) were present in genes that have previously 
been implicated in MDS and are considered to be driver mutations (Figure 1A,C). The total 
number of detected genetic defects in the first sample of each patient correlated with the 
age of the patient (p=0.03, Figure 1B), an observation which is in line with the accumulation 
of genetic alterations during ageing. The most frequent alterations were nonsynonymous 
SNVs (n=144, 82%; Figure 1D). Of the 161 SNVs, 65% (n=105) were transitions, predominantly 
G:CàA:T (53%, Figure 1E). Some mutations were detected in all samples, whereas others 
were only seen at early or late time points, indicating genetic evolution (Supplemental Figure 
1). Based on the VAFs at all available time points (Supplemental Figure 2), mutations were 
clustered and clonal composition and evolution patterns were reconstructed (Figures 2-3). 
Results from high density SNP arrays (Supplemental Table 6) and conventional cytogenetic 
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analysis (Supplemental Table 7) were taken along when reconstructing the clonal evolution.
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Figure 1. Genetic defects. (A) Number of acquired mutations in 11 patients with MDS, as determined by whole 
exome sequencing and confirmed by amplicon-based deep sequencing. In light gray, the number of mutations in 
genes previously implicated in the pathogenesis of MDS are indicated (driver mutations), in dark gray the number 
of mutations not previously implicated in MDS (putative passenger mutations). (B) A positive correlation could be 
observed between age and the number of genetic defects (genetic and cytogenetic defects) at the time of first 
sampling. The Pearson correlation coefficient (r) was determined.(C) For each patient, all mutations in genes 
implicated in MDS are depicted as well as all cytogenetic defects detected by high resolution SNP array and/or 
karyotype analysis (dark gray). * indicates a mutated gene, which is also affected by a copy number gain or loss or 
by a CN-LOH; ‘2’ indicates two different mutations affecting the same gene. (D) Distribution of the different types 
of alterations detected in the total set of patients. (E) Different types of single nucleotide changes detected in all 
patients, with transitions in dark gray and transversions in light gray.
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Clonal evolution in patients treated with supportive care only
Six patients were treated with supportive care only, consisting of transfusions (if needed), folic 
acid and growth factors (erythroid stimulating agent (ESA), granulocyte colony-stimulating 
factor (G-CSF), thrombopoietin (TPO) agonist). In one of these patients (UPN04), just one 
clone of MDS cells was observed, carrying 12 mutations including 3 mutations in recurrently 
mutated genes; one ZRSR2 mutation and two different mutations in TET2 (Supplemental 
Table 5, Supplemental Figure 2). The composition of mutations in this clone remained 
unchanged over the entire observational period of 8 years. Also the clinical condition of the 
patient remained stable (Figure 2A).
Two patients (UPN06 and UPN11) showed a linear evolution pattern in which successive 
clones carrying increasing numbers of mutations overgrew their ancestral clones (Figure 2B-
C). Concomitant with the emergence and expansion of a clone harboring a mutation in NRAS, 
UPN11 progressed from RCMD to RAEB1 and ultimately developed secondary AML (sAML) 
(Figure 2B). UPN06 showed a similar evolutionary pattern (Figure 2C), with the emergence 
of a clone harboring an NRAS mutation, with concomitant progression from RARS towards 
RAEB2. In both patients, the emergence and expansion of an NRAS-mutated clone was 
accompanied by an increase in leukocyte counts.
The other three patients who did not receive disease-modifying treatment showed more 
complex, branching clonal evolution patterns. In patient UPN03 (Figure 2D) two individual 
subclones emerged, which were derived from a common ancestral clone. Despite the 
genetic evolution, the clinical condition of the patient did not evolve significantly over time. 
Eventually, this patient died of prostate cancer. The other two patients with more complex 
branching evolutionary patterns progressed towards sAML (Figure 2E-F). In patient UPN05, 
a KRAS-mutated clone emerged. In patient UPN07, an NRAS-mutated clone was dominant 
at the time of first sampling. Over time, this clone was gradually outcompeted by subclones 
containing an RRAS mutation (and no NRAS mutation). Ultimately, the disease progressed to 
sAML.
Clonal evolution in patients treated with lenalidomide
Five patients who received lenalidomide were analyzed, four of whom carried a deletion 
on chromosome 5q (Figure 3). All four 5q- patients responded very well to lenalidomide 
(Figure 3A-D), resulting in morphological and cytogenetic complete remission. However, 
when considering the total set of somatically acquired mutations, these 4 patients showed 
substantial differences with regard to their clonal evolution pattern. Patient UPN01 (Figure 
3A) initially showed a very good response to lenalidomide, and the MDS clone was reduced 
to 2% of the bone marrow population. This response was gradually lost during lenalidomide 
treatment, as a descendent of the original clone carrying additional heterozygous RELN and 
TP53 mutations slowly expanded, accompanied by a gradual decline in hemoglobin levels. 
TP53 mutations are known to be associated with lenalidomide resistance.20
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Figure 2. Clonal evolution patterns in MDS patients who received supportive care only. (A) Patient with one 
single MDS clone without clonal evolution during the 8 years of follow-up. (B,C) Two patients showing linear 
clonal evolution. In both cases a heterozygous NRAS mutation was acquired (green clones), which associated with 
increased leukocyte levels and disease progression. (D-F) Patients with a more complex branching clonal evolution 
pattern. Vertical dashed lines indicate the investigated sampling moments; PCD, pentoxifylline, ciprofloxacin and 
dexamethasone; tipi+bortezo, tipifarnib and bortezomib.
In the other three 5q- patients, distinct, non-MDS related clonal populations were 
detectable during complete remission. In UPN08 and UPN09 (Figure 3B-C) the MDS clones 
that dominated hematopoiesis before start of lenalidomide treatment (likely all containing 
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del(5q)) diminished under treatment to 0.2% and 2% of the bone marrow population, 
respectively. In both patients, however, one or more clone(s), not carrying any known MDS 
driver mutation, increased in frequency after the suppression of the initial MDS clones. Possibly, 
these clones are not MDS-related since blood values remained normal, BM morphology was 
close to normal (some therapy effects), and there were no MDS driver mutations present. In 
patient UPN08, lenalidomide appeared to suppress all the initial clones present before start 
of lenalidomide treatment (containing amongst others a CSNK1A1 mutation), resulting in a 
durable, complete clinical remission. During treatment, all mutations dropped below a VAF 
of 0.2%, but remained detectable (Supplemental Figure 3). This indicates that the del(5q)- 
containing clones are strongly suppressed by lenalidomide, but not completely eradicated.
Also in the remaining 5q- patient, UPN10 (Figure 3D), clonal populations were still 
detectable during complete remission. Under lenalidomide treatment, cells carrying 5q- and 
8 other mutations were strongly suppressed, but the ancestral clone containing the initial 6 
mutations remained present. Under lenalidomide treatment, small subclones derived from 
this ancestral clone expanded over time, without any of them becoming clearly dominant. 
Also a JAK2 mutation was detected under lenalidomide treatment, which followed a pattern 
very distinct from the other clonal populations (Supplemental Figure 2), and is therefore 
likely a separate, unrelated clone. After 4.5 years of treatment, the patient lost response to 
lenalidomide; the hemoglobin levels gradually declined and the 5q- clone, that had been 
suppressed under lenalidomide, slowly expanded. Because of clinical disease progression, 
the lenalidomide treatment was stopped and the patient underwent an allo-SCT. As a result, 
the MDS cells were undetectable with cytogenetic analysis for more than a year, although 
some patient cells could still be detected as determined by quantitative donor-recipient 
chimerism analysis (<1%, Supplemental Figure 4). Nineteen months after transplantation, a 
clinical relapse was diagnosed in this patient, with re-appearance of the del(5q)-containing 
clone. Targeted sequencing of a panel of 72 driver genes revealed no additional mutations at 
the time of relapse. However, 39 months after transplantation, the MDS progressed to RAEB1 
and additional karyotypic abnormalities and a somatic CUX1 mutation were detected. During 
relapse the patient was treated with 5-azacitidine (hypomethylating agent) for 8 months, 
which led to a reduction in clone size (Figure 3D). Clinically there was an early sign of reduced 
transfusion frequency, but the patient declined further treatment.
The patient without a del(5q) (UPN02, Figure 3E) received lenalidomide for 16 months 
and had stable disease. After discontinuation of lenalidomide treatment, the patient received 
5-azacitidine for 1 year, resulting in a transient reduction in transfusion frequency. Under this 
treatment a subclone containing 5 specific mutations, including a mutation in EZH2, expanded 
at the expense of a subclone that was dominant before start of azacitidine treatment 
(containing an SF3B1 and a CUX1 mutation). Interestingly, after azacitidine treatment was 
stopped, the EZH2-mutated clone disappeared, with concomitant re-expansion of the SF3B1- 
and CUX1-mutated clone.
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Figure 3. Clonal evolution patterns in MDS patients who were treated with lenalidomide. (A-D) Four patients 
harboring a del(5q), who responded well to lenalidomide treatment. UPN01 (A) shows a linear evolution pattern. In 
UPN08, 09 and 10 (B-D) non-MDS related clonal populations increased in frequency under lenalidomide treatment. 
(E) Patient with a normal karyotype and without a major response to lenalidomide treatment. This patient shows a 
branching evolutionary pattern, with a change in clonal composition under azacitidine treatment. Vertical dashed 
lines indicate the investigated sampling moments; PCD, pentoxifylline, ciprofloxacin and dexamethasone.
Clonal composition in different PB and BM cell fractions
In MDS, the generation of mature blood cells from BM stem and progenitor cells is disturbed, 
but not completely abrogated. In theory, different mutations might occur in bone marrow 
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cells at different stages of maturation. In addition, specific mutations might block maturation 
at a particular stage, whereas others might allow maturation up to completely mature 
blood cells. As a result, diverse mutational landscapes may be observed in cells of different 
progenitor cell fractions and maturation stages within a patient. To study this, we isolated 
DNA from various BM stem (HSC) and progenitor fractions (CMP, GMP, MEP) of 6 patients 
(UPN01, 03, 04, 05, 06, 10) at several time points in the course of their disease. All mutations 
detected in the bulk of cells were also detected in all analyzed stem and progenitor fractions, 
albeit sometimes with a somewhat different VAF in the various stem cell fractions (Figure 
4, Supplemental Figure 5). Also mutations that arose later during the course of the disease, 
being characteristic for developing subclones, were present in all stem and progenitor cell 
fractions at roughly equal frequencies. This suggests that both the early and late mutations 
arose in early HSCs that are still capable of differentiation into different myeloid lineages.
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The mutational burdens in BM and PB samples were quite comparable (Supplemental 
Figure 6). In general, the VAFs were somewhat lower in PB, likely caused by a higher percentage 
of lymphoid cells. The PB granulocyte fraction (isolated by density gradient centrifugation) 
exhibited comparable mutational burdens to BM samples, indicating that mutated and non-
mutated myeloid progenitor cells had a similar capacity to form mature granulocytes.
MSCs as germline control
DNA from autologous T cells was subjected to WES, and used as a germline control to 
distinguish somatic mutations acquired in the MDS cells from germline variations. Since some 
reports described MDS-associated mutations in T cells,21 we questioned whether we might 
have missed relevant mutations by using T cell DNA as germline control. Therefore, MSC 
lines were generated from five subjects. DNA from long-term cultured, pure MSC lines was 
subjected to WES and used as germline control to detect mutations in the T cells. No MDS-
associated mutations were found in the T cells of these five patients (Supplemental Table 8), 
indicating that the T cells were not part of the malignant clone.
Discussion
We studied the mutational spectrum and clonal evolution in lower risk MDS patients receiving 
supportive care, as well as in patients who were treated with lenalidomide. Several patterns 
of clonal evolution were observed ranging from a patient with a single clone remaining stable 
for many years to patients with highly dynamic shifts in clonal composition. Especially during 
lenalidomide treatment, clone size and composition changed considerably.
The mechanism behind the beneficial effect of lenalidomide in patients harboring a 
5q deletion has recently been described.22 Lenalidomide stimulates the degradation of 
CSNK1A1, a negative regulator of TP53, which leads to increased TP53-induced apoptosis. 
MDS cells harboring a deletion of 5q have only one remaining CSNK1A1 allele, and are 
therefore thought to be more sensitive to lenalidomide. Many patients eventually develop 
resistance to treatment, which is often accompanied by the acquisition of TP53 mutations.20,23 
Patient UPN01 initially showed an excellent clinical and molecular response to lenalidomide, 
however, gradually a subclone expanded that had acquired a mutation in TP53. This mutation 
could not be detected before treatment with lenalidomide. It would be interesting to know 
what would have happened if lenalidomide treatment had been stopped after achieving 
complete remission. One possibility would be that the TP53-mutated clone would have 
expanded faster, but it is also possible that the ancestral clone lacking the TP53 mutation, 
might have outcompeted the TP53-mutated subclone and regained dominance. In case of 
the latter situation, intermittent treatment might be considered to prevent selection of drug-
resistant clones.24
UPN08 harbored a mutation in CSNK1A1, which is described to be mutated in 5-18% of 
patients with a 5q deletion.25-27 Although the exact biological role of these mutations is still under 
investigation, reports so far show a trend towards a decreased response to lenalidomide and 
Chapter 6
144
a decreased overall survival compared to CSNK1A1 wild-type 5q- patients.25,26 The majority of 
mutations target the amino acids E98 and D140, but some mutations outside these hotspots 
have also been identified. The mutation in UPN08 (G24R) has not yet been described, but is 
predicted to be damaging according to PolyPhen-2 prediction software (http://genetics.bwh.
harvard.edu/pph2/). Remarkably, this patient showed a very good response to lenalidomide 
with a clinical and cytogenetic complete remission maintained for already more than 8 years.
In four of the five patients who were treated with lenalidomide, a significant reduction 
of the total clone size was observed. Interestingly, in three of the four responding patients, 
clonal populations harboring acquired mutations not shared with the MDS cells, emerged 
upon the reduction of the number of MDS cells. In these patients, the application of disease-
reducing treatment may have created an evolutionary bottleneck, after which repopulation 
may have occurred by a limited number of HSCs harboring pre-existing (likely passenger) 
mutations. A similar observation has recently been described after induction chemotherapy 
in AML.28 Interestingly, in UPN10, a clone containing a JAK2 V617F mutation that was already 
present at a low frequency before lenalidomide treatment, expanded after the start of 
lenalidomide. This process may be comparable to the development of clonal hematopoiesis 
in elderly individuals.29-31
After 4 years of treatment, UPN10 gradually lost the response to lenalidomide and 
underwent an allo-SCT. Nineteen months after the transplantation one of the del(5q) clones 
expanded, along with a clinical relapse. Interestingly, this clone seemed to be genetically 
identical to one of the clones that originally responded very well to lenalidomide. Therefore, 
the relapsing clone might have been lenalidomide sensitive, and restarting treatment might 
have been a valid option. However, shortly after relapse a small subclone with an additional 
CUX1 mutation was present, which might respond differently to lenalidomide.
Two patients (UPN02 and UPN10) were treated with 5-azacitidine. In UPN02, the 
major clone decreased under 5-azacitidine treatment, whereas a subclone carrying an 
EZH2 mutation expanded. After 5-azacitidine treatment was stopped, the EZH2-mutated 
subclone diminished and became undetectable, suggesting that the EZH2-mutated subclone 
had a growth advantage under 5-azacitidine and/or the major clone was suppressed under 
azacitidine treatment, both resulting in the same net effect. UPN10 showed an improvement 
of hemogloblin levels and a reduction in clone size upon 5-azacitidine treatment. Treatment 
with 5-azacitidine was stopped after 8 cycles as the treatment was burdensome to the 
patient, who was in poor condition. After discontinuation of 5-azacitidine treatment, the MDS 
clone re-expanded. Our analysis indicates that from a genetic point of view, continuation of 
the treatment might have been justified. This observation is in contrast with the recently 
published data by Merlevede et al.,32 in which no decrease in clone size was observed in 
monocytes from CMML patients treated with hypomethylating agents.
Three patients treated with supportive care eventually progressed to sAML (UPN 05, 
07 and 11). In all three patients, the clone or clones which ultimately developed into sAML 
contained a heterozygous mutation in one of the RAS protein family members. In patient 
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UPN05 and UPN11, a subclone that acquired a mutation in NRAS or KRAS could be detected 
years before sAML was diagnosed. In UPN07, two members of the RAS pathway (NRAS 
and RRAS) were mutated in separate subclones. RRAS mutations are not very frequent in 
hematological malignancies, but some cases harboring mutations in this gene have been 
described.33 One patient with juvenile myelomonocytic leukemia was reported who also 
carried an NRAS and an RRAS mutation in separate clones, whereas after chemotherapy only 
the RRAS-mutated clone could be detected. In UPN07, the initial major clone containing an 
NRAS mutation was also outcompeted by the RRAS-mutated clone over time. During this shift 
in clonal composition, no therapy other than a brief period of ESA was given. Eventually, the 
RRAS-mutated subclones dominated and gave rise to the development of sAML. Previous 
reports have implicated RAS mutations in enhancement of proliferation and progression 
towards sAML.34-37 Together with our data, this may indicate that screening for mutations 
in RAS family members is warranted in lower risk MDS, as acquisition of these mutations 
seems to correlate with the development of more aggressive clones that eventually may 
result in progression towards sAML. Ultimately, patients who acquire RAS mutations might 
be candidates for specific forms of treatment that target the RAS pathway or its downstream 
signaling partners, like MEK inhibitors.38
The analysis of the mutational burdens in various stem and progenitor fractions indicates 
that in general, no gross differences were observed between the different cell populations. 
This suggests that both, early and late MDS-associated mutations, originate in HSCs that 
are still capable of differentiation into the various myeloid lineages, which is in line with the 
analysis of stem cell fractions reported by Woll et al.13 In addition, the mutational burdens 
in BM and PB were quite comparable. This suggests that genetic monitoring of patients on 
the basis of peripheral blood rather than bone marrow, is probably accurate, and provides a 
patient-friendly way of genetic analysis,39 comparable with the monitoring of BCR-ABL levels 
in peripheral blood of chronic myeloid leukemia patients.40
Our study shows that determining the clonal evolution in MDS patients could be 
clinically relevant. First of all, the effect of treatment can be monitored at the molecular level. 
In addition, the outgrowth of subclones harboring mutations associated with resistance (e.g. 
TP53) or disease progression (e.g. NRAS, KRAS) can be detected in an early phase, so that 
treatment may be adapted accordingly.
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Supplemental data
Targeted deep sequencing
The variants detected by WES were validated and quantified by targeted deep sequencing 
on an Ion Torrent Personal Genome Machine (Thermo Fisher Scientific, Waltham, MA, USA) 
to a target depth of coverage of ~10,000x. Sequencing libraries were generated by means 
of two consecutive rounds of PCR, PCR1 and PCR2, both of which were performed using Q5 
Hot Start High-Fidelity Master Mix (New England Biolabs, Ipswich, MA, USA) according to 
the manufacturer’s protocol. In PCR1, the target fragments were amplified and tagged with 
common sequence (CS)-tags (designed by Fluidigm, South San Francisco, CA, USA). For this 
purpose, sequence-specific primers were designed to obtain PCR fragments of approximately 
200 base pairs. CS-tags were attached to these primers (see figure below for primer strategy 
and Supplemental Tables 2-4 for primer sequences). The following touchdown protocols 
were used for PCR1, depending on the primer pairs used:
PCR1 program 1
Step Temperature Time Cycles
1 98˚C 30 sec 1
98˚C 10 sec 10 cycles touchdown 
+ 20 cycles at 58˚C
2 63˚C à 58˚C (delta -0.5˚C) 15 sec
72˚C 10 sec
3
72˚C 2.00 min
1
4˚C hold
PCR1 program 2
Step Temperature Time Cycles
1 98˚C 30 sec 1
98˚C 10 sec 15 cycles touchdown 
+ 15 cycles at 58˚C
2 73˚C à 58˚C (delta -1˚C) 15 sec
72˚C 10 sec
3
72˚C 2.00 min
1
4˚C hold
PCR1 program 3
Step Temperature Time Cycles
1 98˚C 30 sec 1
98˚C 10 sec 10 cycles touchdown 
+ 20 cycles op 63˚C
2 73˚C à 63˚C (delta -1˚C) 15 sec
72˚C 10 sec
3
72˚C 2.00 min
1
4˚C hold
In PCR2, primers containing a CS-tag, a barcode and an adapter (see figure below for primer 
strategy and Supplemental Tables 2-4 for primer sequences), were used to (I) label the PCR 
fragments with a sample-specific Ion Xpress barcode (designed by Thermo Fisher Scientific) 
and (II) add the adapters required for emulsion PCR. The second PCR was performed twice, 
once with the A adapter attached to the forward primer and the truncated P1 (trP1) adapter 
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to the reverse primer (PCR2-A) and vice versa (PCR2-B), making bidirectional sequencing 
possible. The following PCR protocol was used for PCR2:
PCR2 program
Step Temperature Time Cycles
1 98˚C 30 sec 1
98˚C 10 sec
2 60˚C 15 sec 10 cycles
72˚C 10 sec
3
72˚C 2.00 min
1
4˚C hold
Subsequently, PCR products were pooled and purified with Agencourt AMPure XP beads 
(Beckman-Coulter, Fullerton, CA, USA) to eliminate primer dimers. After purification, the 
purity of the pool (based on expected fragment size) was measured on the Agilent 2200 
TapeStation (Agilent Technologies, Santa Clara, CA, USA) using the high sensitivity D1000 
ScreenTape assay (Agilent). The purified pool was diluted to 3 pg/µl and loaded onto the Ion 
OneTouch system (Thermo Fisher Scientific) for emulsion PCR using the Ion PGM Template 
OT2 200 kit (Thermo Fisher Scientific), followed by an enrichment for loaded Ion Sphere 
Particles (ISPs). The quality of the enriched ISPs was checked with the Ion Sphere Quality 
Control Kit (Thermo Fisher Scientific) on the Qubit Fluorometer (Thermo Fisher Scientific). 
Subsequently, the ISPs were loaded onto an Ion 314, 316 or 318 v2 Chip (Thermo Fisher 
Scientific) and sequenced using the Ion PGM Sequencing kit v2 (Thermo Fisher Scientific) on 
the Ion Torrent Personal Genome Machine system (Thermo Fisher Scientific). All steps were 
performed according to the manufacturer’s protocols. The sequencing data were mapped 
to the GRCh37 (hg19) genome reference build and variants were called with the SeqNext 
module of Sequence Pilot software, version 4.2.2 (JSI medical systems, Ettenheim, Germany). 
Besides the automatic calling of variants, all locations where variants were detected by WES 
were manually inspected for each sample.
Primer strategy
PCR1
PCR2
CS1
CS2
Target-specific
Target-specific
CS1
CS2
A-adapter
trP1-adapter
A:
B: CS1
CS2 A-adapter
trP1-adapter
Gene of interest
barcode
barcode
5’
5’
5’
5’
5’
5’
3’
3’
3’
3’
3’
3’
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Supplemental Table 1. Gene panel targeted-capture sequencing
72 driver genes
ASXL1 CUX1 IDH2 PHF6 SMC1A
ASXL2 DCLRE1C IRF1 PIGA SMC3
ATM DDX41 JAK2 PIGT SRSF2
ATRX DNMT3A KDM6A PPM1D STAG1
BCOR EP300 KIT PRPF8 STAG2
BCORL1 ETNK1 KRAS PTPN11 STAT3
BRCC3 ETV6 LUC7L2 RAD21 TET2
CALR EZH2 MLL2 RIT1 TP53
CBL FANCA MPL RUNX1 U2AF1
CDKN2A FANCM MRE11A SETBP1 U2AF2
CEBPA FLT3 NF1 SETD2 WT1
CHEK2 GATA2 NFE2 SF1 ZRSR2
CREBBP GNAS NPM1 SF3A1
CSF3R GNB1 NRAS SF3B1
CTCF IDH1 PDS5B SH2B3
Supplemental Table 2. Primer strategy
PCR Direction Primer build up Sequence primer (5’--> 3’)
PCR1 Forward CS1 - target specific sequence ACACTGACGACATGGTTCTACAxxx
Reverse CS2 - target specific sequence TACGGTAGCAGAGACTTGGTCTxxx
PCR2_A Forward A adapter - barcode - CS1 CCATCTCATCCCTGCGTGTCTCCGACTCAGyyyACACTGACGACATGGTTCTACA 
Reverse trP1 adapter - CS2 CCTCTCTATGGGCAGTCGGTGATTACGGTAGCAGAGACTTGGTCT
PCR2_B Forward trP1 adapter - CS1 CCTCTCTATGGGCAGTCGGTGATACACTGACGACATGGTTCTACA
Reverse A adapter - barcode - CS2 CCATCTCATCCCTGCGTGTCTCCGACTCAGyyyTACGGTAGCAGAGACTTGGTCT
CS: common sequence
xxx: Target specific primer, see supplemental table 3
yyy: Barcode primer, see supplemental table 4
Supplemental Table 3. Target specific primer sequences
Patient Mutation Gene Sequence of F-primer (5’--> 3’) Sequence of R-primer (5’--> 3’)
UPN01 1 CEP89 TTGTGCAGAAACACATCATCCAT TTCTGGGCAGTTTGAGCAGTT
2 DOCK5 TTTAACAATGGAAAGTCCAACTGC CCCAGAACATCCTTACCACAGC
3 OR14I1 TATCTTGGCTGTGTGGCTCAA GTGGTGACTGCCATCTGATAGC
4 PALLD CCCCAAGCAGTTCATCGC CTCGGCGTCGGGGACAT
5 RAD50 GAGATTTCCCTCCTGGAACCA TACTGGGTGCTAAAACTGTGTGG
6 RASA1 CTCGGGACAGTGGACGAAG AAACCACAGATGAAAAGGACAAAGT
7 RELN TGCTGCTCAGAAGAATACTATGACCT CATGACCTGTTCCATTGTGGC
8 TP53 CTCTTGCTTCTCTTTTCCTATCCTGA GCTTGCTTACCTCGCTTAGTGC
UPN02 1 CTH AGAAACATGCCTCCACTGACAC ATAATAAGACTTACTGCTGCCTTCAAAG
2 CUEDC1 GAGACCAGGAGAGCCGCTG CAGCATCACCTCCCTTCTTCAG
3 CUX1 CAAAAGCCATACCCGTCACC GACAGATCAGCCCCTTCCC
4 EZH2 CGCACTTCCTCCTGAATGTACC AAAAGCGTATGAAAGGAGTGTAAGC
5 HCFC2 TATCCCTCCAGGCTGTGCTG CTCATATAACTCATTGCTGTATCTTCCA
6 LMF2 CTACCTGCAAGGAGGACGCT CGTGTCCAGCCCCAGTCT
7 LRRC17 TCTTGTGGCTCAGAGATAACCCTT CACAGACCATCCTTTGTATTCTTCAG
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8 MAST2 TGTTTCTTTCTTGCTTTTCTTCCC GCAGCACGCTGTCTGGAGT
9 MYH1 CTCACTCAGCACAGAACTATTTAAGATTAA TCAGAAATCTCCTCTGTTGGTGAA
10 MYO1B TGGTACAGTTCAGACAGGACAAAGTA AACCAAATTGCACTATTACAAAGGAA
11 ODZ2_1 ACCCGCCTGAAAGCAATG CCCATACTTGTAGAACACCTGGC
12 ODZ2_2 GCGGGTGGAGTGTCCAGT AGTGATTGTAGACATGGGTGATGC
13 PARD6B GCATCGTAGGGTACGTCTTTACAA TCCTGTACTTTGAGCCAGACCTC
14 SEC14L2 CCAGAACTGCCTGAATGTCTGTC CTGTTTCATCTTCTCTTCTGAGGC
15 SF3B1 TGCTGGTCTGGCTACTATGATCTC AAGAAGGGCAATAAAGAAGGAATG
16 TET2 CGTAACTTCGGGGTAAGCCAAG AAAAACTGGTGAAATCTTTAACTGCAT
17 TSPAN17 CCCTGTTCCTGGCTATCGG CGAGAGAACGCCCTGTGC
18 WDR90 AGTGCTGAAGTTTCCCCACTGTG CATCGGTGGAGAAGGCAACA
UPN03 1 ASXL1 GGCTCTCGTTTCTAACAGTTCTTTG GCAGCTTTCTCCCACTCCTCT
2 C20orf195 CTGGACCAGGAGGAGGCA GGTGCTTGGGCAGGACCT
3 COPB2 GATATATGTGTGAAGATTGGGGAGATT TGGCAGCCGTCCAGTTCTA
4 DLGAP1 AAGGGCAGCGTCAACGG GGGCGTGGTAGATGCACAT
5 EZH2 GTGGATGCAACCCGCAAG GACTGAAAAGGGAGTTCCAATTCTC
6 HRH2 GCAACTCCCACAAAACTTCTCTG TGACTTCTGTCCCACTCCACAC
7 PCDHB14 TGAATCTGCACACTATTCTGTGGC TTCCCAGTCAGCAAATCAAGG
8 RFC3 GCGTTGTGGGGAGGACG CGCAGACTCACCAGGTTCC
9 SF3B1 CTTAGGTAATGTTGGGGCATAGTTA AGTTGCTGCTTCAGCCAAGG
10 WDR67 TTAGCCATCCTTGGTGATTGTAACT CCATTTCAGAAGAGTCATTTAATTGTG
11 ZC3H18 AAGTCTCCCAAGAAGAAACTCGG TGACCCAGTGAGGTACATGGTG
12+13 ZNF609 GTGACTCCCCGACCAGTGAC CCTTTGCTATTGGCTCCTGC
UPN04 1 CLCN6 CACAGAAATCCAGCATCCTCAC CCTCAGAGGCGATGTGCTC
2 CLK2 CTCTTCTCAGCCTCTGTGTCCA CTTTGAGGAAATCGAAGGTGCT
3 EPHA8 ACCACGAACCAGGCAGGTAG TGTGTTCCACTTTTCTAAAGGCAA
4 KAT6A GATGCTAATATGCAGAAGAGTAGGGA GTCGTCCTCAGACCCAGCC
5 KIF2B CACATGATCGAAGAGTATCGCAG ACGGTGATGATATCCAGGTCCTT
6 LEF1 CTTCAAGGACGAGGGCGA TCACCAAGGAAGACTTGATGTCAG
7 PFDN6 TCCCATCCCTCCATCAGGA TGATATAGTCCAGCCTCTTCCCTAC
8 TET2_1 AATAACATCCAGGGAACCACAAAG TGAAGTAAGCACCATTCATTTCATT
9 TET2_2 ATGCTAATGGTCAGGAAAAGCAG CCATGAGTTGGAGCCACGG
10 THSD4 GGGACCATGTTCACCTACAAGC AGTGACAAGATTCAAAATCCAAAGAA
11 UGT3A2 CTACTGAAAGCAGAGTTGTGGTTCA CCACCAACTATGCACTGAAGGC
12 ZRSR2 CGATGGTATGCAGGACGACAG ATGCCTCACCACTTGAAAATACTG
UPN05 1 ALDH1B1 CTGGCTGGGCTGACAAGTG CACCTTCATAACCACAGTGTTGC
2 BCOR CGGAAGCACGGAGACTTATTGT TCTCCATGTCCCTCCCCTC
3 CSMD1 GCTGCATGGACGGTTACCAG CGGAACAAATTCTGCTGTAGAACTTA
4 DNMT3A TCACGTTGCCTTTATCCTCCC AGGGTTGACGATGGAGAGGTC
5 DSCAM TCCCGAAATTGAGATCAAAGATG GCTGGAGGAAGTAAAGAACTTACCTG
6 FAM123C AAAAGCCTGCCCTCCCCA GCTCGCTGTCCAACAGGTC
7 FLT3* GCAATTTAGGTATGAAAGCCAGC CTTTCAGCATTTTGACGGCAACC
8 IVNS1ABP TTACATAGGAGTGTGTGCTCTGAATG CAACTTTGTTACAGGATCAAATACATCAC
9 KRAS AAACCTGTCTCTTGGATATTCTCGAC GGCAAATACACAAAGAAAGCCCT
10 MRGPRE CTGGGCTCATCCTCCTCA AAGTAGACGACGGGCTTGGC
11 OR5K3 TGTTAGAGAACTTCTTTTCTGAGGACA AATGCAGAGTGTCTTGGACATCAT
12 PCNX GAAGAAAGAGTGCTGTGCAGG CCCCACTGTTGGTACTCGCT
13 PKHD1 AACAGGTGTTAAAGGTGCCAAAC CTGACACTCAGTACCTCAAAGGTGA
14 PPP1R3A GTACTCCAGAAAGCATGTCTGCTAGA AATGTGAATCATCATTTCTCCCTTC
15 SETBP1 TGAGCGAGTCCCACAGTGAG GAGTACCTCCTTCGGGATTCTGA
16 SMARCC1 GAAAGTCTGTTCTTTTCATCCTCAGA TGTGTCTATTACCTGATGTCGTTTGA
17 SMCHD1 CCTCTCCCCTTCTCTCCTACTCC AATACCTGAAATAGAAGCAGCCATCT
18 U2AF1 CCCAGCAAAATAATCAGCTCTCA TGGCTAAACGTCGGTTTATTGTG
19 ZNF263 TGAGTGATGTGGGTTGGTTCC CCATTGGCTCCAGCTTGAA
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20 ZNF622 TTATGCGAGAGCGAGACATGC GCAGACTCTCAGAATCTCACTTGG
UPN06 1 ASXL2 CGAGCACTTTGCCAGCAGC TTTCAACTTTGGTGAGAGGTTTAGG
2 BEND6 CCCTCTGGAGAGCAACAAACA CAAAGAACAATAAGGCGGGTATTAC
3 CACNA2D3 GCTGTGCTGATAAATGAAAGGGAC CTTAGACTGATGTTCACAGGCAA
4 DPF2 CCTGAGGCACATCAGTTATTCAGT TGGGCAACTTACCTTCAGGG
5 NRAS CAAGTGGTTATAGATGGTGAAACCTG GGCAAATACACAGAGGAAGCCT
6 PTPN21 GGCTAGTTGATGGGGAGTGCT TGTTGATTACTTGAGGCGTTCCT
7 RUNX1 TCCGCTCCGTTCTCTTGC CGGCAGGTAGGTGTGGTAGC
8 SSTR5 GCCGTGCTGGGCTTCTT CAACATCCCGCAAACACCA
9 UBR5 AATTCTCTAGGCAATGAGGAAAGG TCAGAAAATGCTGACTGACCTATCTAT
10 ZNF536 CAAAGACAGCAGCAGCGATG CCTGGGCTTGGAGAAGACC
UPN07 1 C6orf52 GCCCAACCAGAGAGTTCTGC AGCAAATAGAACAGTAACAGCTTTCCT
2 CALY TCTTGGGTCCCTGCCAGC CTGTCCTGAGTCCCCACAGTG
3 CEACAM20 TGTCTCCCTCGCTTGCTTTC CCAGTGGATGGTAATGTTGACG
4 CLUL1 TTTATTCCATTTCTGTCCCCTACTCT TGGCTGAACACATCCTCCATT
5 DAB2 CCACCCCTAATCCTGATCCTTT TGACCAAAGTAGTCAACATCACCAT
6 DUSP12 CTCAATTTGACATTAACTGAATTTATCTGA CTACACTTGTAGAGAACCTCATCTTTCAA
7 EZH2 TATATGGGAGATGAAGTTTTAGATCAGG TTTAGCCCCTTTTTCCAAGAGAA
8 FZD2 CTACGCCACGCTGGAGC CTGTGAGAAGAACATGGAACCATC
9 GMIP ACTCTCCTGATCCTCTGTGGACA GGCACGGTGTTCTATCTCAGC
10 HMGXB3 AGAGGAGGAGGGTGAGGAAGAG AGTCCCAGCAGTCAGAGGC
11 KCNN3 ACAGCCGCAGAATAAAGTGAGAC ACGTGTGTGGTAGGCGATGAT
12 KIAA1429 AGGAGTTAATGAAAAACTCACAATCTCA GCAGCAGCTCTGAAAGGAGTATG
13 METTL2A GGCTCCTACCCTGAAGGTGC GAAGGGGCAGAGTGATTACCAG
14 MN1 GGAAGTCATCATCCCCACCA TCATAGCCCTCGGCGAAG
15 MYO18B CCAATGTCCACAGCAAGACCT AGAGGAAGCAGGTTCTAATCTCTCTG
16 NRAS AACTGGTGGTGGTTGGAGCA CAGGATCAGGTCAGCGGG
17 PTAR1 GGAGAAAGAAGAACCTTTGGGAA ACTGTCTATCACAGTTTGGCTAATCAA
18 REXO4 GGTTTTGGAAAAGCAAGGCG CGTTCTGCGGGAATGAGC
19 RRAS AGACACACAAGCTGGTGGTCG CCAAGGGCTCAGTTCTGGG
20 TACC2 AATCAAGTTGTCTGTGTGGCAGCAGG TTCTTCTACAGCAATAGGAATCTGAGC
21 TET2_1 GCAGTGGAGAGCTACAGGACAA CAGTGATGCCTCATTACGTTTTAGA
22 TET2_2 CAGACAGCGAGCAGAGCTTTC GGGTGATTCCTATTGGGATTCTTT
23 TNRC6A GTCGTTTCTTTGCACAAAGCCAG CCAGCACCATTCCAGTGATTG
24 TRIM3 AGCTTTGCAGAGCAGGCACT GCTGTGCATTCTCATGTGGC
25 TSSK1B AGCTGGAGCCTGAGGGAGAG GACTGCCTGGACATTTGCA
26 ZNF175 TCATACAGGGGAGAAACCTTATGAA ATGCTGAGTATTGACTTCTGGTTGA
27 ZRSR2 GGGAATGTTAGCCTGGACAAACA CAAGCAGAATACTTACGACTGGTACTG
UPN08 1 CSNK1A1 CCAGCCTCCATCTTCGTCTC ATTACCTCGCCGTTGGTGAT
2 FGFR3 CTGGGAGTCTCAGGACAGCC AGAGCTCCTCCACAGGGATGC
3 L1CAM GGGTGTCTTCCTGGACGG AAGTGGGCGTGGCAGATGTA
4 LRRC28 ACCTGAAAGGCTTGCCATCTT CCTGGTTTAGCATATCATCAAGGG
5 MAGEA6 TGTCGTCGGAAATTGGCAGTAC GGCAGGTGGCAAAGATGTACAC
6 MAP2K3 GGTCTTACTGCTCTGTCGTTTTTG GGGCACTGACCTCTGTGGAT
7 SDK2 CTGAGCGGCAGCCTCATG AGCTCATGCCTCTTCCTTCTTC
8 SRCAP CTCACACGCTGACTTTGGCTC AGGGAAGATGCCTGGGAAGC
9 YLPM1 TGGTTGGTATAGGTAGAGATGGAAG AAGAGACACTGTTCAAAGTGGTTGG
10 ZNF141 TTTACCACATCCTCACACTTTGCTA TAAGGGTTGTGAACCTATTAAAGGC
UPN09 1 ABCC8 ATCCCAAGAGTTCCTTGCCAAT TGCTCCTCTCAAGTTAATTCCAGTTT
2 AMIGO2 GAAGGTTCAAGCTGGCAGAACT GGGTTTCCATGAAGGTAGATGC
3 BRAT1 CACGTTGAAGAGTCCTTGTGCTC GGGGTCTCTCTCCAGCAGACA
4 C12orf51 TGGAGACGGACCAGCACAT GGCAGGTGAACGGGATGC
5 C19orf38 AAACGCAGAGAGAGATGCCCT GCAAGGTGGACAGAGGATGG
6 CHRM2 TCATCAGCTTTGACAGGTACTTCTG CCTCCACAGTTCTCACCCCTAC
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7 DDI2 GCATAATTTTTCTGCATGGTGTTT GAAAGGTGGTCTGGGAGCC
8 EIF3L GACCTCACAGAGCAGGAGTTCC CCAGGGGACAGGCATACCT
9 ERMP1 GTGTGGACTTGGCATCACTTTG ACCATGAGAGAGACTGTCCAATAAGA
10 FAM134A GCCATTACAGACTCAGAGCTGTCA CTCCCCATACCCTCGGAGA
11 ITIH6 GCTGAACCATAGCAACCAGGAG AAAGTCAGCATCATCCCCAAAG
12 JAG2 GGTTCTGCGATGAGTGTGTCC CCCCCTACCACTACCTTTGTCAC
13 NCKAP5 TCATCTCAGGTCAGCAGTTCCTC GGCGAGTTTTCAGTCCTTTCTC
14 NXF3 GGGTGGGGAGGTGTCCTTC GCTGTGGGCACTAGGGTGAAC
15 PRDM10 CTACATAGACAGGTTTCTGGGCG TGATAGAGCATAAATTACCTTGAGGTG
16 TMPRSS11B GCACGGCATATCTTCCCAAA GATTTATAGCAAGGATGAAAACTGAAAA
17 TRIM49B ATTTGCTGGTAAAGTAACTTCTTGATAGAC ATACACATGCTTCTCAAAATTTCACAT
18 TRIM77P GTTCCTGGATTATGAATGTGGGA CCTGTCCCTGATTATTTAGATCCG
UPN10 1 CALR* CCTGCAGGCAGCAGAGAAAC ACAGAGACATTATTTGGCGCG
2 CHD4 CGGGTGCTCAGCAGTTCTG GCTCACCTGAATGTCATTATGGG
3 CUX1 ATGCTGTCCCGACCGAAG GGCAGGACCCCCATTACC
4 FRMD8 CGGAGGCTGACCCCAGTC GGGGCAGTACCTTCTCTCTGCTA
5 GFRAL ATTTCAGTCAAAATGCTGGCAG TCTATGTAAGCAGCTTTGCAGTCA
6 JAK2 TGAAGCAGCAAGTATGATGAGCA GCTCTGAGAAAGGCATTAGAAAGC
7 LRRC34 GTGGAATTATTGGTTTCAGGTTGTC TGTTTCCCCAAATGTAGATATGAGAG
8 MLL2 CTTCAAGGACAAGACCATGCTG TCACCTCGTCCCGCTCAA
9 OCA2 TATGGCAGCTTCTCTGAGCGT CTAACTGTTGCTTTGGGCTGAAC
10 PKHD1 GTCAGTCTATATTGACCAGCAGACCT GACTCCTATGTGATACCAAAGTCCATC
11 PRMT7 TCAAGGCTAACCACTTGGAAGATAA TCCAGGGACAGGGTGGG
12 PRPS1L1 GGACCTACATGCTTCTCAAATTCAG GGCGAGACAATAATGCAGTTCTT
13 RSU1 TGTCCTTTCTCTGTCTTTGCAGC CGATGCCAATCCCTTCCTTAT
14 RUNDC3A CCTCACTACATGGACCCTCTCC GCTCACACAGTTGTTGGGCA
15 SLC25A1 GCGGCTTGCAGATCCTGA CCAGATACTGAAGTGAGAGGCACA
16 ZNF283 GGGATCACTGAGGCACACCT CACACGCCCTAAAAATCACAGTATT
17 ZNF8 CAAGGAGCAGAATAACTTGAAGCAG GAATGGATTTGGGCTTGAACTC
UPN11 1 ADAMTS19 ACAAAAACAGAATGTATGAATGGAAGA CTGCCTATATACACGGTGTGGGT
2 ARHGAP36 CAGGTGCCTCCCCATATTCA TGGATCTTCCTCAAGTTCCTGC
3 ASXL1 GATGAGGGAGGTGGCAGAGG GATAAGGCGGCAGTAGTTGTGTTC
4 CDC42SE1 AGTGAGGAGTGGGTTGTCCAA CAGCACACAGTAACTGACTGCTCTT
5 CHMP7 GTCTGTATCAGAACTCGCCCCTC GGACTGTGACCCTCTTCTCCTTC
6 CREBBP AAAGAGCCCCCAGGAGTCAC TCTTGCGTTTGCAGCCC
7 ESPL1 CGTGGTTGCCCCAGGTAGT CAGTTGTCAGTCAGTTCTTCCTCAG
8 JAG2 TCCCTGGAGGCGGAGAAGT AGACGGCATGGCTCCCAC
9 LRP6 GAAGTGAACGTACTACCTTAGTTCCAAA CCAATGATAAATAGCAGCCACTGA
10 LRRC7 GGATTGTTGGTGTTCCCCTG GGGTTCTGGTCCAATTCTGC
11 LYST AGAGTACTTTTTGTTGTGGTTTTTATCTCA TGGAGACCTTCTTCTGTACCTGTTTAA
12 MERTK CCCAGGTGACCTCTGTCGAAT CCTTCCCATCTTTCCACCAA
13 MUC16 CTGCATCCACATCTGCTGCTA GGGACTTCAGAGCTGATACTTGC
14 NRAS AACTGGTGGTGGTTGGAGCA CAGGATCAGGTCAGCGGG
15 NT5E GCCACTAGCATCTCAAATATCAGGA CTACAGTCCATAAATATAATGCCAAGC
16 PTPRS GTCCTTCTCCGCTGGCTG GGCTCGCACTTGGAGGTCAT
17 RIPK4 GGGGACACCAGCAAACTGAT ATTGTTGAGCAGCAGCCACTT
18 RUNX1 CCCACCCCACTTTACATATAATTGA AGGTGAAATGGGCGTTGC
19 SCCPDH ATTGTCGGGAACTCAAAGGTTATT AAACAAAAATATCCCACACTGAATAGAA
20 SMTNL2 GCCTCGTCCTGTGAGCCTC GGCAGCAGACATGGGTGATA
21 U2AF1 CCCAGCAAAATAATCAGCTCTCAT CTGTCTTTGAAAAGAACATGAAGTTTTTAT
22 UTF1 GAAGACCCCGACTCGCC CAGGGACACTGTCTGGTCGAA
UPN indicates unique patient number 
* Gene analyzed by genescan analysis instead of targeted deep sequencing
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Supplemental Table 4. Barcode primer sequences
Barcode No. Barcode Sequence Barcode no. Barcode Sequence 
Ion Xpress_1 CTAAGGTAAC Ion Xpress_26 TTACAACCTC
Ion Xpress_2 TAAGGAGAAC Ion Xpress_27 AACCATCCGC
Ion Xpress_3 AAGAGGATTC Ion Xpress_28 ATCCGGAATC
Ion Xpress_4 TACCAAGATC Ion Xpress_29 TCGACCACTC
Ion Xpress_5 CAGAAGGAAC Ion Xpress_30 CGAGGTTATC
Ion Xpress_6 CTGCAAGTTC Ion Xpress_31 TCCAAGCTGC
Ion Xpress_7 TTCGTGATTC Ion Xpress_32 TCTTACACAC
Ion Xpress_8 TTCCGATAAC Ion Xpress_33 TTCTCATTGAAC
Ion Xpress_9 TGAGCGGAAC Ion Xpress_34 TCGCATCGTTC
Ion Xpress_10 CTGACCGAAC Ion Xpress_35 TAAGCCATTGTC
Ion Xpress_11 TCCTCGAATC Ion Xpress_36 AAGGAATCGTC
Ion Xpress_12 TAGGTGGTTC Ion Xpress_37 CTTGAGAATGTC
Ion Xpress_13 TCTAACGGAC Ion Xpress_38 TGGAGGACGGAC
Ion Xpress_14 TTGGAGTGTC Ion Xpress_39 TAACAATCGGC
Ion Xpress_15 TCTAGAGGTC Ion Xpress_40 CTGACATAATC
Ion Xpress_16 TCTGGATGAC Ion Xpress_41 TTCCACTTCGC
Ion Xpress_17 TCTATTCGTC Ion Xpress_42 AGCACGAATC
Ion Xpress_18 AGGCAATTGC Ion Xpress_43 CTTGACACCGC
Ion Xpress_19 TTAGTCGGAC Ion Xpress_44 TTGGAGGCCAGC
Ion Xpress_20 CAGATCCATC Ion Xpress_45 TGGAGCTTCCTC
Ion Xpress_21 TCGCAATTAC Ion Xpress_46 TCAGTCCGAAC
Ion Xpress_22 TTCGAGACGC Ion Xpress_47 TAAGGCAACCAC
Ion Xpress_23 TGCCACGAAC Ion Xpress_48 TTCTAAGAGAC
Ion Xpress_24 AACCTCATTC Ion Xpress_49 TCCTAACATAAC
Ion Xpress_25 CCTGAGATAC Ion Xpress_50 CGGACAATGGC
No. indicates number
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Supplemental Table 6. Results SNP array
Patient Months from BL Aberration (% of cells) Aberration according to ISCN (hg19 reference)
UPN01 2 del(5q) (70%) 5q15q33.2(95.804.838-154.408.872)x1~2
119 del(5q) (90%) 5q15q33.2(95.804.838-154.408.872)x1~2
UPN02 BL CN-LOH4q (75%) 4q21.23qter(85.662.390-190.921.709)x2 hmz
60 CN-LOH4q (90%) 4q21.23qter(85.662.390-190.921.709)x2 hmz
UPN03 BL no abn (1-22)x2,(XY)x1
93 no abn (1-22)x2,(XY)x1
UPN04 BL no abn (1-22)x2,(XY)x1
72 no abn (1-22)x2,(XY)x1
UPN05* BL trisomy 8 (20%) (8)x2~3
loss ETV6 (90%) 12p13.2(11867287-12027012)x1
23 loss ETV6 (40%) 12p13.2(11867287-12027012)x1
48 no abn (1-22)x2,(XY)x1
79 loss ETV6 (90%) 12p13.2(11867287-12027012)x1
84 loss ETV6 (90%) 12p13.2(11867287-12027012)x1
gain KMT2A (60%) 11q23.3(118338477-118354345)x3
UPN06 BL trisomy 21 (50%) (21)x2~3
20 trisomy 21 (40%) (21)x2~3
57 trisomy 8 (60%) (8)x3
CN-LOH14q (100%) 14q11.2qter(23431738-107285437)x2 hmz
trisomy 21 (75%) (21)x3
63 trisomy 8 (90%) (8)x3
CN-LOH14q (95%) 14q11.2qter(23431738-107285437)x2 hmz
trisomy 21 (95%) (21)x3
64 trisomy 8 (100%) (8)x3
CN-LOH14q (95%) 14q11.2qter(23431738-107285437)x2 hmz
trisomy 21(100%) (21)x3
UPN07 BL no abn (1-22)x2,(XY)x1
23 no abn (1-22)x2,(XY)x1
38 trisomy 8 (40%) (8)x2~3
44 complex including trisomy (3,5,7,9,10,12,16,17,22)x1~2
8 (20-30% ) 4q13.3q24(72018147-102866413)x2~3
4q24qter(102866413-191000000)x1~2
(8)x2~3
UPN08 BL del(5q) (90%) 5q21.3q34(82169433-161991376)x1
112 no abn (1-22,X)x2
UPN09 BL del(5q) (60%) 5q14.3q34(86890558-162823229)x1~2
53 no abn (1-22,X)x2
UPN10 3 del(5q) (10%) 5q15q33.3(98131505-156829473)x1~2
del(13q) (10%) 13q13.1q14.3(32377128-53622642)x1~2
49 no abn (1-22,X)x2
UPN11 BL gain ERG 21q (90%) 21q22.13(39593444-39950442)x3
29 gain ERG 21q (100%) 21q22.13(39593444-39950442)x3
UPN indicates unique patient number; BL, baseline; hmz, homozygous; CN-LOH, copy-neutral loss of heterozygosity; 
no abn, no abnormalities. *SNP-array results influenced by lymphocytosis.
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Supplemental Table 7. Results cytogenetic analysis
Patient Months from BL Results karyotype analysis and FISH
UPN01* 2 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[8]/46,XX[2]
19 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[10]
30 45,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[1]/46,XX[19]
33 46,XX[20]
38 46,XX[20]
44 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[2]/46,XX[8]
50 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[2]/46,XX[8]
56 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[5]/46,XX[5]
61 46,X,del(X)(p11),del(5)(q15q33),add(16)(q24)[5]/46,XX[5]
67 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[6]/46,XX[4] 
80 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[4]/46,XX[6]
94 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[7]
102 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[10]
109 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[7]/46,XX[3]
116 46,X,del(X)(p11),del(5)(q13q33),add(16)(q24)[10]
119 FISH: del5q31 [175/200]
UPN02 BL 46,XY[20]
8 46,XY[20]
38 46,XY[20]
53 47,XY,+del(1)(p11)[2]/46,XY[18]
60 47,XY,+del(1)(p11)[2]/46,XY[15]
UPN03 BL 46,XY,?del(13)(q33)[4]/46,XY[28]
88 46,XY[20]
96 46,XY[20]
UPN04 -3 46,XY[20]
17 46,XY[20]
29 46,XY[20]
48 46,XY[20]
72 46,XY[20]
UPN05 BL 47,XY,+8[5]/46,XY[5]
23 47,XY,+8[2]/46,XY[18]
31 46,XY[4] + FISH: no trisomy 8 [200]
48 FISH: no trisomy 8 [200]
56 FISH: no trisomy 8 [200]
79 46,XY[20]
84 46,XY[20]
UPN06 BL 47,XY,+21[7]/46,XY[3]
17 47,XY,+21[8]/46,XY[2]
20 47,XY,+21[4]
57 47,XY,+21[3]/48,sl,+8[7]
63 47,XY,+21[1]/48,sl,+8[9]
UPN07 BL 46,XY[20]
36 47,XY,+8[2]/46,XY[8]
38 47,XY,+8[3]/46,XY[7]
41 47,XY,+8[3]/46,XY[7]
43 47,XY,+8[2]/46,XY[8]
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44 47,XY,+8[2]/70~73,XXY,+Y,+2,-3,add(4)(q31),-5,+6,-7,+8,-9,-10,+11,+11,
-12,+13,+13,+14,+15,-16,-17,+18,+19,+20,-22,+mar,inc[cp5]/46,XY[3]
UPN08 -2 46,XX,t(1;10)(q32.3;q26.1),del(5)(q13q33)[10]
4 46,XX,t(1;10)(q32.3;q26.1),del(5)(q13q33)[8]/46,XX[2]
7 46,XX,t(1;10)(q32.3;q26.1),del(5)(q13q33)[10]
17 46,XX,t(1;10)(q32.3;q26.1),del(5)(q13q33)[9]/46,XX[1]
28 46,XX,t(1;10)(q32.3;q26.1),del(5)(q13q33)[10]
34 46,XX,t(1;10)(q32.3;q26.1),del(5)(q13q33)[1]/46,XX[19]
39 46,XX[20]
45 46,XX[20]
50 46,XX[20]
56 46,XX[6]
61 46,XX[6] + FISH: no del 5q [200]
67 46,XX[20]
79 FISH: no del 5q or -5 [200]
98 46,XX[30] + FISH: del 5q [7/300], is around cut-off of probe set (2%)
112 46,XX[20] + FISH: no del 5q [200]
127 FISH: del 5q [7/200], is around cut-off of probe set (2%)
UPN09 BL 46,XX,del(5)(q13q33)[6]/46,sl,del(9)(q22q32)[4]
6 FISH: del 5q [6/200], is around cut-off of probe set (2%)
8 46,XX,del(5)(q13q33)[5]/46,XX[15] 
14 46,XX[20]
21 46,XX[20]
26 46,XX[6] + FISH: no del 5q or -5 [200]
32 46,XX[20]
37 46,XX,del(5)(q13q33)[3]/46,XX[8]
53
46,XX,del(5)(q13q33)[2]/46,XX[12] + FISH: del 5q [7/200], is around cut-off 
of probe set (2%)
69 46,XX,del(5)(q13q33)[4]/46,XX[11]
UPN10 BL 46,XX,del(5)(q15q33)[5]/46,sl,del(13)(q12q14)[4]
3 46,XX,del(5)(q15q33),del(13)(q12q14)[2]/46,XX[8]
6 46,XX[20] 
11 46,XX[20] 
18 46,XX[20] 
29 46,XX[20] 
40 46,XX[27] 
49 46,XX[30] 
62 FISH: no del 5q or -5 [200]
79 FISH: no del 5q or -5 [200]
85 FISH: no del 5q or -5 [200]
93 FISH: del 13q [85/200], del5q31 [73/200]
112
46,XX,trp(1)(q21q32),del(5)(q15q33),del(13)(q12q14)[6]/46,XX,+der(1;13)
(q10;q10),del(5)(q15q33),del(13)(q12q14),-13[3]/46,XX[1]
UPN11 BL 46,XY[20]
9 46,XY[20]
20 46,XY[20]
* del(X)(p11),add(16)(q24)[8] is possibly t(X;16)(p11;q24)
BL indicates baseline; FISH, fluorescence in situ hybridization; sl, stemline.
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Supplemental Figure 1. Comparison of VAFs measured in the first and last bone marrow sample of each patient. 
Variants located on the X- or Y-axis indicate mutations only present in the first or last sample. Many clones can 
already be distinguished by comparing these two samples. However, clonal composition cannot be fully resolved, as 
some mutations belonging to different (sub)clones cluster together (UPN02, UPN05, UPN09), and some mutations 
will be missed (UPN02, UPN10) when only the first and last sample are investigated, without intermediate time 
points. VAFs of mutations in regions harboring a copy number variation are corrected for local ploidy. For UPN07, 
the penultimate sample was used, since the last sample had a very complex karyotype. Mutations are color-coded 
to match the (sub)clones as depicted in figures 2 and 3.
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Supplemental Figure 3. Mutations still detectable in remission time points of patient UPN08. Mutations can still 
be detected at low VAF (~0.2%) under lenalidomide treatment, which indicates the presence of remaining MDS cells 
(~0.4%).
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Supplemental Figure 4. Chimerism analysis in PB samples of UPN10 after allo-SCT. The percentage of blood 
cells with a patient-specific single nucleotide polymorphism (SNP TRIM39) is depicted, as well as the percentage 
of blood cells with a patient-specific mutation (mut ZNF8). Patient cells could still be detected after allo-SCT (<1%). 
Approximately one year after SCT, the mutated cells started to increase in frequency, causing a relapse of MDS. 
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Supplemental Figure 5. Comparison of VAFs in myeloid progenitor fractions. HSCs, CMPs, GMPs and MEPs were 
sorted from BM samples of 6 different patients: (A) UPN01, (B) UPN03, (C) UPN04, (D) UPN05, (E) UPN06, and (F) 
UPN10. The VAFs in all different progenitor fractions are compared. VAFs are not corrected for local ploidy.
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Supplemental Figure 5 (continued). Comparison of VAFs in myeloid progenitor fractions.
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Supplemental Figure 5 (continued). Comparison of VAFs in myeloid progenitor fractions. 
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Supplemental Figure 6. Comparison of VAFs in different PB and BM fractions. For some time points, multiple PB or 
BM fractions were analyzed. The comparison of different fractions per time point is depicted for patient: (A) UPN01, 
(B) UPN04, (C) UPN05, (D) UPN07, (E) UPN08, (F) UPN09 and (G) UPN10. VAFs are not corrected for local ploidy.
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Supplemental Figure 6 (continued). Comparison of VAFs in different PB and BM fractions.
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Supplemental Figure 6 (continued). Comparison of VAFs in different PB and BM fractions.
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Supplemental Figure 6 (continued). Comparison of VAFs in different PB and BM fractions.
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Supplemental Figure 6 (continued). Comparison of VAFs in different PB and BM fractions.
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Supplemental Figure 6 (continued). Comparison of VAFs in different PB and BM fractions.
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Supplemental Figure 6 (continued). Comparison of VAFs in different PB and BM fractions. 
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Thesis objective
Hematological malignancies are a heterogeneous group of disorders, both in terms of clinical 
features and molecular aberrations. The last few years, many genetic aberrations have been 
discovered in these malignancies. One class of genes that is frequently affected is the class of 
epigenetic regulators. The aim of my thesis was to investigate genetic defects in epigenetic 
regulators and to determine the consequences of these aberrations on epigenetic processes 
and survival. In addition, we investigated the clonal evolution in MDS patients and correlated 
the evolutionary patterns with clinical parameters and therapy response, to get a better view 
of the (genetic) evolution of the disease and the influence of treatment on this evolution.
Genetic defects in PRC2 components in myeloid malignancies
The PRC2 complex plays an important role in transcriptional regulation by mediating the 
formation of H3K27me3 marks, which are associated with transcriptional repression. The 
PRC2 complex consists of three core members: EZH2, SUZ12 and EED.1 Mutations have 
been described in EZH2, the catalytically active component of the complex. Loss-of-function 
mutations in EZH2 were found in 6% of patients with myelodysplastic syndromes (MDS), 
6% of patients with myeloproliferative neoplasms (MPN) and 12% of patients belonging to 
the MDS/MPN intermediate group.2,3 EZH2 mutations confer a poor prognosis in myeloid 
malignancies.2
In chapter 2, we investigated whether other proteins of the PRC2 complex are also 
mutated in myeloid malignancies, namely the proteins EED, SUZ12, EZH1 and JARID2. We 
sequenced 326 patients and detected 13 novel variants in EED, SUZ12 and JARID2 (7 missense, 
6 silent) in 19 patients. Sequencing of available T cell DNA showed that 4 of these variants (all 
missense) were not somatically acquired. For the remaining 9 variants (3 missense, 6 silent), 
T cell DNA was not available. It therefore remains possible that PRC2 components other than 
EZH2 are mutated, albeit at a very low frequency (<1%).
Other groups confirmed a very low frequency of SUZ12 and EED mutations in myeloid 
malignancies.5,6 They were able to show that some EED and SUZ12 variants were acquired 
and led to a decreased H3K27me3 level.5 Interestingly, acquired mutations in PRC2 
members (SUZ12, EED and EZH2) are also described in T-cell leukemias,7 with remarkably 
high frequencies (combined 42.2%) in early T-cell precursor acute lymphoblastic leukemia 
(ETP-ALL).8 This indicates that the PRC2 complex is also important for the regulation of gene 
expression during T cell development. It is currently unknown why the incidence of PRC2 
mutations and the affected PRC2 members differ between myeloid malignancies and T-cell 
leukemia.
The impact of TET2 mutations and expression on overall survival in AML
TET2 mutations have been described in various types of myeloid malignancies. The results 
regarding the impact of TET2 mutations on overall survival in AML have been controversial. 
Several studies reported a negative effect on overall survival, whereas others did not 
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show an effect.9-12 This inconsistency might be caused by the type of treatment, the size 
of the investigated cohorts, and possible bias because most cohorts were not prospectively 
collected. Therefore, we assessed the frequency and prognostic impact of TET2 mutations 
in a large prospectively collected cohort of AML patients included in the AML12 clinical 
trial. In our cohort, TET2 mutations were present in 7.6% of the patients and conferred an 
independent poor prognostic effect. The negative impact of TET2 mutations was also evident 
in the group of patients with poor cytogenetic risk factors and in the group of patients with 
DNMT3A mutations (also associated with poor prognosis), which strengthens our finding. 
Since TET2 mutations lead to loss of function and are associated with a poor prognosis, we 
investigated whether decreased expression of TET2 also affects survival. We observed an 
adverse prognosis for patients with decreased TET2 isoform 1 mRNA expression, indicating 
that TET2 mutations and decreased expression are both markers of poor prognosis in AML.
Interestingly, TET2 mutations have also been described in 5-10% of older individuals 
with clonal hematopoiesis without evidence for an hematological disease.13,14 Clonal 
hematopoiesis (with a median of 20% of hematopoietic cells involved14) is observed in more 
than 10% of individuals above 65 years. The most frequently detected mutations in these 
individuals are mutations in DNMT3A, TET2 and ASXL1. Clonal hematopoiesis is associated 
with a significantly increased risk of developing hematological malignancies, but this risk is 
small (1%/year).14-16 This suggests that TET2 (and also ASXL1 and DNMT3A) mutations lead 
to clonal expansion, but that additional genetic defects are required to induce malignant 
transformation.
Correlation of TET2 mutations with clinical and molecular parameters in AML
TET2 mutations in our AML cohort were mutually exclusive with IDH1/2 mutations, which 
confirms the results of other studies.17 Mutant IDH proteins gain the function to convert the 
TET cofactor α-ketoglutarate (αKG) into the oncometabolite 2-hydroxyglutarate (2HG), which 
is a competitive inhibitor of the TET proteins.18,19 This may explain why mutations in TET2 and 
IDH1/2 are mutually exclusive. Recent studies showed that heterozygous WT1 mutations also 
anti-correlate with mutations in TET2, IDH1 and IDH2.20 The transcription factor WT1 plays 
an important role in recruiting TET proteins to the genome.21 Inactivating mutations in WT1 
may inhibit the recruitment of TET proteins and thereby the demethylation of WT1 targets. 
Although TET proteins have more targets than only WT1 targets, there is a large overlap in 
differentially methylated and hydroxymethylated regions in TET2, IDH1/2 and WT1 mutant 
AML when compared to other AML samples.20 This implies that TET2, IDH1, IDH2 and WT1 
mutations have a comparable role in leukemogenesis.
TET2 mutations in AML correlated with older age and were almost exclusively present in 
the group of patients with normal cytogenetics. TET2 mutations frequently co-occurred with 
NPM1 mutations. Also FLT3-ITD was frequently observed in these patients, but did not reach 
significance in our cohort. Interestingly, both TET2 and IDH mutations frequently co-occurred 
with mutations in the methyltransferase gene DNMT3A, indicating that they may cooperate 
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during malignant transformation. This is intriguing since these genes have opposing roles; 
DNMT3A mediates methylation whereas TET proteins mediate demethylation, making 
it unlikely that both are targeted by loss-of-function mutations. The majority of DNMT3A 
mutations do target one specific amino acid (R882), which might hint towards a gain-of-
function effect. The biological relevance of this co-occurrence is currently unknown. Future 
studies should give insight into their cooperation during leukemogenesis.
Consequences of TET2, IDH1, IDH2 and DNMT3A mutations on hydroxymethylation
The initial step mediated by TET proteins is the conversion of 5mC to 5hmC. We used 
immunofluorescence (chapter 3) to determine the effect of TET2 mutations on this first 
conversion step. We could show that TET2 mutations result in loss of function, since the 
mutants were unable to produce 5hmC when they were overexpressed in cell lines. When 
overexpressing wild-type and mutant TET2 together, 5hmC could still be formed, which 
indicates that the mutants do not function in a dominant-negative manner with respect to 
the formation of 5hmC. In addition, we developed an HPLC-MS/MS method (chapter 4) to 
accurately measure global 5mC and 5hmC levels in the DNA of AML patients. In line with the 
in vitro experiments, we observed a significant decrease in the levels of 5hmC in patients with 
TET2 mutations compared to patients without mutations in TET2.
We also used this HPLC-MS/MS method to investigate the effect of IDH1/2 and DNMT3A 
mutations on the formation of 5hmC. We observed a significant decrease in the levels of 
5hmC for patients with IDH1/2 mutations, while DNMT3A mutations alone (without co-
occurring TET2 or IDH mutation) did not significantly affect 5hmC levels. Furthermore, we 
observed no additive effect on the 5hmC level when DNMT3A was mutated in addition to 
TET2 or IDH1/2. This demonstrates that these mutations do not cooperate with regard to 
5hmC dysregulation. At the time of our study, the link between WT1 mutations and TET2 
mutations was not yet described. Recent studies show that 5hmC levels are also decreased 
in WT1-mutated patients.20
Elevated 5hmC levels in AML patients
Besides decreased 5hmC, some patients had elevated 5hmC levels when compared to healthy 
CD34+ cells and the majority of AML patients. When analyzing the overall survival of three 
5hmC groups (low, intermediate and high), the group with high 5hmC showed a statistically 
significant poor overall survival compared to the intermediate group, while the survival of the 
low and intermediate group were comparable. MLL aberrations and AML1-ETO translocations 
were enriched in patients with high levels of 5hmC (Table 1). This raised the question: what 
causes the elevated 5hmC level in patients with MLL and AML1-ETO aberrations? A recent 
paper by Huang et al.22 described elevated TET1 mRNA levels and increased global 5hmC 
levels in MLL-rearranged leukemia. They showed that TET1 plays an essential oncogenic role 
in MLL-rearranged leukemia. As a follow-up to this study they showed that miRNA-26a and 
-29a, both targeting TET1, are downregulated in MLL-rearranged leukemia compared to 
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healthy controls.23 Overexpression of these miRNAs inhibited MLL-fusion mediated leukemic 
transformation by downregulating TET1 and its downstream targets. These two studies 
together suggest that transcriptional repression of miRNA-26a and -29a, likely mediated by 
the MLL-fusion protein, are required for the aberrant overexpression and potent oncogenic 
role of TET1 in MLL-rearranged leukemia. These results may explain the elevated 5hmC levels 
that we observe in MLL-rearranged patients. Another factor that might influence 5hmC 
levels in patients with MLL and AML1-ETO aberrations is the expression of CXXC proteins. 
CXXC proteins are able to downregulate TET protein levels in a dose-dependent manner, 
with a concomitant decrease in 5hmC levels.24 Kuhln et al.,25 recently showed that CXXC5 
mRNA expression was downregulated in AML patients with MLL rearrangements or AML1-
ETO fusion proteins. It would be interesting to investigate whether CXXC5 downregulation 
in these patients resulted in elevated TET protein levels and increased hydroxymethylation.
Differential effect of TET2 and IDH1/2 mutations on overall survival
In the AML12 study cohort we demonstrated that both TET2 and IDH1/2 mutations lead 
to decreased levels of 5hmC. However, when looking at the survival data, TET2 mutations 
correlated with a poor prognosis, whereas IDH1/2 mutations showed an intermediate 
prognosis. This indicates that, although both affect 5hmC levels, there are differences 
between these groups of patients. One difference is that IDH mutations not only affect the 
activity of TET proteins, but also the activity of multiple other αKG-dependent dioxygenases. 
This implies that the effect of IDH mutations would be more severe than TET2 mutations, 
which is not in line with the survival analysis. A possible explanation might be that IDH 
mutations on their own are more pathogenic than TET2 mutations, but that TET2 mutations 
are often accompanied by other aberrations that together result in a negative influence on 
survival. In addition, it might be that IDH-mutated cells respond better to therapy than TET2-
mutated cells, thereby resulting in a better overall survival for IDH-mutated patients. More 
research should be performed to clarify this difference in survival.
Role of aberrant 5hmC in leukemogenesis
An important unanswered question is how altered 5hmC levels contribute to leukemogenesis. 
A deregulated 5hmC level suggests a defect in the balance of methylation and demethylation, 
which may result in the silencing of tumor suppressor genes or activation of oncogenes. 
However, using HPLC-MS/MS we observed only minor changes in global 5mC levels. 5mC 
levels were slightly increased in IDH-mutated patients compared to TET2-mutated patients 
and the wild-type group. This difference between TET2- and IDH-mutated patients might be 
explained by the fact that active demethylation is more severely affected in IDH-mutated 
patients because all three TET enzymes are inhibited by 2HG, while in TET2-mutated patients 
only TET2 is affected. Since 5hmC is 100 times less abundant than 5mC, a decrease in 5hmC 
(caused by inhibited demethylation) might not always be visible at the global 5mC level, but 
may rather affect 5mC at specific loci. Therefore, we analyzed the promoter methylation of 2 
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genes P15 and MYOD, and showed an increased P15 promoter methylation in patients with 
decreased 5hmC levels. Genome-wide methylation studies should be performed to identify 
more genes that are aberrantly methylated in patients with TET2, IDH1/2 and WT1 mutations. 
This might give insight in the genes that are implicated in leukemogenesis.
Treatment possibilities directed against aberrant 5hmC levels
Since promoter hypermethylation is frequently observed in hematological malignancies, 
hypomethylating agents (decitabine and azacitidine) are currently used for patients that 
are ineligible for intensive chemotherapy or stem cell transplantation.26 As TET2, IDH and 
WT1 mutations are characterized by a promoter hypermethylation phenotype,20,27 patients 
with these mutations may particularly benefit from this treatment (Table 1). Several studies 
addressed the question which genetic defects predict response to hypomethylating agents.28-33 
Some studies indeed show that TET2-mutated patients respond better to this therapy,29-31 
while other studies did not confirm this correlation.32,33 This suggests that the correlation 
is not very strong and may depend on the size and type of the investigated cohort. Hence, 
studies in large prospectively collected cohorts are required to confirm the correlation. If the 
group of TET2-, IDH1/2- and WT1-mutated patients turns out to be good responders, 5hmC 
may be an important marker to select for patients that benefit from this treatment. Since 
most of the low 5hmC patients can now be characterized on the genetic level by TET2, IDH1, 
IDH2 or WT1 mutations, mutational screening may be used instead.
Another possible therapeutic option might be the administration of vitamin C (Table 1). 
Vitamin C is an essential cofactor for TET proteins, that enhances TET-mediated generation 
of 5hmC. A study in melanoma cells demonstrated that vitamin C could lead to an increase in 
5hmC and a decrease in tumor-cell invasiveness and growth in vitro.34 Whether vitamin C also 
has positive effects for myeloid malignancies remains to be elucidated.
Table 1. Genetic defects linked to aberrant 5hmC levels in myeloid malignancies
Aberrant 5hmC levels in myeloid malignancies
TET2 mutations IDH1/2 mutations WT1 mutations MLL-rearrangements AML1-ETO
5hmC level
(Potential) 
cause
TET2 loss of 
function
2HG inhibits TET 
function
Inhibits TET 
recruitment to 
genome
Increased TET1 expression 
through decreased miR-
26a and -29a expression 
and/or decreased CXXC5 
expression
Decreased CXXC5 
expression, likely 
causing increased TET 
expression
(Potential) 
targeted 
treatment 
options#
Hypo-me agents 
Vitamin C
Hypo-me agents 
Vitamin C 
IDH1/2 inhibitors 
DOT1L inhibitor*
Hypo-me agents 
Vitamin C
DOT1L inhibitor* -
# Treatment options besides standard therapies as chemotherapy and stem cell transplantation
* DOT1L inhibitor: Inhibits DOT1L, an H3K79 methyltransferase. This treatment was shown to be effective in MLL-
rearranged and IDH1/2-mutated leukemia.35
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The effect of azacitidine treatment on global 5mC and 5hmC levels
We are currently investigating the effect of the hypomethylating agent 5-azacitidine on global 
5mC and 5hmC levels in MDS/AML patients. The patients received azacitidine for 7 consecutive 
days, once every 4 weeks. We measured 5(h)mC levels on day 1 (prior to azacitidine 
administration) and on day 7 of each treatment cycle. We observed different patterns of 5mC 
levels during treatment (Figure 1). Some patients showed a drop in global 5mC level after the 
first treatment cycle (Figure 1B), while others did not respond at all (Figure 1A). Interestingly, 
some patients showed an oscillating pattern, with high 5mC levels on day 1 and low levels on 
day 7 of each treatment cycle (Figure 1C). The effects on global 5hmC levels were less 
pronounced. Currently, clinical response to azacitidine treatment can only be evaluated 
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Figure 1. Different 5mC patterns in azacitidine-treated patients (preliminary unpublished data). 5mC and 5hmC 
levels measured on day 1 and day 7 of each azacitidine treatment cycle. (A) No change on 5mC level. (B) Drop in 
global 5mC level after the first treatment cycle, subsequently 5mC remains low. (C) Oscillating 5mC pattern. UPN 
indicates unique patient number.
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after approximately 5 treatment cycles, which is a rather long time. The different 5mC 
patterns might predict, in an early phase, which patients will respond; a drop in 5mC after 
the first cycle might indicate responders, whereas an oscillating 5mC pattern and no 5mC 
change might indicate partial responders and non-responders, respectively. We are currently 
expanding our cohort of patients to analyze correlations with clinical response. We will also 
perform sequence analysis of 19 AML-associated genes (including DNMT3A, TET2, IDH1, IDH2 
and WT1) to determine whether mutations underlie the different 5mC patterns. In addition, 
we will focus on the patients with oscillating 5mC patterns and perform 450k methylation 
profiling to investigate whether the same genomic regions are demethylated after each 
treatment cycle.
Aberrant 5-hydroxymethylcytosine levels in other types of cancer
Besides hematological malignancies, deregulated 5hmC levels have also been observed 
in many solid cancers, including breast cancer, melanoma and brain tumors.36-38 Several 
mechanisms could be responsible for the altered 5hmC levels. Four genes that play a role 
in the Krebs cycle, namely IDH1, IDH2, SDH and FH, are mutated in various types of solid 
cancers. These 4 genes are able to affect the activity of the TET proteins by changing the 
levels of metabolites (2HG, succinate and fumarate) that compete with the TET co-factor 
αKG.19,39 In addition, changes in expression of TET, IDH and CXXC proteins are linked to altered 
5hmC levels in cancer. The fact that altered (hydroxy)methylation is frequently observed in 
cancer, suggests that the (de)methylation pathway might be an important target for cancer 
therapy, but (as also described in chapter 5) several unanswered questions still need to be 
addressed.
First of all, it remains unclear whether deregulated 5hmC levels are a cause or 
consequence of cancer. TET2 mutations in hematological malignancies are often early events, 
suggesting that deregulated 5hmC is important for the initiation of cancer.16,40 In several solid 
cancers 5hmC levels correlate with the stage of the disease, which suggests that 5hmC levels 
either change as a consequence of cancer progression, or promote cancer progression.37,41 
Secondly, the exact biological function of 5hmC marks is not completely clear. Besides being 
an intermediate in the demethylation pathway there is evidence that 5hmC may have other 
functions as well. One possibility is that 5hmC marks themselves influence transcriptional 
regulation, which may affect the expression of oncogenes and tumor suppressor genes. 
However, the impact of 5hmC marks on transcription is still ambiguous. In some tissues 5hmC 
correlates with gene activation, while in other tissues no correlation has been observed.42,43 
Future research should clarify the role of 5hmC dysregulation in the pathogenesis of cancer. 
Finally, it will be very interesting to determine whether the levels of the other demethylation 
intermediates, 5-formyl- and 5-carboxylcytosine, are also altered in cancer, especially since 
genome-wide techniques to detect these marks are currently available.44
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Clonal evolution in myelodysplastic syndromes
A variety of genetic abnormalities underlies the heterogeneity of MDS. Within the bone 
marrow of an individual patient, several clones of cells with their own set of mutations may 
be present simultaneously. This clonal composition may change during the disease course 
when additional genetic defects are acquired or under influence of therapy. We investigated 
the clonal composition and evolution in MDS patients and observed diverse evolutionary 
patterns. Some patients remained stable for many years, while others showed more dynamics 
in the clonal composition. In several patients a correlation could be observed between the 
outgrowth or reduction of a clone and changes in treatment. This emphasizes the need for 
a thorough genetic monitoring during follow-up and the importance to develop therapeutic 
strategies aiming to eradicate multiple different (sub)clones.
Conclusion
In this thesis we investigated genetic defects in myeloid malignancies, with an emphasis on 
defects in epigenetic regulators. An important finding from our studies is that TET2 mutations 
are loss-of-function mutations that deregulate 5hmC levels. Besides TET2 mutations, more 
ways to deregulate 5hmC levels have been described in hematological malignancies and 
various types of solid cancers. Although the exact biological function of 5hmC is unclear, the 
fact that it is deregulated in many types of cancer and that epigenetic changes are reversible, 
makes it an interesting target for cancer therapy. Hopefully, future research will result in 
the development of effective epigenetic therapies that are able to restore the (hydroxy)
methylation levels and thereby suppress cancer. In chapter 6, we demonstrated the genetic 
heterogeneity and clonal evolution in MDS patients. These results may have implications for 
treatment and follow-up. First of all, the study emphasizes the importance to perform unbiased 
genetic monitoring during follow-up to get a complete picture of all tumor cells in a patient, 
since some clones may disappear, whereas new clones can arise during the disease course. In 
addition, the results indicate that therapies should be directed against all subclones in order 
to be able to eradicate all tumor cells. Given that next generation sequencing techniques are 
becoming cheaper and more accessible, these might be implemented in routine diagnostics 
and follow-up of patients with myeloid malignancies in the near future.
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English summary
The production and maturation of blood cells (hematopoiesis) is an important and tightly 
regulated process in our body. All our blood cells are derived from a small population of 
hematopoietic stem cells that reside in the bone marrow. When the blood cells are fully 
matured they move from the bone marrow to the peripheral blood. We have different types 
of blood cells in our body, with their own specific functions. Red blood cells play an important 
role in oxygen transport throughout the body, platelets are essential for coagulation and 
the different types of white blood cells play an important role in the immune system. Blood 
cells have a limited life span, therefore it is important that new blood cells are produced 
continuously. Daily, around 500 billion new blood cells are produced in our body.
Hematological malignancies are characterized by a disturbed production and/or 
maturation of blood cells. This is caused by mistakes in the genetic material (DNA) of a 
hematopoietic stem or progenitor cell. All cells in our body contain DNA that is built up by the 
4 building blocks A (adenine), G (guanine), C (cytosine) and T (thymine). A gene is a small piece 
of DNA sequence that contains the information for the synthesis of a protein. It is estimated 
that the human body consists of around 20,000 genes that code for proteins. These proteins 
are essential for the formation and function of the cells in our body and it is therefore very 
important that DNA is copied correctly during cell division. However, sometimes a mistake 
(mutation, for example an A is changed into a G) may occur. A mutation in the DNA of a 
hematopoietic progenitor cell may lead to different types of hematological malignancies, 
depending on the type of blood cell and the gene in which the mutation occurred. In this 
thesis we investigated hematological malignancies in which cells belonging to the myeloid 
lineage are affected: myeloid malignancies. Examples of myeloid malignancies are acute 
myeloid leukemia and myelodysplastic syndromes. Due to new treatment strategies the 
survival of these patients has improved considerably the last few years, but a substantial 
amount of patients still die from their disease. With our research we hope to learn more 
about the pathogenesis of myeloid malignancies. This information may then be used for 
better prognostication and the development of new therapies.
In this thesis we mainly investigated mutations in genes that play a role in epigenetics. 
Epigenetic modifications are changes on top of (‘epi’) the genetic code (‘genetics’). These 
modifications regulate which regions of the DNA can (gene activation) and which cannot 
(gene repression) be used to synthesize proteins. Epigenetic modifications can be present on 
the DNA itself (e.g. DNA methylation) or on the proteins (histones) around which the DNA 
is wrapped (histon modifications). Ultimately, all these epigenetic modifications make sure 
that different genes are activated in blood cells compared to for example skin or heart cells.
In chapter 2 of this thesis we investigated genes that code for proteins that are involved in 
the synthesis of the histon modification ‘histon 3 lysine 27 trimethylation’ (H3K27me3). This 
modification is associated with gene repression. The protein complex that is responsible for 
the formation of this modification is the polycomb repressive complex 2 (PRC2). Mutations 
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in the most important protein of this complex, EZH2, are found in 6-12% of patients with 
myeloid malignancies. It has been shown that EZH2 mutations result in a reduction of 
H3K27me3 marks. In chapter 2, we investigated whether other proteins of the PRC2 complex 
are also mutated in myeloid malignancies, namely the proteins EED, SUZ12, EZH1 and JARID2. 
We investigated 326 patients and found 3 missense variants in de genes EED and SUZ12 that 
might play a role in the pathogenesis. We therefore concluded that mutations in other PRC2 
proteins than EZH2 can be present in myeloid malignancies, albeit at a very low frequency 
(<1%).
In chapter 3 and 4 we investigated the TET2 protein, which plays a role in the DNA 
methylation pathway. DNA methyltransferase (DNMT) proteins can methylate DNA, an 
epigenetic modification which is associated with gene repression. TET proteins convert 
methylated cytosines (5mC) into hydroxymethylated cytosines (5hmC), a first step that will 
ultimately lead to removal of the methyl group (demethylation) and consequently reversal 
of gene repression. In chapter 3 we screened a cohort of 357 AML patients for mutations in 
the TET2 gene. We demonstrated that TET2 mutations occur in 7.6% of the AML patients. 
Patients with a TET2 mutation had a worse overall survival compared to patients without TET2 
mutations. Besides mutations in TET2, we saw that TET2 expression also differed between 
AML patients. Patients with a lower TET2 expression had a worse overall survival compared 
to patients with a higher TET2 expression. The cause of the decreased TET2 expression in 
these patients is not yet known. Furthermore, we investigated the effect of TET2 mutations 
on the function of the protein by using a cell line model. We compared cells in which a normal 
TET2 protein was overexpressed with cells which overexpressed a mutant TET2 protein. All 
six tested mutants where unable to form 5hmC, whereas 5hmC could clearly be detected in 
cells overexpressing a normal TET2 protein. Therefore, we concluded that the tested TET2 
mutant proteins were no longer able to convert 5mC into 5hmC; the mutations lead to loss 
of function. Hence, TET2 mutations inhibit demethylation in blood cells which may lead to 
aberrant gene expression.
In chapter 4 we set up a technique to measure 5hmC levels in DNA. We measured 5hmC 
levels in 206 AML patients and correlated these levels with mutations in various genes. With 
this technique we confirmed that TET2 mutations lead to a decreased 5hmC level. Besides 
TET2, three other proteins that play a role in the DNA methylation process are also mutated 
in AML: DNMT3A, IDH1 and IDH2. DNMT3A is one of the methyltransferases that mediates 
DNA methylation. We demonstrated that mutations in DNMT3A did not affect the total 5hmC 
level in a cell. On the other hand, patients with an IDH1 or IDH2 mutation had a decreased 
5hmC level. Mutated IDH proteins produce the metabolite 2-hydroxyglutarate, which inhibits 
TET proteins. This explains why 5hmC levels are reduced in this group of patients. In addition 
to decreased 5hmC levels, we also observed increased 5hmC levels in some AML patients. 
The exact cause of the elevated 5hmC levels is unclear and requires further research. We 
investigated whether aberrant 5hmC (decreased or increased) had an effect on prognosis. We 
showed that elevated 5hmC levels were associated with a worse overall survival. All together, 
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the studies in chapter 3 and 4 show that aberrant 5hmC levels occur in AML patients and may 
correlate with a worse prognosis.
In chapter 5 we summarized all literature regarding aberrant 5hmC levels in cancer. It 
turned out that aberrant 5hmC levels are present in many different types of cancer. The cause 
of the aberrant 5hmC levels differs per tumor type. TET2 mutations are exclusively found in 
hematological malignancies, whereas mutations in IDH1 and IDH2 occur in hematological 
malignancies and other cancer types. In addition, mutations in the proteins SDH and FH can 
cause reduced 5hmC levels. Mutations in these genes are not reported in hematological 
malignancies but do occur in various solid cancers. Besides mutations, changes in gene 
expression (e.g. TET2, IDH1, IDH2, TDG) and miRNA expression (e.g. miRNA22, -26 and -29) 
are reported as a cause of aberrant 5hmC in cancer. Because aberrant 5hmC levels occur in 
many types of cancer and correlate with a worse prognosis in several cases, it is an interesting 
new target for cancer therapy.
In chapter 6, we identified the mutations in all genes of 11 MDS patients. In healthy 
persons, thousands of different hematopoietic stem cells are responsible for the formation 
of blood cells. In patients with MDS a large part of the blood cells is derived from the same 
progenitor cell and therefore has the same set of mutations, which we call a clone. MDS is 
not always a stable disease, during the disease course more mutations can be acquired and 
cells with different sets of mutations (different clones) may compete with each other. By 
following MDS patients during their disease course, we could unravel the clonal evolution in 
these patients. We observed different evolutionary patterns; some patients remained stable 
for many years, while others showed a complex clonal evolution. We also correlated the 
evolutionary patterns to therapy. In several patients a correlation could be observed between 
the outgrowth or reduction of a clone and changes in treatment. This information may be 
used to determine the effectiveness of treatment and for early detection of clones that are 
resistant to therapy.
Conclusion
In this thesis, we made several important observations that may contribute to a better 
treatment of cancer patients. First of all, we demonstrated that aberrant 5hmC levels are 
present in hematological malignancies. Since epigenetic modifications are reversible, aberrant 
5hmC is an interesting new target for cancer therapy. Furthermore, we demonstrated in 
chapter 6 that the clonal evolution in MDS patients can be complex and that this can be 
influenced by treatment. By following all genetic defects during the disease course, the effect 
of therapy can be monitored and resistant clones can be discovered in an early stage. If 
possible, treatment can be adapted accordingly.
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De aanmaak en uitrijping van bloedcellen (hematopoëse) is een belangrijk en strak 
gereguleerd proces in ons lichaam. Al onze bloedcellen ontstaan uit een kleine populatie 
hematopoëtische stamcellen die zich bevinden in het beenmerg. Wanneer de bloedcellen 
uitrijpen gaan ze vanuit het beenmerg naar het bloed. We hebben verschillende typen 
bloedcellen in ons lichaam, met ieder een eigen specifieke functie. De rode bloedcellen 
spelen een belangrijke rol bij het vervoer van zuurstof door ons lichaam, de bloedplaatjes 
zijn essentieel voor de bloedstolling en de verschillende soorten witte bloedcellen hebben 
een belangrijke rol in het afweersysteem. Bloedcellen hebben een beperkte levensduur en 
daarom is het belangrijk dat er continu nieuwe cellen worden aangemaakt. Naar schatting 
worden er dagelijks 500 miljard nieuwe bloedcellen gemaakt in ons lichaam.
Bij hematologische maligniteiten is de aanmaak en/of uitrijping van bloedcellen 
verstoord. Dit wordt veroorzaakt door fouten in het erfelijk materiaal (DNA) van een 
hematopoëtische stam- of voorloper cel. Alle cellen in ons lichaam bevatten DNA dat is 
opgebouwd uit de bouwstenen A (adenine), G (guanine), C (cytosine) en T (thymine). Een 
gen is een kort stukje DNA code dat de informatie bevat voor de synthese van een eiwit. 
Naar schatting bestaat het menselijk lichaam uit ongeveer 20.000 genen die coderen voor 
eiwitten. Deze eiwitten zijn essentieel voor de vorming en functie van de cellen in ons 
lichaam. Het is daarom erg belangrijk dat tijdens het delen van cellen het DNA correct wordt 
gekopieerd, echter kan hier wel eens een fout (mutatie, bijv een A is veranderd in een G) 
in optreden. Een mutatie in het DNA van een hematopoëtische voorlopercel kan leiden tot 
verschillende soorten hematologische maligniteiten, dit is afhankelijk van het type bloedcel 
en het gen waar de mutatie in is opgetreden. In dit proefschrift hebben we hematologische 
maligniteiten onderzocht waarbij de witte bloedcellen behorende tot de myeloïde reeks zijn 
aangedaan: myeloïde maligniteiten. Onder de myeloïde maligniteiten vallen onder andere 
acute myeloïde leukemie en het myelodysplastisch syndroom. Myeloïde maligniteiten komen 
relatief veel voor onder ouderen. Alhoewel de overleving de laatste jaren substantieel vooruit 
is gegaan door nieuwe therapieën, overlijden er nog steeds relatief veel mensen aan hun 
ziekte. Door genetisch onderzoek hopen we meer te weten te komen over het ontstaan van 
myeloïde maligniteiten. Deze informatie kan vervolgens worden gebruikt bij het ontwikkelen 
van nieuwe therapieën.
We hebben in dit proefschrift met name onderzoek gedaan naar mutaties in genen die 
een rol spelen in de epigenetica. Simpel gezegd zijn epigenetische modificaties, veranderingen 
bovenop (‘epi’) de genetische code (‘genetica’). Deze modificaties kunnen ervoor zorgen dat 
bepaalde stukken DNA wel (genactivatie) of niet (genrepressie) kunnen worden omgezet 
naar eiwit. Epigenetische modificaties kunnen op het DNA zelf plaatsvinden (bijvoorbeeld 
DNA methylatie) of op de eiwitten (histonen) waar het DNA omheen zit gewikkeld (histon 
modificaties). Uiteindelijk zorgen al deze epigenetische modificaties ervoor dat er in 
bloedcellen andere genen actief zijn dan in bijvoorbeeld huid- of hartcellen.
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In hoofdstuk 2 van dit proefschrift hebben we genen onderzocht die coderen voor 
eiwitten welke betrokken zijn bij de vorming van de histon modificatie ‘histon 3 lysine 27 
trimethylatie’ (H3K27me3). Deze modificatie zorgt voor genrepressie. Het eiwitcomplex dat 
verantwoordelijk is voor de vorming van deze modificatie is het polycomb repressive complex 
2 (PRC2). Mutaties in het belangrijkste eiwit uit dit complex, EZH2, zijn gevonden in 6-12% 
van verschillende myeloïde maligniteiten. Uit onderzoek is gebleken dat EZH2 mutaties 
ervoor zorgen dat het PRC2 complex minder H3K27me3 kan vormen. In hoofdstuk 2 hebben 
wij onderzocht of andere eiwitten uit het PRC2 complex ook gemuteerd zijn in myeloïde 
maligniteiten, namelijk de eiwitten EED, SUZ12, EZH1 en JARID2. We hebben 326 patiënten 
onderzocht en 3 missense varianten gevonden in de genen EED en SUZ12, die mogelijk een 
rol kunnen spelen bij het ontstaan van de ziekte. We hebben daarom geconcludeerd dat 
mutaties in andere PRC2 eiwitten dan EZH2 kunnen voorkomen in myeloïde maligniteiten, 
maar dat deze niet erg frequent zijn (<1%).
In hoofdstuk 3 en 4 hebben we onderzoek gedaan naar het TET2 eiwit, een eiwit dat 
een rol speelt in het DNA methylatie proces. DNA methyltransferase (DNMT) eiwitten zorgen 
voor DNA methylatie, een epigenetische modificatie die geassocieerd is met genrepressie. 
TET2 eiwitten zetten DNA methylatie (5mC) om in hydroxymethylatie (5hmC), een eerste 
stap die uiteindelijk leidt tot het weghalen van de methylgroep (demethylatie) en daarbij 
het ongedaan maken van de genrepressie. In hoofdstuk 3 hebben we een cohort van 357 
AML patiënten gescreend voor mutaties in het TET2 gen. We hebben aangetoond dat TET2 
mutaties voorkomen in 7,6% van de AML patiënten. Patiënten met een TET2 mutatie hadden 
gemiddeld een slechtere overleving dan patiënten zonder TET2 mutatie. Naast mutaties 
in TET2 zagen we dat de expressie van het TET2 gen ook verschilt tussen AML patiënten. 
Patiënten met een lagere TET2 expressie hadden een slechtere overleving dan patiënten met 
een hogere TET2 expressie. De oorzaak van de lagere TET2 expressie in deze patiënten is 
nog onbekend. Daarnaast hebben we onderzocht wat het effect is van TET2 mutaties op de 
functie van het eiwit door gebruik te maken van een cellijn model. We hebben cellen die een 
gezond TET2 eiwit tot overexpressie brengen vergeleken met cellen die een gemuteerd eiwit 
tot overexpressie brengen. De zes TET2 mutanten die we hebben getest in dit model waren 
niet in staat om 5hmC te vormen, terwijl 5hmC duidelijk aan te tonen was in de cellen waarin 
een gezond TET2 eiwit tot overexpressie werd gebracht. Hieruit kunnen we concluderen dat 
de mutaties ervoor zorgen dat het TET2 eiwit niet meer in staat is om 5mC om te zetten in 
5hmC; de mutaties leiden tot verlies van functie. TET2 mutaties remmen dus de demethylatie 
in bloedcellen wat kan leiden tot afwijkende expressie van genen.
In hoofdstuk 4 hebben we een techniek opgezet waarmee we 5hmC levels in DNA 
kunnen meten. We hebben 5hmC levels in 206 AML patiënten gemeten en de levels 
gecorreleerd met mutaties in verschillende genen. Met deze techniek hebben we bevestigd 
dat TET2 mutaties inderdaad leiden tot een verlaagd 5hmC level. Naast TET2 mutaties komen 
er in AML patiënten ook mutaties voor in 3 andere genen die een rol spelen in het DNA 
methylatie proces: DNMT3A, IDH1 en IDH2. DNMT3A is één van de DNA methyltransferases 
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die zorgt voor DNA methylatie. We hebben aangetoond dat mutaties in DNMT3A geen effect 
hebben op het totale 5hmC level in een cel. Patiënten met een IDH1 of IDH2 mutatie hadden 
daarentegen wel een verlaagd 5hmC level. Mutaties in IDH1 en IDH2 zorgen ervoor dat het 
IDH eiwit het metaboliet 2-hydroxyglutaraat gaat maken, een molecuul dat TET eiwitten remt. 
Dit verklaart waarom 5hmC levels verlaagd zijn in deze groep patiënten. Naast verlaagde 
5hmC levels hebben we ook verhoogde 5hmC levels gemeten in een aantal AML patiënten. 
De exacte oorzaak van deze verhoogde 5hmC levels is nog niet bekend en vergt verder 
onderzoek. We hebben vervolgens geanalyseerd of afwijkend 5hmC (verlaagd of verhoogd) 
een effect heeft op de overleving. Uit deze analyse is gebleken dat verhoogd 5hmC correleert 
met een slechtere overleving. De studies in hoofdstuk 3 en 4 laten dus zien dat afwijkende 
5hmC levels voorkomen in AML patiënten en kunnen correleren met een slechte overleving. 
In hoofdstuk 5 is de literatuur samengevat omtrent afwijkende 5hmC levels in kanker. 
Het is gebleken dat 5hmC levels afwijkend zijn in vele verschillende kankersoorten. De 
oorzaak van de veelal verlaagde 5hmC levels verschilt per kanker type. TET2 mutaties zijn 
uitsluitend gevonden in hematologische maligniteiten, terwijl mutaties in IDH1 en IDH2 
zowel voorkomen in hematologische maligniteiten als andere typen tumoren. Daarnaast 
kunnen mutaties in de eiwitten SDH en FH ook leiden tot een verlaagd 5hmC. Mutaties in 
deze eiwitten zijn niet gerapporteerd in hematologische maligniteiten maar komen wel voor 
in andere typen tumoren. Naast mutaties zijn ook verschillen in genexpressie (bijv. TET2, 
IDH1, IDH2, TDG) en miRNA expressie (bijv. miRNA22, -26 en -29) beschreven als oorzaak 
voor een afwijkend 5hmC level in kanker. Het feit dat afwijkend 5hmC veel voorkomt bij 
kanker en in een aantal gevallen ook nog eens correleert met een slechte prognose, maakt 
afwijkend 5hmC een interessant nieuw aangrijpingspunt voor therapie.
In hoofdstuk 6 hebben we de mutaties in alle genen van 11 MDS patiënten in kaart 
gebracht. In gezonde personen zorgen duizenden hematopoëtische stamcellen voor de 
vorming van alle bloedcellen. Bij patiënten met MDS zijn een groot deel van de bloedcellen 
afkomstig van dezelfde voorlopercel en die hebben dan ook dezelfde set mutaties, dit noemen 
we een kloon. MDS is niet altijd een stabiele ziekte, tijdens het ziekteverloop kunnen er 
mutaties bijkomen en kan er competitie optreden tussen cellen met meer of minder mutaties 
(verschillende klonen). Door MDS patiënten te volgen tijdens het ziekteverloop hebben we 
de klonale evolutie in deze patiënten in kaart kunnen brengen. We hebben verschillende 
evolutionaire patronen waargenomen; sommige patiënten blijven stabiel voor meerdere 
jaren terwijl andere patiënten een complexe klonale evolutie laten zien. We hebben de 
evolutiepatronen gecorreleerd aan de behandeling. In verscheidene patiënten was een 
correlatie waar te nemen tussen het uitgroeien of verdwijnen van een bepaalde kloon en het 
aanpassen van de behandeling. Deze informatie kan erg waardevol zijn bij het bepalen van de 
effectiviteit van een geneesmiddel en om vroegtijdig klonen cellen te detecteren die resistent 
zijn voor de therapie.
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Conclusie
In dit proefschrift hebben we een aantal belangrijke observaties gedaan die bij zouden kunnen 
dragen aan een betere behandeling van kankerpatiënten. Allereerst hebben we aangetoond 
dat 5hmC levels afwijkend zijn in hematologische maligniteiten. Aangezien epigenetische 
modificaties omkeerbaar zijn, is afwijkend 5hmC een interessant nieuw target voor 
kankertherapie. Daarnaast hebben we in hoofdstuk 6 aangetoond dat de klonale evolutie in 
MDS patiënten complex kan zijn en dat dit beïnvloed kan worden door therapie. Door tijdens 
het ziekteverloop van een patiënt de genetische afwijkingen volledig in kaart te brengen kan 
het effect van de behandeling bekeken worden en kan in een vroeg stadium een resistente 
kloon worden ontdekt. Indien mogelijk kan vervolgens de therapie worden aangepast.
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Daar is ie dan…mijn proefschrift. Hopelijk hebben jullie nu een beetje een idee waar ik de 
afgelopen jaren zo druk mee bezig ben geweest. Uiteraard had ik dit allemaal niet kunnen 
doen zonder de hulp van velen van jullie. Daar wil ik jullie graag voor bedanken.
Allereerst Joop, bedankt dat je mij de mogelijkheid hebt geboden om bij laboratorium 
hematologie stage te lopen. Deze stage heeft me erg enthousiast gemaakt voor genetisch 
onderzoek en hematologie, zodat ik ook graag mijn promotieonderzoek in deze richting 
wilde gaan doen. Gelukkig had je ook toen een plekje (PhD positie) voor mij beschikbaar. 
Ik vond het erg fijn dat jij mijn supervisor was tijdens mijn promotietraject! Je was altijd 
enthousiast over nieuwe data en nieuwe ideeën. Daarnaast zorgde je er altijd voor dat we de 
onderzoeksvraag niet uit het oog verloren. En ook als het onderzoek even wat minder liep 
wist jij altijd positief en relaxed te blijven en dit aan mij (en onze groep) over te dragen. Een 
gave die niet veel mensen hebben (en die ik zelf zo nu en dan ook wel wat meer zou willen 
hebben). Daarnaast stond je deur ook altijd open voor persoonlijke dingen en voelde je vaak 
goed aan wanneer ik wel een goed gesprek kon gebruiken. Ook een hele fijne eigenschap van 
een supervisor, bedankt!
Bert, ook jouw inbreng tijdens mijn PhD is van groot belang geweest. Jij had altijd net weer een 
iets andere kijk op het onderzoek, wat in combinatie met Joop heeft geleid tot hele mooie en 
goed lopende projecten. Je enthousiasme en oneindige hoeveelheid aan onderzoeksideeën 
waren daarbij erg belangrijk. Ook je kritische blik op de artikelen die ik heb geschreven vond 
ik altijd erg waardevol. Ik hoop dat jij en Joop nog lange tijd zo’n goed onderzoeksduo blijven 
vormen. 
Lieve dames en heer van de moleculaire diagnostiek. Bij jullie ben ik begonnen met mijn 
stage en voelde ik me meteen ‘thuis’. Met name de gezellige sfeer en de behulpzaamheid 
van iedereen vond ik echt heel fijn. Het meest heb ik samen mogen werken met het TET 
sequencing groepje: Marion, Ellen en Patricia. Marion, die het nooit een probleem vond 
om als ‘charmante assistente op te treden’, zoals ze dat zelf altijd zei. Ellen, met haar altijd 
grappige uitspraken ‘LeOOOnie, kanonne’, eeenOOOrme piek, chapeau chapeau etc. En 
Patricia, die meteen begreep wat een pruttelplaat was. Hopelijk zullen jullie zo af en toe nog 
profijt hebben van deze handige term. Tijdens mijn PhD heb ik het ook altijd leuk gevonden 
om weer een project samen met jullie, de moleculaire diagnostiek, te mogen doen. Ook 
toen kon ik altijd voor vragen, hulp en gezellige gesprekken bij jullie terecht! Adrian, Ellen en 
Evelyn, jullie waren altijd attent, meelevend en bereid om te helpen. Evelyn, jij had zelfs al 
zingend de PCRs ingezet voor ik goed en wel klaar was met de uitleg. Louis, bij jou kon ik altijd 
terecht voor vragen over computers of PCR. Laura, jij wist als geen ander mee te praten over 
de leraren op het Saxion. En Marion, ik vond het erg fijn dat jouw deur altijd open stond voor 
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een persoonlijk gesprek! Tot slot de nieuwste diagnostiek collega’s Aniek en Tamara. Aniek 
bedankt voor al je hulp bij de next generation sequencing projecten en Tamara bedankt voor 
de gezelligheid het afgelopen jaar. 
Patricia, met jou klikte het al goed tijdens mijn stage, misschien toch door onze twentse 
roots?! Je was altijd erg behulpzaam en betrok me meteen bij de groep, wat het samenwerken 
extra leuk maakte. Ook tijdens mijn PhD mocht ik al snel weer met jou en Ellen samenwerken, 
wat ik stiekem erg leuk vond. Maar ook toen dit project was afgerond was je altijd bereid om 
me ergens mee te helpen, van het zoeken naar informatie over vitamine C tot het voorzien 
van chocola in moeilijke tijden. Daarnaast gaan we zo af en toe eens gezellig een middagje 
shoppen en bijkletsen, samen met Saskia. Ik zou zeggen, deze middagjes houden we erin! 
Leuk dat je mij wilt bijstaan als paranimf tijdens mijn verdediging!
Thessa, wij hebben zowel tijdens mijn stage als tijdens mijn promotietraject veel samengewerkt, 
kortom de ideale paranimf om vragen aan door te spelen. Jij was altijd bereid om te helpen, 
zowel met pipetteren, dagen lang sequenties analyseren als figuren ontwerpen. We hebben 
samen vele hoogtepunten, maar ook frustraties meegemaakt in het onderzoek. Ik vond het 
altijd fijn om die met je te kunnen delen! Daarnaast hebben we ook buiten werktijd veel leuke 
dingen samen gedaan: samen sporten, met Melle en Joep spelen en een fotografie cursus 
volgen. Ik ben daarom blij dat ook jij mijn paranimf wilt zijn.
Sylvie, Saskia L, Laurens (en Thessa nogmaals). Naast jullie behulpzaamheid en gezelligheid 
op het lab, vond ik onze klim-avondjes altijd erg gezellig. Met name onze klimvakantie in 
Monthermé zal ik nooit vergeten! Inmiddels is het gezelschap uitgebreid met jonge aanwas 
en zijn we overgestapt op etentjes, ook altijd erg gezellig. Een traditie die we zeker voort 
moeten zetten, hopelijk binnenkort ook weer af en toe met Sylvie?!
Saskia en Hanny, mijn 'cache-collega’s'. Ik heb er altijd erg van genoten om na een lange 
werkdag even gezellig met jullie op pad te gaan om een cache te zoeken. Of natuurlijk in het 
weekend met als afsluiting een high tea. Een traditie die we ook zeker voort moeten zetten!
Anne, tussen het harde werken door was jij ook altijd in voor een gezellig uitstapje: een 
filmpje kijken (voor mij heel toepasselijk ‘TED2’) of een concert in Doornroosje. Succes nog 
met het afronden van je promotietraject en verdere carrière. Met jouw mentaliteit gaat dat 
zeker goed komen!
Mijn eerste groepje kamergenoten. Jimmy, jij was in die tijd mijn enige Nederlands sprekende 
collega in de aio-kamer. Naast je passie voor wetenschap, heb ik ook mogen genieten van je 
passie voor fotografie en journalistiek. Ik vond het erg leuk om met je mee te mogen naar 
een interview met Matt Simons en om een fotografie cursus bij je te volgen! Let’s switch to 
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English to thank my foreign colleagues. Dear Mari, thank you for being such a nice colleague 
on the TET2 project! Besides working, we also had a lot of fun. You tried to make new lyrics 
for the TET2 (tattoo) song, which was really funny. And I enjoyed visiting the SYTYCD theater 
tour together. Dear Italian colleagues (Davide and Niccolo), it was always fun with you two in 
the room, never quiet, always joking. Although I couldn’t follow many of the conversations in 
Italian, I do recognize some words now (but maybe not the best ones to remember…). Dear 
Pedro, we started our PhD on the same project, and also in the end we worked together. 
Thank you for the nice collaboration and for functioning as my English dictionary every now 
and then. Dear Leilei, I will remember you as the always enthusiastic colleague, and I really 
enjoyed being your paranymph at your big day.
Mijn nieuwe kamergenoten Rinske en Florentien. Florentien, jouw aanwezigheid in de aio-
kamer houdt de decibel productie van onze kamer goed op peil nu onze buitenlandse collega’s 
er niet meer zijn! Je bent altijd vrolijk, positief ingesteld en in voor gezellig kletsen tussen het 
harde werken door. Jij komt er wel als arts en onderzoeker! Rinske, je bent begonnen als mijn 
student en inmiddels zijn we collega’s en hebben we er samen met Anne al een congres met 
stedentrip op zitten. Toch leuk als het zo goed klikt met je collega’s!
Ook alle andere collega’s van de moleculaire unit wil ik bedanken. Gorica, bedankt voor het 
inwerken op het PRC2 project en de leuke samenwerking. Ruth, bedankt voor al het werk 
dat je hebt gedaan voor het TET en 5hmC project! Van honderden DNAtjes zuiveren tot op 
vele manieren stabiele lijnen proberen te maken, niets was je te gek. Jolanda, bedankt voor 
de gezelligheid en hulp bij mijn MSC-gerelateerde vragen. Maaike bedankt voor de gezellige 
tijd! Misschien hadden we toch meer samen moeten werken nu blijkt dat TET2 en WT1 
belangrijke interactie partners zijn.
Mijn verschillende projecten waren nooit geslaagd zonder de samenwerking met andere 
units en groepen. Allereerst wil ik de morfologie, IFT en BMT unit bedanken voor alle 
hulp. Meerdere malen hebben jullie gegevens voor mij mogen opzoeken waar jullie altijd 
probleemloos tijd voor maakten, of heb ik gebruik gemaakt van de door jullie zorgvuldig 
ingevroren patiënten cellen. Mijn onderzoek had weinig raakvlakken met de stollings unit, 
maar ook jullie waren altijd behulpzaam of in voor een praatje als ik weer eens bij de 
nanodrop kwam meten. Daarnaast natuurlijk onze directe buren, de GVL unit. Ik vond het erg 
fijn dat ik altijd bij jullie terecht kon voor vragen over buffy coats, sorteren enz. En misschien 
nog wel belangrijker, ik heb altijd erg genoten van de gezelligheid tijdens het lunchen, de high 
beers (of ice tea) en vierdaagse feesten! Tenslotte Nelleke, jij bent ook onmisbaar voor onze 
afdeling. Bedankt voor alle hulp tijdens mijn promotie, van het regelen van meetings tot het 
inseinen wanneer Joop weer op zijn plek te vinden was.
Ook wil ik graag alle hematologen en researchverpleegkundigen bedanken. Zonder patiënten-
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gegevens en patiëntenmateriaal was dit onderzoek niet mogelijk geweest. In het bijzonder 
wil ik graag Theo, Gerwin, Petra en Marjan bedanken. Theo en Gerwin, jullie bijdrage bij onze 
werkbesprekingen en het verzamelen van patiëntenmateriaal zijn essentieel geweest voor 
mijn onderzoek. Petra, jouw betrokkenheid bij de klonale evolutie studie was erg waardevol. 
Onze visie vanuit de onderzoekskant in combinatie met jouw klinische visie heeft geleid tot 
een heel mooi verhaal, waarvoor dank! Marjan, ons gezamenlijke project loopt nog, maar 
heeft al wel de discussie van mijn proefschrift gehaald. Hopelijk zal dit werk resulteren in een 
mooi artikel!
Daarnaast heb ik ook samengewerkt met andere groepen binnen en buiten het Radboud. 
Allereerst wil ik graag Ron en Arno bedanken voor de hulp en discussies rondom onze 5hmC 
projecten. Ook heb ik veel samengewerkt met de afdeling genetica, waarbij ik in het bijzonder 
Roland en Marian wil bedanken voor hun bijdrage. Furthermore, I would like to thank Seishi, 
Kenichi and Hiroo for the nice collaboration on the clonal evolution project. Tot slot wil ik 
graag Gerbrig, Edo en Hein bedanken voor de leuke en goede samenwerking bij het (nog 
lopende) tMDS/tAML project.
Naast de mensen die direct betrokken zijn geweest bij mijn promotieonderzoek, wil ik ook 
graag de mensen bedanken die hebben gezorgd voor de nodige ontspanning naast het werk. 
Marcia en Manon, ik heb altijd erg genoten van onze wekelijkse etentjes in Nijmegen en het 
samen sporten. We konden het altijd hebben over ons werk, maar daarnaast konden we ook 
juist uitgebreid over niet-werkgerelateerde dingen kletsen. Onze jaarlijkse weekendjes weg 
waren altijd erg gezellig: lekker ontspannen, een poging doen Manon enthousiast te maken 
voor het geocachen ;-), winkelen en uit eten. Ook al wonen we nu wat verder uit elkaar, 
hopelijk blijft ons contact nog net zo goed en houden we onze jaarlijkse uitjes in stand!
Lieve Maron, we kennen elkaar via turnen en zijn nu al jaren hele goede vriendinnen! 
Bedankt voor alle leuke jaren en alle ontelbare dingen die we al samen hebben meegemaakt: 
wedstrijden turnen of bezoeken, stedentrips, vakanties enz. Ik vind het heel fijn dat ik altijd 
alles met je kan delen, zowel leuke dingen als frustraties. Hopelijk blijft dit nog heel lang zo en 
kunnen we nog vele stedentrips en vakanties aan onze lijst toevoegen!
Lieve Chan, ook wij zijn vriendinnen geworden door turnen, maar inmiddels hebben we 
veel meer dezelfde interesses. Naast het turnen, hebben we beide Biologie en Medisch 
laboratorium onderzoek gestudeerd op het Saxion en zijn we beide een beetje besmet met 
het geocache virus. Dit zorgt ervoor dat we altijd genoeg leuke dingen hebben om gezellig 
over te kletsen!
Maaike, Niels, Chantal, Mike en nogmaals Maron (alias de ‘date’-groep). Het is altijd leuk om 
weer naar twente te gaan voor een ‘date’ met jullie. Gezellig naar de film, naar een concert, 
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uit eten, een weekendje weg, naar de escape room, alles kan. Op naar nog veel meer gezellige 
uitstapjes! En bedankt voor jullie altijd oprechte interesse in mijn promotieonderzoek, of….
jullie interesse in wanneer het feestje nou eindelijk zou komen.
En daarnaast wil ik ook graag alle vrienden bedanken die ik wat minder vaak zie, maar met 
wie het altijd gezellig is om weer even bij te kletsen.
Tot slot natuurlijk mijn familie. Familie van de Kroeze- en Nijhuis-kant, bedankt voor jullie 
interesse in mijn onderzoek. Pap en mam, zonder jullie steun had ik mijn promotieonderzoek 
niet kunnen doen. Bedankt voor alle hulp en jullie begrip als ik weer eens een weekend in 
twente was, maar voornamelijk werkend achter de computer doorbracht. Yvet, jij begrijpt 
natuurlijk als geen ander wat het doen van promotieonderzoek inhoudt. Bedankt voor 
alle hulp, discussies over mijn project, inspiratie voor het maken van figuren en voor het 
functioneren als spellingscontroleuse.
Leonie
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Abbreviations of gene names, protein names and domain names are not included in the list.
2HG 2-hydroxyglutarate
2OG 2-oxoglutarate
5caC 5-carboxylcytosine
5fC 5-formylcytosine
5hmC 5-hydroxymethylcytosine
5hmU 5-hydroxymethyluracil
5mC 5-methylcytosine
5q- deletion of (part of) the q-arm of chromosome 5
95%CI 95% confidence interval
%5hmC/G percentage 5-hydroxymethylcytosine/guanine
%5mC/G percentage 5-methylcytosine/guanine
αKG α-ketoglutarate
aa amino acid
aCML atypical chronic myeloid leukemia
ACN acetonitrile
AIC  akaike information criterion
AITL angio-immunoblastic T-cell lymphoma
ALL acute lymphoblastic leukemia
allo-SCT allogeneic stem cell transplantation
AML acute myeloid leukemia
Ara-C cytosine arabinoside
auto-SCT autologous stem cell transplantation
BER base excision repair
BL baseline
BM bone marrow
BSA bovine serum albumin
CCR continuous complete remission
CD catalytic domain
cDNA complementary DNA
chr chromosome
CML chronic myelogenous leukemia
CMML chronic myelomonocytic leukemia
CMP common myeloid progenitor
CNA copy number alteration
CN-LOH copy-neutral loss of heterozygosity
CpG cytosine  - phosphate  - guanine
CR complete remission
CS common sequence
CV  coefficient of variation 
DNA deoxyribonucleic acid
DNMT DNA methyltransferase
eCFP enhanced cyan fluorescent protein
ECOG Eastern Cooperative Oncology Group
eGFP enhanced green fluorescent protein
ELN European LeukemiaNet
EMA European Medicines Agency
EORTC European Organisation for Research and
 Treatment of Cancer
ESA erythroid stimulating agent
ESC embryonic stem cell
ET essential thrombocythemia
FAB French-American-British (classification system)
FCS fetal calf serum
FDA Food and Drug Administration
FISH fluorescence in situ hybridization
FSC forward scatter
G-CSF granulocyte-colony stimulating factor
GIMEMA Gruppo Italiano Malattie EMatologiche
 dell’Adulto
GMP granulocyte-macrophage progenitor
H2AK119ub histone 2A lysine 119 ubiquitination
H3K27(me3) histone 3 lysine 27 (trimethylation)
H3K4(me3) histone 3 lysine 4 (trimethylation)
HDAC histone deacetylase
hmz homozygous
HPLC-MS/MS high performance liquid chromatography-mass
 spectrometry/mass spectrometry
HR hazard ratio
HSC hematopoietic stem cell
int intermediate
IPSS(-R) international prognostic scoring system(-revised)
ISCN international system for human cytogenetic
 nomenclature
iso isoform
ITD internal tandem duplication
JMML juvenile myelomonocytic leukemia
KO knock-out
LOH loss of heterozygosity
MBD methyl binding domain
MDS myelodysplastic syndrome
MDS/MPN-U myelodysplastic/myeloproliferative neoplasm -
 unclassifiable
MeDIP methylated DNA immunoprecipitation
MEP megakaryocyte-erythrocyte progenitor
miR microRNA
miRNA microRNA
MNC mononuclear cell
MPN myeloproliferative neoplasm
mRFP monomeric red fluorescent protein
mRNA messenger ribonucleic acid
MSC mesenchymal stromal cell
mut mutated
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n number
N/A not analyzed
ND not determined
NGS next generation sequencing 
No. number
noCR no complete remission
NOS not otherwise specified
O-GlcNAc O-linked N-acetylglucosamine
OS overall survival
PB peripheral blood
PBS phosphate buffered saline
PCR polymerase chain reaction
PFA paraformaldehyde
PMF primary myelofibrosis
PRC1 polycomb repressive complex 1
PRC2 polycomb repressive complex 2
PS performance status
pts patients
PV polycythemia vera
qPCR quantitative polymerase chain reaction
RA refractory anemia
RAEB refractory anemia with excess of blasts
RAEB1 refractory anemia with excess of blasts, type 1
RAEB2 refractory anemia with excess of blasts, type 2
RAEBt refractory anemia with excess of blasts in
 transformation
RARS refractory anemia with ringed sideroblasts
RCMD refractory cytopenia with multilineage dysplasia
RNA ribonucleic acid
sAML secondary AML
SCT stem cell transplantation
SNP single nucleotide polymorphism
SNV single nucleotide variant
SSC side scatter
Std standard
TBC tuberculosis
TCA tricarboxylic acid
TPO thrombopoietin
UNK unknown
UPD uniparental disomy
UPN unique patient number
VAF variant allele frequency
WBC white blood cell count
WES whole exome sequencing
WHO World Health Organization (classification system)
wt wild-type

